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heterozygously and homozygously deleted in combination with Mycn overexpression. We injected these
genetically modified primary cells into mice to determine if Arid1a loss collaborates with Mycn
overexpression during NCC transformation. We evaluated tumor growth kinetics, characterized the
pathological features and gene expression profiles of resulting tumors, and evaluated the Arid1adependent differentiation traits of tumors and primary NCCs in vivo and in vitro. We found that Arid1a
loss caused a gene expression and phenotypic shift to an immature cell identity. Furthermore,
heterozygous loss of Arid1a during transformation of primary murine NCCs resulted in tumors that
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analysis demonstrated that gene expression profiles of Arid1a heterozygous tumor samples significantly
correlated with previously established mesenchymal gene signatures found in high-risk NBL patients. Our
model causally tested the clinical observation that 70% of high-risk MYCN amplified NBL patient tumors
include 1p36 LOH. Our results support the hypothesis that ARID1A is a 1p36 tumor suppressor candidate
that collaborates with MYCN to transform NCCs into high-risk NBL. Last, our model suggests that a shift
in cell identity may be connected to NBL initiation.

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Biomedical Sciences

Research Advisor
Kevin W. Freeman, Ph.D.

Keywords
1p36, development, oncogene, pediatric cancer, stem cells, tumor suppressor

Subject Categories
Developmental Biology | Medicine and Health Sciences

This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/510

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER
DOCTOR OF PHILOSOPHY DISSERTATION

Arid1a Haploinsufficiency Initiates Neural Crest
Transformation in a Mouse Model of Mycn-driven
Neuroblastoma
Author:
Kirby A. Wallace

Advisor:
Kevin W. Freeman, Ph.D.

A Dissertation Presented for The Graduate Studies Council of
The University of Tennessee Health Science Center
in Partial Fulfillment of the Requirements for the
Doctor of Philosophy degree from
The University of Tennessee
in
Biomedical Sciences/Cancer and Developmental Biology
College of Graduate Health Sciences

May 2020

Copyright © 2020 by Kirby A. Wallace.
All rights reserved.

ii

ACKNOWLEDGEMENTS
It is a privilege and a pleasure to have worked with my doctoral training research
advisor Dr. Kevin Freeman. His guidance expanded my interest in science and my ability
to pursue scientific knowledge philosophically and experimentally. The skills and
approaches to problem solving that I gained through working with Dr. Freeman will
benefit me throughout my entire career. I wish him all the best in his future endeavors!
I would like to thank my committee members for their attention to and support of
my project throughout graduate school. Each committee member has contributed to my
scientific training and for that I am extremely grateful. I would especially like to thank
Dr. Andy Davidoff for his significant role in resourcing and supporting my doctoral
research project.
My previous and current lab members have taught me many scientific and life
lessons during my doctoral program. I would like to thank each person for their time
spent helping me move this work forward. Thank you to Rachelle Olsen and Joel Otero
for their early help getting this project off the ground and thank you to the new lab
members for inspiring the continuity of this work.
Graduate school would not have been the same without Dr. Jesus García-López, a
post-doctoral scientist I had the privilege of working with and learning from during my
time in the Freeman lab. His perspective during the early days of my project helped me
see the beauty of science, and his advice throughout graduate school helped me navigate
tough hurdles.
Finally, I would like to sincerely thank a new Freeman lab member Chelsea
DeVaux for the contributions she made to this project. I am very grateful for her
willingness to learn and to jump in to move experiments forward, and I wish her all the
best as she continues her journey in science.
I am grateful for my time working in the Davidoff lab, and would like to thank
each member of the team for their inclusiveness and support of my project. I would
especially like to thank Dr. Dongli Hu for his help and advice during critical experiments
and Mark Brimble for his support of this project and scientific camaraderie.
This research project would not have been possible without the support of the
many thoughtful scientists I was fortunate enough to work with. The Microscopy Core,
Flow Cytometry Core, and Veterinary Pathology Core at St Jude Children’s Research
Hospital made meaningful contributions. I am grateful for the contributions made by
Krista Millican during critical experiments, and appreciate the opportunity to work with
her. Notably, Dr. Heather Tillman was my longest standing collaborator and she
contributed significantly to the completion of this project. I learned many scientific and
life lessons from her throughout graduate school and it was a privilege to work with her.

iii

The bioinformatics portion of this project would not have been possible without
collaborative help from Dr. Neil Hayes and Jeremiah Holt. Jeremiah’s work and the
support from Dr. Neil Hayes positively impacted the outcome of this project. Jeremiah’s
willingness to collaborate across laboratory projects helped me considerably while
working with him and I wish him well as he continues his MD/PhD training.
I would also like to thank those in the Department of Oncology and the
Department of Surgery at St Jude for their support. I would especially like to thank Dr.
Mark Hatley and Dr. Jun Yang for their interest in my project and for their suggestions. I
would also like to thank them and their lab members for their generosity in sharing
reagents, equipment and time. It was a pleasure to learn from and work with all of them.
I would like to sincerely thank the following colleagues for their thoughtful
dissertation review and comments: Dr. Jesus García-López, Ph.D.; Rachael Wood; Dr.
Carolyn Jablonowski, Ph.D.; and Dr. Lisa Miller, Ph.D.; I am grateful for the time
invested in reading my work and giving meaningful feedback.
I would like to thank my family members for their support of my academic goals,
especially my mother, Jill Wallace, my father, Truman Wallace and my sister Kaitlin
Wallace for their encouragement and unwavering support of my graduate school
endeavors no matter how challenging.
I would like to thank Dr. Danny Lewis for launching me on the path of cancer
research. I would not have had the opportunities to pursue a career in science and my
eventual Ph.D. without him. His mentorship throughout my career so far has helped me
in ways that no graphs can measure.
I would also like to thank the friends I’ve made in graduate school for their kind
words and companionship that endured from start to finish of this journey. I would like to
thank Lee Pribyl for his encouragement to participate in student government. It was a
pleasure to serve on many UTHSC councils with him. I would especially like to thank
Rachael Wood for her friendship and camaraderie. Her steadfast attitude toward scientific
challenges demonstrates the strength of her character that is also exemplified by her
kindness and loyalty as a friend.
Last, I cannot begin to express my thanks to my husband, Patrick Woods. He
listened to endless amounts of scientific conjecture and speculation about experimental
decisions with unlimited patience and kindness. His excitement about my professional
accomplishments helped me experience graduate school as a joy and a privilege and his
support was pivotal in helping me complete my degree.
This work would not have been possible without grant funding from the
Department of Defense (DOD W81XWH1810477 and DOD W81XWH1410090).

iv

ABSTRACT
Mouse models of cancer are critical for developing therapeutic treatments for
pediatric patients. Recent sequencing studies of neuroblastoma (NBL) patient tumors
have uncovered precise deletions in the chromatin remodeler and tumor suppressor gene
(TSG) ARID1A. Additional causal studies supported ARID1A’s candidacy as a putative
1p36 TSG in MYCN-driven NBL. This study aimed to causally test Arid1a loss during
Mycn-driven NBL initiation through the development of a mouse model of high risk
NBL.
In this study, we modified a Mycn-driven mouse model of NBL to incorporate Cre
mediated deletion of floxed Arid1a. Briefly, in freshly isolated embryonic day 9.5
primary trunk neural crest cells (NCCs), Arid1a was heterozygously and homozygously
deleted in combination with Mycn overexpression. We injected these genetically
modified primary cells into mice to determine if Arid1a loss collaborates with Mycn
overexpression during NCC transformation. We evaluated tumor growth kinetics,
characterized the pathological features and gene expression profiles of resulting tumors,
and evaluated the Arid1a-dependent differentiation traits of tumors and primary NCCs in
vivo and in vitro.
We found that Arid1a loss caused a gene expression and phenotypic shift to an
immature cell identity. Furthermore, heterozygous loss of Arid1a during transformation
of primary murine NCCs resulted in tumors that pathologically and molecularly model
human high-risk, MYCN amplified NBL. Gene set enrichment analysis demonstrated that
gene expression profiles of Arid1a heterozygous tumor samples significantly correlated
with previously established mesenchymal gene signatures found in high-risk NBL
patients.
Our model causally tested the clinical observation that 70% of high-risk MYCN
amplified NBL patient tumors include 1p36 LOH. Our results support the hypothesis that
ARID1A is a 1p36 tumor suppressor candidate that collaborates with MYCN to transform
NCCs into high-risk NBL. Last, our model suggests that a shift in cell identity may be
connected to NBL initiation.
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CHAPTER 1.

INTRODUCTION

Neuroblastoma
NBL is the most common extracranial pediatric solid tumor, and accounts for 15
percent of pediatric cancer deaths each year. NBL tumors are inherently heterogeneous,
which results in a disease with poor prognosis and outcomes. The children’s oncology
group (COG) stratifies patients into one of three risk groups at diagnosis: low,
intermediate, or high (Coughlan et al., 2017; Davidoff, 2012). Forty percent of patients
diagnosed are HR with metastatic spread with primary disease arising in the adrenal
glands (Coughlan et al., 2017). HR NBL is classified based on Shimada histology,
mitotic-karyorrhexis index (MKI), Schwannian stromal content, age at diagnosis, and
MYCN amplification (MNA) (Davidoff, 2012; Jiang et al., 2013; Peuchmaur et al., 2003;
Shimada et al., 1999). Age at diagnosis has been shown to correlate with patient
outcomes. Patients diagnosed at <18 months of age are most likely to be low or
intermediate risk, while patients >18 months are more likely to be diagnosed with HR
disease (Davidoff, 2012; J. R. Park et al., 2013). Furthermore, most HR patients are
between 18 months and 12 years old (Davidoff, 2012). Current patient stratification
approaches highlight the uneven distribution of patient outcomes across risk groups.
Low and intermediate-risk patients have positive prognosis and a 95% chance of survival;
however, HR patients have a much worse prognosis of event free survival and a 30-50%
chance of 5-year survival (Coughlan et al., 2017; Davidoff, 2012; Pinto et al., 2015;
Tolbert & Matthay, 2018).
Current neuroblastoma therapy options
NBL treatment regimens are dependent on the stage of tumor at diagnosis and
rely on patient groups defined by either the COG clinical trial protocol, or the
International Neuroblastoma Risk Group (INRG) system (Coughlan et al., 2017;
Davidoff, 2012). According to COG protocol, risk stratification determines treatment
protocol, with the number of treatments increasing as disease severity increases. For
example, low risk patients often receive no chemotherapy treatment or are treated with a
chemotherapy regimen consisting of 1 or more agents paired with surgery(Coughlan et
al., 2017; Davidoff, 2012). Outcomes measure near 100% for 5-year survival rates
(Coughlan et al., 2017). Intermediate NBL patients are treated with four or more
chemotherapeutic agents paired with surgery, and 5-year survival rates are stable at 93%
(Coughlan et al., 2017; Davidoff, 2012; Nakagawara et al., 2018). In contrast to these two
groups, HR patients receive an arsenal of treatments. Patients receive cycles of
chemotherapy that include eight or more types of chemotherapeutic agents (Coughlan et
al., 2017). Furthermore, surgery is required, and additional therapies may be paired with
these two treatments. Additional therapeutic options often used to treat HR patients
include myeloablative radiation followed by stem cell transplant, along with GD2
immunotherapy, and retinoic acid differentiation therapy(Coughlan et al., 2017;
Davidoff, 2012). Five-year survival rates for these patients recently measured at 46%
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(Coughlan et al., 2017; García-López et al., 2020). In summary, risk stratification
correlates with outcomes. Fewer treatments are required to treat low and intermediaterisk disease—fortunately producing great outcomes; however, therapeutic regimens for
HR patients are intensive and outcomes are poor (Coughlan et al., 2017; Davidoff, 2012;
J. R. Park et al., 2013; Tolbert & Matthay, 2018). Consequently, the development of
precision medicine that incorporates newly identified biomarkers and therapeutic agents
remains integral to improving outcomes and patient lives (D. T. W. Jones et al., 2019; J.
R. Park et al., 2013; Pugh et al., 2013).
We propose that improving outcomes will be addressed through identifying the
oncogenic drivers of this disease. We hypothesize that furthering the field’s knowledge of
the initiating tumorigenic events of HR disease will provide new insights into the disease
origin. Our aim is to expose underlying weaknesses of HR NBL that can be
therapeutically exploited. The following literature review highlights three key areas of
research: chromosomal abnormalities that underlie HR NBL, conclusions that can be
drawn from other fields of study describing our genes of interest, and the unresolved
questions we aim to answer.
Chromosomal lesions that define high risk neuroblastoma
Intratumoral heterogeneity that correlates to patient outcomes has been connected
to the genetic events that underlie NBL (Garrett M. Brodeur, 2003). One approach to
improving our understanding of how this disease will progress is identification and
evaluation of molecular and cellular consequences of the genetic lesions harbored in NBL
tumors (Garrett M. Brodeur, 2003; Garrett M. Brodeur et al., 2014). Many chromosomal
gains and losses are evident in NBL, notably gain of 17q, MYCN amplification, and loss
of material at 11q , 14q, and 1p (Attiyeh et al., 2005; Garrett M. Brodeur, 2003; Davidoff,
2012; C. T. Fong et al., 1989; Jiang et al., 2013). Despite the frequency of genetic lesions,
the only chromosomal event currently used to clincially stratify patients is MYCN
amplification (Tolbert & Matthay, 2018). However, the genetic perturbations found in
NBL demonstrate patterns of overlap, suggesting either synergy, or mutual exclusivity;
identification of cooperating mutations may provide new therapeutic opportunities
(Garrett M. Brodeur et al., 2014). One illustration of this concept is loss of heterozygosity
at 1p36.1-1p36.3 has perplexed the NBL community for over 30 years (C. T. Fong et al.,
1989) Interestingly, this region is an example that demonstrates both overlapping and
mutually exclusive genetic events. This is highlighted by the work published twenty four
years ago. Caron, et al identified two regions of deletion in 1p36, a distal and proximal
region (Caron et al., 1995). The distal region of deletion is mutually exclusive of MYCN,
and contains the smallest region of common deletion (Caron et al., 1995; García-López et
al., 2020; White et al., 2005).The larger proximal region of deletion coincides with
MYCN amplification (MNA) (Caron et al., 1995; García-López et al., 2020). The
combination of proximal deletion of 1p36 and MYCN amplification are correlated in 1520% of all NBL cases. Tumors with 1p36 loss of heterozygosity (LOH) and MYCN
amplification are HR, frequently metastatic, frequently relapse post-therapy and result in
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poor patient outcomes with survival rates of approximately 30 percent (Attiyeh et al.,
2005; Caron et al., 1995; Jiang et al., 2013).
MYCN Amplification
MYCN is one of three members of the MYC family of bHLH-LZ transcription
factors that promote the expression of their gene targets by binding to promoters and
enhancers (Rickman, Schulte, & Eilers, 2018; Ruiz-Pérez, Henley, & ArsenianHenriksson, 2017). During development, N-myc is expressed in a restricted number of
tissues and is responsible for the rapid proliferation of the developing central nervous
system (CNS) (Rickman et al., 2018). In cancer, the MYC gene family is frequently
deregulated, often via gene amplification (Lin et al., 2012; Rickman et al., 2018; Van
Dang et al., 2016). MYCN is an oncogene that is overexpressed in five nervous system
cancers, and in six non-neuronal tumors (Rickman et al., 2018). MYCN amplification
(MNA) was discovered in year 1983 by Schwab and colleagues and was defined as an
oncogenic driver of NBL (Schwab, 1983, Nature). MNA often results in 50 to 400 gene
copies per cell and a corresponding increase in N-Myc protein expression (Maris &
Matthay, 1999). MNA is a predominant driving mutation in NBL and is used as a
biomarker of tumor aggressivity at diagnosis that designates HR disease. In NBL, MYCN
is not clonally acquired, and has been shown to initiate NBL across multiple species in
experimental models, implicating it as a driving oncogenic lesion in NBL (García-López
et al., 2020; Olsen et al., 2017; Rickman et al., 2018; Weiss, Aldape, Mohapatra,
Feuerstein, & Michael Bishop, 1997).
Therapeutic targeting of MYCN
In pre-clinical models of NBL performed by multiple research groups, MYCN
expression during varying stages of SNS development initiated NBL across mouse,
zebrafish, and primary cell models (García-López et al., 2020; Olsen et al., 2017;
Rickman et al., 2018; Tsubota & Kadomatsu, 2018; Weiss et al., 1997; Zhu et al., 2012).
Despite knowing for decades that MYCN amplification is fundamental to NBL
oncogenesis, development of inhibitors for clinical use has lagged due to several physical
limitations of precision medicine. First, transcription factors (TFs) that reside in the
nucleus are difficult to effectively target, which limits drug delivery options (Garrett M.
Brodeur et al., 2014). Second, unbound MYCN is largely unstructured, which results in a
lack of binding pockets (Rickman et al., 2018; Ruiz-Pérez et al., 2017). Third, the
structure of MYCN is determined by its binding partner MAX, and crystal structures of
the heterodimer do not indicate obvious targetable sites (Rickman et al., 2018; Ruiz-Pérez
et al., 2017). Therefore, there are currently no target-specific treatments for HR MYCN
amplified NBL. Taken together, an alternative approach to therapeutic development for
MYCN-driven NBL is necessary.
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MYCN versus MYC
MYC is the founding member of the MYC family. There are three family
members that include MYC, MYCN, and MYCL (C-Myc, N-Myc, and L-Myc proteins,
respectively). MYC is the most frequently mutated gene in this family, and consequently
has been studied across the broadest variety of cancers (Dang, 2012; Lin et al., 2012).
Review articles often refer to MYC as a starting point for understanding the
characteristics and oncogenic effects of MYCN. In the past, MYC and MYCN were
considered to behave with similar activity, and differences were attributed to differential
temporal or localized expression (Malynn et al., 2000). However, as studies expand,
differences between these two genes and their differential regulation of genes is evident,
especially in the context of cancer. To highlight this point, differences in MYC activity
and binding across a variety of cancer types has been linked to “C-Myc target signatures”
(Lin et al., 2012). However, even the C-Myc-dependent targets display little overlap
across different cancers and are considered cancer type specific (Lin et al., 2012).
Independent studies of MYC and MYCN amplified cancers suggest a similar method of
oncogenic action that is exerted on cancer-specific gene targets (Lin et al., 2012; Zeid et
al., 2018).
The frontiers of MYCN research
An emerging concept regarding MYC family proteins is “enhancer invasion.”
Both C-Myc and N-Myc have been shown to preferentially bind high-affinity promoters,
but in cases of oncogenic overexpression of these proteins, they begin binding, or
invading, low-affinity promoters (Lin et al., 2012; Rickman et al., 2018; Van Dang et al.,
2016; Zeid et al., 2018). One interpretation of enhancer invasion in cancers with MYC or
MYCN amplification is that the epigenetic landscape predetermines the genetic profile
that is then modulated by MYC/MYCN (Lin et al., 2012; Rickman et al., 2018). Briefly,
MYC and MYCN have similar promoter binding signatures, and recent studies have
suggested that the differences seen in MYC or MYCN gene expression profiles are due to
their binding of open enhancer regions when overexpressed, as in amplified cases (Zeid
et al., 2018). The differential gene expression patterns seem to be tissue specific and
determined by two factors: 1. the epigenetic landscape that controls open enhancer
regions, and 2. other cooperating enhancer binding proteins (Lin et al., 2012; Zeid et al.,
2018). Therefore, the concept of enhancer-driven transcription is one rationale that may
explain the cancer-type-dependent roles of MYCN (Zeid et al., 2018). In summary, the
most promising approaches to targeting MYCN overexpressed tumor types are the
identification of MYCN regulated downstream events that can be therapeutically
exploited. Establishing the enhancer regulating proteins that synergize with MYCN may
uncover therapeutic vulnerabilities in key pathways.
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MYCN amplification and its correlation with 1p36 loss of heterozygosity
Deletions on 1p were first discovered in 1977 by Brodeur, et al., and are
correlated with MYCN amplification (G M Brodeur, Sekhon, & Goldstein, 1977; C. T.
Fong et al., 1989). The high frequency of 1p36 LOH suggests that deletion of this region
is a driving event in NBL and that 1p36 harbors one or more tumor suppressor genes
(TSGs) (Garrett M. Brodeur, 2003; C. T. Fong et al., 1989; Versteeg et al., 1995). 1p36
LOH is a hemizygous deletion, without reduplication, found on one of the two sister
chromosomal alleles, and gene mapping has identified that approximately 500 genes may
be lost in this region (C. T. Fong et al., 1989). Due to the vast number of TSG candidates
lost, the second 1p36 allele has been thoroughly studied for additional inactivating point
mutations that may correspond to crucial TSG candidates. However, identifying the
important gene or genes in this region has been difficult because inactivating point
mutations were not found on the second allele until recently. In 2013, using whole exome
and whole genome sequencing of 74 distinct patient tumors, Sausen, et al. identified point
mutations that resulted in biallelic ARID1A deletions in 3 cases, and independent ARID1A
point mutations in an additional 3 cases (Sausen et al., 2013). Furthermore, in support of
the original findings of Caron and colleagues, when sequences from patient samples in
the St Jude TARGET dataset were separated by MYCN status, Arid1a was included in the
region of deletion at 1p36 only when MYCN was amplified (García-López et al., 2020).
However, when MYCN was wild-type, Arid1a was not always deleted (García-López et
al., 2020). Taken together these results suggested that ARID1A inactivation is a loss of
function oncogenic event in NBL and positioned ARID1A as a TSG candidate for MNA
NBL.
The Tumor Suppressor ARID1A
Although pediatric cancers have a lower mutational burden than adult cancers,
recent large pediatric cancer analyses have identified epigenetic aberrations as the top
contributors to pediatric diseases (Gröbner et al., 2018; Lawlor & Thiele, 2012; Ma et al.,
2018). Epigenetics is commonly defined as the regulation of “DNA templated processes”
through chromatin modification (Dawson & Kouzarides, 2012). ARID1A (AT-Rich
interacting domain containing protein 1A) is a TSG that is frequently mutated across 25
adult and pediatric cancer types including NBL (R. C. Wu, Wang, & Shih, 2014).
ARID1A is essential for the ability of the SWI/SNF (Switch/Sucrose Non-Fermenting)
chromatin remodeling complex to bind DNA and is the most mutated member of this ~15
subunit complex (S. Jones et al., 2012; Kadoch et al., 2013; Wiegand et al., 2010; R. C.
Wu et al., 2014). ARID1A has causally been identified as a context dependent TSG
(Guan, Wang, & Shih, 2011; Sun, Wang, et al., 2017; S. C. Wang et al., 2019; R. C. Wu
et al., 2014). Arid1a serves multiple roles in cellular modulation as a known epigenetic
regulator of enhancers (Alver et al., 2017; Mathur et al., 2017; Raab, Resnick, &
Magnuson, 2015; Son & Crabtree, 2014), cell signaling through P13K and dna damage
pathways (Chandler et al., 2015; Hu et al., 2018; Lord et al., 2016; Shen et al., 2018,
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2015) as well as crucial roles in liver and hematopoietic differentiation (Han et al., 2019;
Sun, Chuang, et al., 2017; Sun, Wang, et al., 2017).
SWI/SNF
Mutated epigenetic mechanisms have been proposed as initiating events in
cancers with mostly silent genomes (Flavahan, Gaskell, & Bernstein, 2017), which
applies to most childhood cancers including NBL. SWI/SNF is the most mutated
chromatin remodeling complex in cancer (Kadoch et al., 2013; J. N. Wu & Roberts,
2013). One role of chromatin remodelers is to partner with transcription factor genes to
define lineages and restrict chromatin accessibility as developmental processes progress
(Flavahan et al., 2017). Precisely timed chromatin restriction is required for proper
differentiation, and perturbation of this step is proposed as a “major factor” of
tumorigenesis (Flavahan et al., 2017). The SWI/SNF complex binds to promoter and
enhancer regions, but preferentially binds to and regulates the opening and closing of
chromatin at enhancer regions during development to determine lineage commitment
(Alver et al., 2017; Raab et al., 2015).
SWI/SNF was identified in yeast and is known as BAF (Brahma associated
factor) in human cells (Son & Crabtree, 2014). As differentiation occurs during
development, the BAF complex adapts by acquiring different sub-unit compositions
(Raab et al., 2015; Son & Crabtree, 2014). Whether these adaptations cause
differentiation to proceed or are the result of differentiation is currently unclear.
Regardless, ARID1A is present in the complex in mutual exclusivity of other ARID family
members, specifically ARID1B and ARID 2. ARID 1A and ARID1B are components of the
BAF complex, which is the most commonly identified complex across tissue types.
ARID1A and ARID 2 are components of pBAF (polybromo BAF), a complex involved in
the differentiation of various tissue types (Raab et al., 2015). One study in HepG2 cells
used gene silencing technology to sequentially ablate expression of each Arid protein
(Raab et al., 2015). Next, the chromatin binding regions of overlap and exclusive binding
sites were identified for each Arid protein. Although there were sites of overlap, each
protein was shown to differentially bind chromatin sites (Raab et al., 2015). This finding
was interesting given the context that Arid proteins have been shown to bind
promiscuously to chromatin (Dallas et al., 2000). Furthermore, each Arid protein
regulated a different gene program (Raab et al., 2015). It is currently unclear how BAF
binding sites are decided. However, this data suggests that genetic mutations or ablation
of one ARID protein may cause the complex to be redirected to a new binding location,
resulting in new chromatin characteristics, and possibly cellular deregulation.
To summarize, ARID1A deletions and mutations result in a new complex by
allowing either Arid1b or Arid2 to engage with the BAF or pBAF complex, respectively.
One possible outcome of this altered composition is the targeting of the SWI/SNF
complex to new chromatin sites, resulting in downstream gene expression differences.
Whether ARID1B, or ARID 2 will engage in the complex following ARID1A mutation is
dependent on tissue type and developmental stage. One limitation of current cancer
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studies is that mutated SWI/SNF components are identified, but the resulting complex
makeup is not often resolved. As demonstrated in studies by Kadoch, et al.,
immunoprecipitation of SWI/SNF complex components following identification of a
subunit mutation, such as Arid1a deletion, will be a necessary step in elucidating how
SWI/SNF mutations result in a new complex composition that drives cancer and other
diseases (Kadoch et al., 2013).
Types of ARID1A mutations
ARID1A is frequently mutated in ovarian clear cell carcinoma, gastric cancer,
breast cancer, pancreatic cancer, prostate cancer, and hepatocellular carcinoma (Kadoch
et al., 2013; J. N. Wu & Roberts, 2013; R. C. Wu et al., 2014). The majority of mutations
have been identified in genome sequencing screens and immunohistochemistry (IHC)
analyses (Kadoch et al., 2013; J. N. Wu & Roberts, 2013). Mutations are often frameshift or nonsense and are predicted to be loss of function (Bitler, Fatkhutdinov, & Zhang,
2015; Mathur, 2018; J. N. Wu & Roberts, 2013). Of the genetic mutations identified, both
homozygous and heterozygous mutations occur. In a large screen of 3,000 tumor
samples, only 7% demonstrated complete ARID1A protein ablation (J. N. Wu & Roberts,
2013). Overall, IHC based screens on tumor sections resolved that ARID1A protein
expression is often reduced to a range between 75-45% loss (J. N. Wu & Roberts, 2013).
This suggests that homozygous deletion of ARID1A may be necessary in some contexts,
but heterozygous loss of function may be sufficient in others. Furthermore, ARID1A is a
potential heterozygous TSG in multiple cancer types, which further supports its
candidacy as a 1p36 LOH TSG.
Therapeutic targeting of ARID1A mutant tumors
Due to the high rates of ARID1A mutations across cancer types, multiple groups
are working to identify druggable targets in these ARID1A mutated cancers (Bitler et al.,
2017; Ogiwara et al., 2019; R. C. Wu et al., 2014). Targeting loss of function oncogenic
drivers has been a long-term issue in therapeutic development. In the 1990s, gene therapy
was developed with the idea of correcting loss of function genetic events. Re-expression
of the gene of interest using a viral vector that included an engineered copy of the lost
gene was expected to correct these loss of function mutations. However, difficulty in
delivery, uptake, off-target effects and long-term expression of the new gene insert has
significantly impeded the use of this therapeutic option (Birkeland, Ludwig, Spector, &
Brenner, 2016). An alternative approach used to therapeutically target loss of function
drivers is the identification of druggable pathways altered following gene loss, or
identification of extracellular membrane proteins overexpressed following loss of the
gene of interest. The field of therapeutics is rapidly developing new drug options, notably
small molecule inhibitors (SMIs) are considered a powerful option for precision therapy
in NBL (Garrett M. Brodeur et al., 2014). Recently, efforts to target ARID1A mutant
cancer using precision medicine focus on the development of synthetic lethal small
molecule inhibiters (SL-SMIs) (Gorrini & Mak, 2019; Helming et al., 2014; Ogiwara et
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al., 2019; J. N. Wu & Roberts, 2013). The Arid1a field has currently used SL-SMIs to
target three main groups: PRC2 complex members, namely EHZ2 inhibitors, other
SWI/SNF complex members, specifically ARID1B, and new candidates that have
recently been identified as downstream of ARID1A.
EZH2 inhibitors
PRC2 is a chromatin remodeling complex that compacts chromatin and has been
shown to antagonize SWI/SNF (B. G. Wilson et al., 2010). EZH2 is the catalytic subunit
of this complex, and deposits methyl marks on histone 3 lysine 27 (H3K27), causing
repression of gene transcription (B. G. Wilson et al., 2010). In ovarian clear cell
carcinoma (CCC), EZH2 inhibitors were found to notably cause apoptosis in Arid1a
mutant cells (Bitler, Aird, et al., 2015; Bitler, Fatkhutdinov, et al., 2015). EZH2 inhibitors
are currently in clinical trials for B-cell lymphoma, and have shown promising results
(Bitler, Fatkhutdinov, et al., 2015). In summary, further pre-clinical testing of EZH2
inhibition will be needed to determine if this is a beneficial option for Arid1a mutant
cancers and possibly other SWI/SNF mutant cancer types (Bitler, Fatkhutdinov, et al.,
2015).
ARID1B inhibitors
In 2014, Helming et al. identified ARID1B as an “Achilles heel” of ARID1A
mutant ovarian cancer cell lines (Helming et al., 2014). Inhibition of ARID1B using
shRNA reduced cell proliferation and colony formation in ARID1A mutant cell lines
OVISE and TOV21G, but not ARID1A wild-type cell lines ES-2 or 293T (Helming et al.,
2014). Additionally, depletion of ARID1B caused the SWI/SNF complex to dissociate in
ARID1A mutant cells (Helming et al., 2014). Together these data suggested that targeting
ARID1B gene products may be a viable therapeutic option for ARID1A mutant cancer
types. However, as discussed above, ARID1B may not be present in the complex in all
tissue types. Therefore, ARID1B inhibition may apply to some, but not all ARID1A
mutant cancers. Identification of the SWI/SNF composition in each ARID1A mutated
cancer, and empirical testing of the inhibitors of interest will be necessary for appropriate
development of this therapeutic approach.
Downstream targets of ARID1A
Multiple groups have identified potential roles for ARID1A in DNA damage
signaling. Small molecule inhibitors targeting ATR and PARP were tested in the ARID1A
knockout colorectal cells HCT119 by two groups (Lord et al., 2016; Shen et al., 2015).
Both compounds were shown to selectively target ARID1A mutant cells. However, in an
additional study, the ovarian cancer cell line MCF10A was depleted of ARID1A using
esiRNA (endonuclease-prepared small interfering RNA), and the cells were screened for
chemical-genetic interactions (Hu et al., 2018). Paired with the Cancer Therapeutics
Response Portal (CTRP), 496 cells were found to be resistant to etoposide (Hu et al.,
2018). Furthermore, 10 patients in clinical trials with rucaparib, a PARP inhibitor were
analyzed for progression free survival (Hu et al., 2018). The patients demonstrated
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significantly lower progression free survival than the other cohort patients, suggesting
that the PARP inhibitors do not improve patient outcomes in endometroid or high-grade
serous ovarian cancer (Hu et al., 2018). Furthermore, prediction and testing of possibly
synergistic DNA damaging agents may improve pre-clinical results (Hu et al., 2018). In
conclusion, further pre-clinical testing in multiple pre-clinical models will be necessary to
determine the potency of targeting the DNA damage response in ARID1A mutant cancers.
ARID1A deletions were also found to cause a vulnerability to inhibitors of the
glutathione synthesis metabolic pathway (Gorrini & Mak, 2019; Ogiwara et al., 2019).
APR-246, a glutathione inhibitor, reduced tumor burden in an Arid1a mutant cancer
model, but not in an ARID1A wild-type in vivo model (Ogiwara et al., 2019). Additional
experiments also suggested that this pathway may include multiple synthetic lethal
options for targeting Arid1a mutant cancers. APR-246 has shown promise in p53
deficient acute myeloid leukemia and chronic lymphatic leukemia clinical trials
(Deneberg et al., 2016). Glutathione antioxidant synthesis is applicable to many ARID1A
depleted cancers, and further testing will be necessary to determine whether the effects
are cancer-type dependent or generally apply to ARID1A mutant cancers.
In summary, the downstream effects of ARID1A mutations will likely be cancer
specific, therefore requiring validation of each ARID1A mutated cancer type.
Furthermore, combinations of SL-SMIs and chemotherapeutics during pre-clinical testing
may provide the best prediction of the efficacy of these new precision medicines in
patients.
Cell Identity
One of the major burdens across cancer genetic and tumorigenesis fields is the
lack of identification of the cell of origin in many cancer types. In NBL, cell phenotypes
evaluated in clinical and basic research studies of patient tumors settings support the view
that this tumor type originates in sympathoadrenal precursors arising from the trunk
neural crest cell (NCC) lineage. Decades of developmental studies also support this
concept. Therefore, there is consensus in the NBL community that defines this cell type
as the most probable cell of origin of NBL. Recent advances in developmental research
have focused on thoroughly mapping decision branchpoints and defining gene expression
profiles in NCCs with the goal of specifying how cell fate decisions are made (Furlan et
al., 2017; Soldatov et al., 2019). These recent studies provide clarity to the regulation of
NCC identity during development and will be described in more detail in the discussion
section
The nervous system originates in the outermost embryonic layer, the ectoderm,
and is spawned from the neural tube (Squire et al., 2003). At this point, the central
nervous system is developed to innervate the brain and spinal cord, where branches of
neurons connect and communication among the three germ layers begins (Squire et al.,
2003). Next, the sympathetic nervous system (SNS) is born from the ectoderm (Squire et
al., 2003). The location at the origin of the neural crest specification restricts what fate
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the cells will acquire (Dupin, Creuzet, & Le Douarin, n.d.). There are four classifications
of neural crest cells: cranial, vagal, trunk, and sacral (Squire et al., 2003). Each of these
give rise to different categories of cells (Figure 1-1).
At mouse embryonic day 9.5 trunk NCCs positioned ventral to the developing
neural tube begin a migratory excursion initiated by a network of transcription factors.
The extensive migration of these NCCs result in the contribution to a variety of
specialized tissue types throughout the body. These include the heart, cranial facial
bones, melanocytes, adrenal chromaffin cells, sympathetic neurons and ganglia (enteric,
dorsal root, sympathetic, and parasympathetic) (Chan, Anderson, & Gonsalvez, 2018;
Squire et al., 2003). Trunk NCCs migrate throughout the body and form the SNS and
adrenal medulla. NBL arises predominately in the adrenal medulla, but may occur
anywhere along the parasympathetic ganglia, demarcating it as a cancer of the developing
SNS (Jiang et al., 2013; Schulte & Eggert, 2015). This review will focus on concepts and
cell types that comprise the SNS.
Neural crest cells
NCCs are found only in vertebrate organisms and migrate extensively during
development to give rise to the SNS. They arise at the “crest” of the closing neural tube,
ventral to the neural plate, at the border of epidermal ectoderm (Chan et al., 2018).
Extrinsic factors such as location of origin, timing of migration, cell-to-cell contact and
signaling greatly influence the internal TF cascades that determine each cell’s fate. Trunk
neural crest cells (NCCs) give rise to the developing SNS, which includes
parasympathetic and sympathetic ganglia (Schwann cells), sympathetic neurons, and
chromaffin cells of the adrenal medulla (Chan et al., 2018). These motile cells journey
throughout the body to eventually connect organs to their host. This connection serves to
prepare the body to respond to stimuli through endocrine signaling events of the adrenal
glands, resulting in a “fight or flight” response. The first step in the trunk NCC
differentiation process, is delamination, then migration to the developing dorsal aorta,
next, these cells coalesce, and receive signals that specify them to the sympathetic fate
(Etchevers, Dupin, & Le Douarin, 2019; Huber, 2015; Mirsky et al., 2008). Secreted
homing signals such as SDF-1, BMPs, and other cytokines and growth factors in the local
environment direct NCCs to their final destinations (Squire et al., 2003). Intracellularly,
TF master regulators such as SOX9, HAND2, GATA3, ASCL1, TCF4, SLUG and TWIST1
modulate cellular programs that determine localization and fate. NCCs are highly
adaptive, or plastic, requisite to the ability to respond to and thrive in the numerous
environmental conditions that must be adapted to during their extensive migratory
journey (Squire et al., 2003).
During pre-migration, NCCs morphology is epithelial, with columnar shape and a
polar apical top with strong cell-to-cell adhesion junctions (Squire et al., 2003).
Furthermore, the cells are multipotent prior to migration (Chan et al., 2018; Soldatov et
al., 2019). When the migratory program is initiated, NCCs undergo an epithelial to
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Figure 1-1. Schematic of neural crest origins.
(A) Schematic depicting the locations in the embryo that give rise to different varieties of
neural crest. Top to bottom: cranial (orange), vagal (blue), trunk (green), and sacral
(magenta).
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mesenchymal transition (EMT), losing cell-to-cell adhesion, adopting a fibroblastic shape
and motile behavior (Chan et al., 2018; Squire et al., 2003). During delamination, NCCs
begin demonstrating patterns of gene expression that indicate a fate bias (Soldatov et al.,
2019). The EMT program is initiated by a combination of epigenetic factors and TFs
(Bajpai et al., 2010). In zebrafish embryos, the pBAF complex (containing ARID2) was
shown to regulate the initiation of NCC migration, specification, and multipotency
through the TFs Twist1, Slug and Sox9 (Bajpai et al., 2010). These experiments
connected epigenetic regulators, particularly SWI/SNF, to the regulation of a cascade of
TFs involved in NCC EMT. This study also causally identified these TF genes as master
regulators of EMT migratory programs in the neural crest. One outstanding question
arising from this topic is how deregulation of the EMT migratory program contributes to
disease, specifically NBL and other crest-related pathologies.
NBL arises at different stages during early developmental, and presents with
many genetic lesions, resulting in substantial intratumoral, and intertumoral heterogeneity
(Boeva et al., 2017; Garrett M. Brodeur, 2003; van Groningen et al., 2017). A recent
study established that MNA NBL cell lines are addicted to transcription factors that are
up-regulated in this cancer sub-type (Durbin et al., 2018). Independent knockdown of the
up-regulated transcription factors led to a reduction of colony size in MNA cell lines, but
not controls (Durbin et al., 2018). These transcription factors have been linked to cell
identity during NCC development, and NBL disease progression. Addition studies have
worked to better define the cell identities in NBL tumors. One group worked to classify
three cell identities in a panel NBL tumors and cell lines (Boeva et al., 2017). Resulting
cell identity groups consisted of (I) noradrenergic, (II) NCC, and (III) mixed cell
identities (Boeva et al., 2017). Primary tumor samples were composed of mixed cell
identities, meaning both noradrenergic and NCC cells were present (Boeva et al., 2017).
They found that the NCC NBL identity was associated with recurrent super enhancers in
transcription factors that regulate mesenchymal cell identity (Boeva et al., 2017).
The second study characterized patient NBL tumors by sorting for stemness, then
identifying a “super-enhancer-associated transcription factor network” (van Groningen et
al., 2017). Two NBL patient samples were sorted by CD133 expression into positive and
negative groups and these cells were analyzed by whole-genome sequencing (van
Groningen et al., 2017). Two transcription factor gene signatures were developed from
the analysis: adrenergic (ADRN) and mesenchymal (MES) (van Groningen et al., 2017).
Both signatures included classic NBL markers. ADRN genes included the neuronal
signature master regulators DBH, GATA2, GATA3, PHOX2A, and PHOX2B (van
Groningen et al., 2017). MES genes included several EMT regulators SNAI2, VIM, FN1,
YAP1, SOX9 and PRRX1 (van Groningen et al., 2017). These signatures were consistent
with the super-enhancer regulated transcription factors identified previously (Boeva et al.,
2017). Furthermore, van Groningen et al. demonstrated that these two cell types could be
reprogrammed to interconvert, or trans-differentiate by enforcing an ADRN cell identity
to convert to an MES identity when PRRXI expression was enforced (van Groningen et
al., 2017). These results suggest that the MES cell type is more immature than the ADRN
complement, because the signature overlaps with a NCC EMT signature (van Groningen
et al., 2017). This study also suggested that both tumor types originate from an earlier
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stem-like precursor, although this initiating cell has not been identified. Furthermore,
these studies point to the importance of the master regulators controlling cell identity and
suggest that differential expression of these genes may influence NBL disease
progression and treatment outcomes.
Cancer models of initiating oncogenic events
The NBL field and other pediatric cancer fields establish their findings using
classic cancer models often developed by adult cancer specialists. This includes the use
of established cancer cell lines, or patient derived material (D. T. W. Jones et al., 2019).
Both are extremely powerful tools for high-throughput screening and drug development.
However, one weakness of these approaches is the lack of ability to identify and test
initiating events underlying the disease of interest. In the approaches listed above, the
cancer cells are already transformed, and additionally may have been exposed to
chemotherapeutics or other mutating events, complicating the interpretation of existing
mutations and how they contribute to the disease (Tsubota & Kadomatsu, 2018). In NBL,
genetically engineered mouse models (GEMMs) have laid a strong foundation for testing
possible cancer-initiating genetic events in isolation. One fundamental example of a
GEMM model that causally implicated MYCN as an oncogenic driver of NBL is the
mouse model developed by Weiss et al. (Weiss et al., 1997). This mouse model leverages
the TH promoter to drive MYCN expression in sympathetic neurons and is the most
widely used mouse model of NBL. However, it is challenging and time intensive to test,
screen and capture early transforming events, especially in a variety of combinations
using current GEMM approaches. An alternative approach to GEMM models in the NBL
field has been to induce NCCs from human stem cells (Huang et al., 2016). Although
promising, one limitation of primary cells is the challenge of matching culture conditions
to in vivo conditions, especially throughout many stages of developmental changes.
Another complication is the limited ability to expand and manipulate primary cells in
vitro using current engineering strategies. These challenges led to the development of an
additional cancer model that can complement the field’s current approaches to solving
developmental cancer questions, such as how normal cell identity is transformed into a
cancerous cell state.
Neural tube explants have been a classic method in the developmental field, and
extensive experimentation has been completed in drosophila, chick embryos, zebrafish,
and now mouse models (Squire et al., 2003). Applying the neural tube explant procedure
to existing GEMM applications allows GEMM and in vitro modifications to be employed
in one cell population while connecting in vivo and in vitro testing.
Previously, our laboratory developed a trunk NCC transformation technique using
neural tube explants. In the first iteration of this method, wild-type embryos were
generated, and at day 9.5, the embryos were harvested from the uterine horn. Next, the
neural tube was resected and placed in culture. Neural crest cells located on the trunk
migrated onto the dish for 48 hours before the neural tube was removed. Mycn
overexpression was enforced in vitro to recapitulate MNA, and the modified NCCs were
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flank injected back into mice. As expected, Mycn was sufficient to transform the primary
NCCs into a tumor that molecularly and pathologically recapitulated human MNA NBL
(Olsen et al., 2017).
One trait intrinsic to NCCs is their migratory ability (Chan et al., 2018; Etchevers
et al., 2019; Furlan et al., 2017; Squire et al., 2003). NCC migration properties, paired
with their progenitor cell plasticity, makes them well suited for studying early stages of
SNS development (Etchevers et al., 2019). The NCC model described above provides an
advantage to other established models by using NCCs at a stage of development where
they have undergone EMT and are primed to receive differentiation signals. Capturing
NCCs during this time allowed us to ask the question, what genetic lesions are
transformative in progenitor cells during development, and through what mechanisms?
The main approach in early experiments with this model has been to model NBL
chromosomal alterations and to test whether these abnormalities during early SNS
development redirect normal properties of NCCs into an un-regulated cancerous cell. The
ability to study the effects of genetic events, one at a time, or in combination, to inject the
cells, and generate tumor tissue and tumor derived cell lines (TDCLs) provides a tool that
combines developmental and cancer approaches. We have applied traits of NCCs to
enable systematic testing of the genetic events that underlie this disease of development.
At embryonic day 9.5 (e9.5), trunk NCCs follow either a dorsal or ventrolateral
migration stream (Squire et al., 2003). Between e9.5 and e11.5, mouse trunk NCCs
undergo a sequence of binary decisions that result in four different cell identities
(Soldatov et al., 2019). NCCs migrate in streams (Furlan et al., 2017). The flow of NCCs
continues through cell to cell, tail to head contact that results in a chain-like structure of
NCCs that allow other migrating NCCs to use as an internal ladder, or path to follow to
the more distant NCC population sites, such as the adrenal medulla (Squire et al., 2003;
Furlan et al., 2017). Recently, a landmark paper was published that highlighted how celltype-specific deletions influence adrenal medulla formation (Furlan et al., 2017). Using
cell fate mapping techniques in multiple mouse models, NCC chains were found to be
necessary for migratory cells to populate the adrenal medulla (Furlan et al., 2017).
Furthermore, mutation of the migratory cells also resulted in a lack of adrenal medulla
colonization (Furlan et al., 2017). These findings suggest that mutations in multiple cell
types that differentiate into the SNS may cause abnormal adrenal medulla pathology
(Etchevers et al., 2019; Furlan et al., 2017). However, the experiments presented by
Furlan, et al. were focused on developmental questions of SNS development, rather than
transformative events during development.
Defining the Critical Questions to Address
What is the oncogenic action of MYCN?
In normal development, a pulse of MYCN expression is necessary for enforced
proliferation of the developing SNS. One outstanding question is how MYCN expression
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transitions from pushing normal proliferation to causing deregulated oncogenic
proliferation. Amplification of MYCN in NBL is an established oncogenic event, but the
events that transpire to exert its oncogenic actions are not well understood (Rickman et
al., 2018; Zeid et al., 2018). One theory describes MYCN expression as additive, meaning
higher MYCN expression causes higher expression of its target genes, mostly those that
increase proliferation and stemness, therefore leading to uncontrolled growth (Rickman et
al., 2018). However, in 2017 an article was published that contributed an understanding
of MYCN that was crucial to addressing part of this question. MYCN has an established
role in binding promoters with canonical E-boxes. However, approximately 50 percent of
its binding sites are at non canonical E-boxes (Rickman et al., 2018). In NBL, MYCN was
shown to bind to the promoters of genes that are part of the NBL gene signature, such as
Hand2, Twist1, Phox2b, Ascl1, and Sox9 (van Groningen et al., 2017; Zeid et al., 2018).
This emerging evidence suggests that the aberrant binding of MYCN at enhancers may be
a potent part of how MYCN exerts its oncogenic activity (Rickman et al., 2018; Zeid et
al., 2018). The most current literature draws a picture depicting normal MYCN binding at
open promoters with conserved E-box sites, but when amplified, invading the open
enhancers of lineage factors, leading to tissue specific gene expression that is associated
with oncogenic behavior, or “oncogenic enhancer-driven transcription” (Zeid, 2018, Nat
Gen).
Does loss of Arid1a result in a synergistic relationship with MYCN?
Arid1a has been implicated as a TSG in numerous cancer types and has additional
roles in developmental models. During normal conditions, ARID1A has been identified as
necessary for the G2-S checkpoint, is present in the BAF complex, and has been shown
to regulate lineage commitment during hematopoiesis (Han et al., 2019; Kadoch et al.,
2013; Shen et al., 2015). One developmental study determined that complete ablation of
Arid1a resulted in a fewer SNS TH+ neurons in comparison to heterozygous Arid1a
deletion (Gao et al., 2008). A study of adult liver cancer identified overexpression of
ARID1A in primary tumor tissue, and loss of ARID1A in metastatic clones (Sun, Wang, et
al., 2017). Sun, et al. interpreted this result as an indication that ARID1A is a suppressor
of metastasis, but not initiation in their model (Sun, Wang, et al., 2017; Yoshida,
Sokoloff, Welch, & Rinker-Schaeffer, 2000). Studies involving ARID1A suggest that a
combination of methods and tools from multiple disciples will be necessary to further our
understanding of ARID1A. One question that is raised when considering whether
ARID1A has a TSG role in NBL, is what is the TSG function of ARID1A in this cancer?
Considering that this a disease of development, we hypothesized that ARID1A deletion
can contribute to the formation of mutant NCCs by altering normal differentiation
patterns and resulting in transformation into NBL. Approaching this question requires
tools that span the boundary of in vivo and in vitro studies and allow a model that enables
the transformation of primary cells. To accomplish this, techniques that bridge cancer
biology and developmental biology fields were modified and applied to this disease
context. The study of the ARID1A TSG in a dose dependent, tissue specific, and an NBL
sub-type specific cell state will allow the connection between the oncogenic effects of
MYCN and epigenetic deregulation due to Arid1a loss to be tested. Developing an
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approach to model and combine possible synergistic NBL initiating events is critical for
connecting the genetic lesions that underlie this aggressive and lethal sub-type of NBL to
NCC deregulation and transformation.
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CHAPTER 2.

METHODOLOGY

Neural Crest Cell Methods
Neural crest cell isolation
Neural crest cells were derived from Arid1a floxed mice (Gao et al., 2008). First,
two to three female mice were placed in individual cages, and in the afternoon of day 0,
one male mouse was place in each cage. The following morning, and day 0.5, the males
were all removed, and female mice were checked for plugs, and weighed with weights
and plugged status documented for each female. Plugged females were condensed into
the fewest possible cages, and breeding cards were updated. On day 8.5, in the afternoon,
the females are weighed again, and females gaining <1g were excluded from further
experimentation and added back to their original colony for monitoring. Females gaining
1g were palpated, and pregnant females were separated for embryo extraction.
The next morning on day 9.5, instruments and dissecting equipment were
sterilized for 15 minutes with 70% ethanol, and fresh Chemically Defined Medium
(CDM) was prepared (Fukuta et al., 2014). Embryos were dissected from each pregnant
female and placed in sterile PBS on ice. Embryos were kept on ice, and two at a time
were moved to the dissection scope for dissection. Embryonic sacs were removed, one by
one using sterile sharp tweezers, and extracted whole embryos were placed in a 60mm
rubber coated petri dish in sterile PBS using a blunted pipette. Once all embryos were
extracted, the neural tubes were dissected. Insect dissection pins were used to pierce the
eye and tail tip and extend the embryo, next a scalpel was used to separate the neural tube
and include somites 23-19. The cuts were made caudal to the heart, and .5cm from the
tail’s end. Each neural tube was extracted, and five were placed in each well of a 24-well
sterile tissue culture treated plate.
Next,1x collagenase and dispase (Sigma, 10269638001), was used to gently
dissociate the neural tube tissue during five minutes of titeration with a Pasteur pipette.
The dissociated neural tubes were rinsed in PBS and moved into individual wells
containing 50 μl of CDM. Next, a 20 μl pipette was used to transfer the embryo and ~10
μl of media to a fibronectin-coated 96-well tissue culture treated plate containing 100 μl
of CDM. In 4hrs, the neural tubes were observed for attachment to the plate, and an
additional 100 μl of CDM was added. At 48 hours following plating, the neural tubes and
tissue were removed from the plate and collected into individual sterile Eppendorf tubes,
leaving behind the attached populations of NCCs. At this point, additional media may be
added. The harvested neural tube tissue was subjected to genotyping for the floxed
Arid1a allele. The NCCs were monitored for confluency, and all of the cells were
accutased, alike genotypes were combined then plated in an appropriate-sized dish
(500,000 cells/10 cm fibronectin coated tissue culture petri dish). Media must be
refreshed every three days, and cell stocks need to be frozen as the highest priority. Next,
the cells were expanded and modified for experiments, and mouse injections.
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Modification of neural crest cells
Neural crest cells were cultured in CDM, genotyped, pooled by genotype, and
transduced with Adeno-Empty-iGFP or Adeno-CRE-iGFP virus at MOI of 3 or 11,
respectively (virus purchased from University of Iowa viral vector core Ad-GFP # VVCU of Iowa-4, Ad5CMVeGFP; Ad-Cre-GFP #VVC-U of Iowa-1174, Ad5CMVCreeGFP). Cells were sorted at 72 hours post transduction for GFP expression, and resulting
Arid1a+/flox, Arid1a+/-, Arid1aflox/fox, or Arid1a-/- cells were cultured up to 12 passages.
Neural crest cell derivation was previously described (Olsen et al., 2017).
Tumor measurement cutoffs and statistics
Tumor measurements began when tumors were approximately 5mm x 5mm.
Tumor initiation was considered complete at 300 mm3, and survival end points were
measured at 1500 mm3. Animals were humanely euthanized according to SJCRH
IACUUC regulation standards. Study measurements were reported at 300 mm3 and 1500
mm3 and statistics were calculated at these time points.
Tumor studies in SCID mice
The following primary cell isolations were used for the experiments in SCID
mice. Arid1a+/flox (WT), Arid1a+/- (HET) (isolated 10/15/2017 plate 3), Arid1aflox/fox
(WT), or Arid1a-/- (KO) (isolated 8/15/2016). The primary NCCs were transduced for 24
hours with MYCN-iRES-GFP virus (viral prep10/29/2013; Addgene #35394) at an MOI
of 1. Cells at 85% confluence were resuspended using accutase and counted, then
pelleted and resuspended in 1:1 PBS and Matrigel. Female severely compromised
immunodeficient (SCID) mice from Taconic were purchased at 6 weeks of age and
quarantined for 1 week before subcutaneous injections (C.B-Igh-1b/IcrTac-Prkdcscid).
Mice were anesthetized with isofluorane for 5 minutes and injected on the right flank
subcutaneously with a two-fold titration beginning with 6 x106 cells, down to 0.75 x106
cells per mouse.
Tumor studies in nude mice
Female homozygous athymic nude mice (Crl:NU-Foxn1nu) were purchased from
Jackson Laboratories at 6 weeks of age (Cat #088), held for at least one week before
injecting with Arid1a+/flox, Arid1a+/-, Arid1aflox/fox, or Arid1a-/- primary neural crest cells
transduced for 24 hours with MYCN-iRES-RFP virus at an MOI of 3 (Addgene #35393).
Cells at 85% confluence were resuspended using accutase and counted, then pelleted and
resuspended in 1:1 PBS and Matrigel. Mice were anesthetized with isofluorane for 5
minutes and injected on the right flank subcutaneously with 1.5 x106 cells per mouse.
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Tumor harvest procedure
In all animal studies, tumors were measured every other day, beginning at 200
mm3, and mice were euthanized when tumors reached 2000mm3. All animal studies
were conducted in compliance with protocols approved by the St Jude Children’s
Hospital Institutional Animal Care and Use Committee. Tumors were harvested
immediately following euthanasia for all experiments. At harvest, one cross section was
placed in 4% neutral buffered paraformaldehyde for immunohistochemistry analysis. The
remaining tumor was sectioned into 1mm pieces in a dish containing chemically defined
media, and distributed into tubes for protein, RNA, and DNA processing before being
flash frozen in liquid nitrogen, and was also distributed into tubes containing freezing
medium (CDM + 10% DMSO) before subsequent cryopreservation for viable cell
storage.
Derivation of cell lines from fresh tumor sample
To derive tumor cell lines, the remaining media from the harvest was collected,
and live cells were pelleted, and resuspended in red blood cell lysis buffer for 10 minutes
with brief vortexing at 0, 5, and 10 minutes. Cells were re-pelleted, and resuspended in
CDM + 20% FBS, plated on fibronectin coated 10 cm dishes, and maintained at 37ºC 5%
CO2 with 5 mL of media added the following day, and changed the second day. Media
patterns (fresh media on day 0, add 5 mL of media on day 1, full media change on day 2)
were followed until samples were confluent and frozen in stocks.
Neuroblastoma Cell Lines
SK-N-AS, SY5Y, SK-N-SH, SK-N-DZ, Kelly, IMR-32, and SK-N-BE2 were
purchased from American Type Culture Collection (ATCC) and cultured according to
manufacture instructions. A table listing a summary of genetic information from Harenza,
et al. for MYCN and 1p36 status in common neuroblastoma cell lines are listed in
Appendix A Table A-1 (Harenza et al., 2017).
Pathology and IHC Analyses
Tumors were fixed in 10% neutral buffered formalin, embedded in paraffin,
sectioned at 4 μm, stained with hematoxylin and eosin (HE). All formalin-fixed,
paraffin-embedded (FFPE) tissues were sectioned at 4 μm, mounted on positive charged
glass slides (Superfrost Plus; Thermo Fisher Scientific, Waltham, MA), and dried at 60°C
for 20 minutes. The IHC procedures and antibodies used for mouse tissue to detect
protein markers are listed in Table A-2. All HEs and IHCs were reviewed by light
microscopy and interpreted by a board-certified veterinary pathologist Dr. Heather
Tillman (HT). IHCs were scanned at a 20x (objective lens) magnification using an
Aperio ScanScope XT scanner. Immunoreactivity was quantified as a weighted IHC

19

score (0-300) using a modified version of the Color Deconvolution algorithm and
ImageScope software (Leica Biosystems).
Immunoblotting
Detailed descriptions that are project-specific may be found in Chapters 3 and 4.
In summary, samples were collected either by centrifugation for five minutes at 3,000
RCF at 4°C, were resuspending in PBS, then centrifugation was repeated. PBS was
aspirated, and pellets were frozen until further processing. Otherwise, samples were
collected on ice by washing 1x with PBS, then adding RIPA buffer (Thermo Scientific,
PI89900) and 2x Halt Protease Phosphatase inhibitor. Samples were scraped into a tube,
vortexed for 10 seconds and lysed for 20 minutes rotating at 4ºC. Samples were sonicated
for 10 second intervals totaling 30 seconds, then lysates were cleared by centrifugation.
Samples were incubated for 30 minutes in 1x SDS-loading buffer with 9% BME and
50ug of total lysate was separated by gel electrophoresis on 4-20% tris-glycine gels
(BioRad #4561094) at 300V for 25 minutes. Samples were transferred according to
protein size. PVDF Membranes were blocked for 1 hour at room temperature (RT) in
PBS .1% Tween 20 (PBST)/5% (w/v) milk. Membranes were probed with primary
antibodies incubated o/n at 4ºC with gentle shaking. Next, membranes were washed with
PBST and incubated with secondary antibody (1:4000, Cell Signaling Technologies) in
PBST/5% (w/v) milk for 1 hour at RT. Membranes were washed in PBST and protein
signal was detected using chemiluminescent substrate (Genesee Scientific #20-302).
Antibody concentrations and protein sizes reference Table A-3.
RNA-Sequencing
Tumor tissues were flash frozen in liquid nitrogen and stored at -80°C. The
Qiagen RNeasy kit was used to purify RNA from tissue samples. Approximately 15 ug of
tumor tissue was resected and homogenized for one minute in Qiagen buffer RLT plus
βME. Next, 800 ul were removed, and samples were spun down for 5 minutes at 3000
rpm. Supernatant was removed, and 600 ul was passed through a Qiashredder column.
Each tumor type was represented in biological quadruplicates. Samples were eluted in 50
ul of RNAse/DNAse free water, and 500 ng/sample was given to the Hartwell Center at
St Jude CRH for an RNA purity check, and RNA sequencing analysis.
Processing of RNA-sequencing results
Bioinformatics data processing and analysis was performed by Jeremiah Holt.
FASTQ files were aligned to the mm10 genome and transcript level estimates were
generated with counts in units of transcripts per million (TPM). Next, transcripts with
less than ten total counts across all samples were filtered, and the remaining genes were
normalized and log2 transformed using the regularized log transformation (rlog) function
in the DESeq2 R package (M. I. Love, Huber, & Anders, 2014). Samples were then
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averaged to give mean expression values for the remaining genes for each experimental
group. DESeq2 and all downstream analyses were conducted using R version 3.6.1 (R
Core Team, 2019).
Differential gene expression analysis
The DESeq2 package was employed again to analyze genes that were
differentially expressed between sample groups. DEGs were generated based on three
comparisons of experimental groups: HET vs WT1, KO vs WT2, and HET vs KO. Log2
fold changes and adjusted P-values (Benjamini-Hochberg correction) were then used for
downstream analyses.
Consensus clustering and unsupervised analysis
For unsupervised clustering of the normalized gene expression data, we first
limited the gene set to only include those that were most variable with a median absolute
deviation (MAD) greater than the 75th percentile. Next, ConcensusClusterPlus was
implemented using the hierarchical clustering method with average linkage and one
minus the Pearson’s correlation coefficient as the distance measure, and k=2 clusters was
used for downstream analysis (Wilkerson & Hayes, 2010).
Supervised analyses
A supervised approach was employed using previously reported gene sets
characterizing genetic signatures in neuroblastoma. The first used a predictor based on
the MES and ADRN gene sets generated from human neuroblastoma cells (van
Groningen et al., 2017). For the purposes of applying this predictor to a murine model,
we used only the genes from the MES and ADRN sets that had orthologs in the murine
genome. Next, we applied an integrative correlations method to select only those genes
which displayed similar expression patterns between the human and mouse models
(Parmigiani, Garrett-Mayer, Anbazhagan, & Gabrielson, 2004). Only the genes with
positive integrative correlation coefficients (ICC) were used for the mouse predictor, and
three genes were omitted due to the MES and ADRN labels having inconsistent results
with the human predictor. A gene set enrichment analysis was then conducted for the new
MES and ADRN gene signatures derived from the murine predictor (Olsson et al., 2011;
Subramanian et al., 2005). The second supervised approach used a mesenchymal gene
signature and a list of neuroblastoma master regulator genes from (Furlan et al., 2017) to
visualize differences in gene expression between sample groups based on previously
characterized genes.
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CHAPTER 3.

ARID1A IS A CRITICAL TUMOR SUPPRESSOR GENE IN 1P36
DELETED, MYCN AMPLIFIED NEUROBLASTOMA
Introduction

Neuroblastoma is the most common extracranial pediatric solid tumor, and
accounts for 15 percent of all pediatric cancer deaths (Maris, 2010; Maris, Hogarty,
Bagatell, Cohn, & Susan, 2007). High-risk (HR) NBL patient survival remains poor,
between 30-50% (Cohn et al., 2009; Maris, 2010). These poor outcomes are a result of
multiple tumor characteristics including heterogeneity that is characterized by a multitude
of chromosomal gains, translocations, and deletions that result in aggressive and difficult
to treat disease. Fifteen to thirty three percent of NBL patients are affected by one
subtype of high risk NBL that is driven by the oncogenic event MYCN amplification
(MNA) (Garrett M. Brodeur, 2003; Davidoff, 2012; Jiang et al., 2013; Nakagawara et al.,
2018; Rickman et al., 2018)). The majority of HR MNA cases include 1p36 loss of
heterozygosity (LOH), and this genetic lesion is found in 35% of overall NBL patients
(Garrett M. Brodeur, 2003). Due to the high rates of 1p36 LOH in NBL patients, LOH at
1p36 is expected to be an initiating event in MNA NBL. Furthermore, patients with 1p36
LOH and MNA have poor overall survival (46%) relative to patients with 1p36 deletions
alone (85%) (Attiyeh et al., 2005). Decades of sequencing studies have led to a list of
putative 1p36 tumor suppressor genes (TSGs) including CASZ1, P75, CAMTA1, and
CHD5 (Garrett M. Brodeur, 2003). However, despite mapping efforts, the critical 1p36
TSGs that collaborate with MYCN in NBL initiation remain unidentified.
One issue complicating the identification of 1p36 TSGs in NBL cases with MNA
and 1p36 heterozygous deletions, is that point mutations have rarely been identified on
the second allele for any putative TSGs. This suggests that loss of a single allele of the
1p36 TSG candidate is sufficient to promote tumor initiation or progression (Garrett M.
Brodeur, 2003; Caron et al., 1995; Jiang et al., 2013). Therefore, we predict that the 1p36
TSG demonstrates haploinsufficiency. In 2013, following whole genome and whole
exome sequencing analysis of a large NBL patient cohort, Sausen et al discovered point
mutations in the TSG Arid1a, which highlighted Arid1a as a putative 1p36 TSG (Sausen
et al., 2013). Recently, an additional study confirmed Arid1a as a 1p36 gene of interest in
MYCN-driven NBL(García-López et al., 2020). Garcia-Lopez, et al engineered large
1p36 deletions in combination with MNA, and identified significant deletions in Arid1a
were enriched in the final tumors of a tumor evolution study (García-López et al., 2020).
Arid1a is a TSG candidate that is frequently mutated across 25 adult and pediatric
cancer types including NBL (R. C. Wu et al., 2014). Arid1a is the DNA-binding subunit
of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex and
in cancer, is the most commonly mutated member of this multi-subunit complex (S. Jones
et al., 2012; Kadoch et al., 2013; Wiegand et al., 2010). Studies completed in adult cancer
models have provided substantial evidence that Arid1a is a context specific TSG and a
regulator of cell renewal and identity (Flavahan et al., 2017; Huether et al., 2014; Mathur,
2018; Sun, Chuang, et al., 2017). Epigenetic remodelers are the most frequently mutated
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genes in pediatric cancers, however, pediatric cancer studies focused on Arid1a mutations
have not been explored. The growing evidence of Arid1a mutations as a TSG in many
cancer types highlight the necessity of causal Arid1a studies in the correct cellular
context. Therefore, it is necessary to characterize Arid1a mutations in a pediatric cancer
model of MYCN-driven NBL.
NBL is a disease of development that arises from trunk neural crest cells (NCCs)
(Jiang et al., 2013). Trunk NCCs are a highly migratory population of progenitor cells of
the developing sympathetic nervous system (SNS). During normal development NCCs
undergo an epithelial to mesenchymal transition (EMT), migrate, then specify into the
SNS (Furlan et al., 2017; Jiang et al., 2013; Kuo & Erickson, 2010). During development,
NCCs transiently express high levels of N-Myc (day 9.5), before gradual downregulation,
differentiation, and quiescence (Jiang et al., 2013; Zimmerman et al., 1986). Arid1a is
also expressed at day 9.5 NCCs, (Chandler & Magnuson, 2016), and is necessary for
proper development of NCC derived cell types (Chandler & Magnuson, 2016; Gao et al.,
2008). Taken together, results suggest that Arid1a deletions are expected to deregulate
enhancers and subsequently disrupt normal lineage commitment. The proposed
mechanism of Arid1a mutation mediated oncogenic action is via a block development,
expected to result in a highly proliferative population of mutant progenitor cells (Eroglu
et al., 2014; Mathur, 2018; B. G. Wilson et al., 2010; M. R. Wilson et al., 2019). The
regulated expression of Arid1a and MYCN have been validated independently and both
were determined as necessary for lineage commitment of NCCs. However, one question
that remains is whether Arid1a deletions paired with MYCN OE confers a tumorigenic
advantage during NBL initiation. To provide the appropriate modeling of this
combination of mutations, it is necessary to employ both cancer and developmental
approaches.
The body of work presented in this study aimed to combine foundational tools of
both developmental and cancer biology into a novel mouse model of pediatric cancer.
This study sought to determine if Arid1a loss is a driver of NCC transformation that
collaborates with MYCN overexpression (OE) in NBL tumorigenesis. To address this
question, we generated primary trunk NCCs, introduced Arid1a heterozygous or
homozygous deletions, then enforced MYCN OE to generate NBL as previously
described (García-López et al., 2020; Olsen et al., 2017). Next, these modified cells were
subcutaneously injected into immunocompromised mice and tumorigenesis was
evaluated. Here, we systematically test Arid1a wild-type, heterozygous, and knockout
(WT, HET, KO) doses in NCCs combined with MYCN OE. Next, tumorigenesis, tumor
lineage commitment, and primary cell differentiation were evaluated. Finally, multiple
sequencing techniques were used to cross-validate the genes that were mutated or
aberrantly regulated as a consequence of Arid1a and MYCN genetic lesions.
Implementation of a developmental cancer model, downstream sequencing analysis,
expression analysis of primary cells and tumors, and functional studies before and after
transformation resulted in the identification of disrupted transcription factor signaling
circuits that are critical to the control of EMT and cell identity.
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Materials and Methods
Cell culture
Neural crest cells were derived from Arid1a floxed mice, bred to generate day 9.5
embryos before neural tube excision and culture. Neural crest cells were cultured in
chemically defined media, genotyped, pooled by genotype, and transduced with EmptyiGFP or CRE-iGFP virus at MOI of 3 or 11, respectively. (Virus purchased from
University of Iowa viral vector core Ad-GFP # VVC-U of Iowa-4, Ad5CMVeGFP; AdCre-GFP #VVC-U of Iowa-1174, Ad5CMVCre-eGFP). Cells were sorted at 72 hours
post transduction for GFP expression, and resulting Arid1a+/flox, Arid1a+/-, Arid1aflox/fox,
or Arid1a-/- cells were cultured up to 12 passages. Neural crest cell derivation and was
previously described (Olsen, 2017, Oncogene), and enforced MYCN expression was
previously described (Olsen, 2017, Oncogene; Garcia-Lopez, 2020, Cell Reports).
Tumor studies in SCID and nude mice
Arid1a+/flox, Arid1a+/-, Arid1a flox/fox, or Arid1a-/- primary neural crest cells
transduced for 24 hours with MYCN-GFP virus at an MOI of 1. Cells at 85% confluence
were resuspended using accutase and counted, then pelleted and resuspended in 1:1 PBS
and Matrigel. Female severely compromised immunodeficient (SCID) mice from Taconic
were purchased at 6 weeks of age and quarantined for 1 week before subcutaneous
injections (C.B-Igh-1b/IcrTac-Prkdcscid). Mice were anesthetized with isofluorane for 5
minute and injected on the right flank subcutaneously with a two fold titration beginning
with 6 x106 cells, down to 0.75 x106 cells per mouse.
Female homozygous athymic nude mice (Crl:NU-Foxn1nu) were purchased from
Jackson Laboratories at 6 weeks of age (Cat #088), held for at least one week before
injecting with Arid1a+/flox, Arid1a+/-, Arid1aflox/fox, or Arid1a-/- primary neural crest cells
transduced for 24 hours with MYCN-RFP virus at an MOI of 3 (Addgene #35393). Cells
at 85% confluence were resuspended using accutase and counted, then pelleted and
resuspended in 1:1 PBS and Matrigel. Mice were anesthetized with isofluorane for 5
minutes, and injected on the right flank subcutaneously with 1.5 x106 cells per mouse.
Tumors were harvested immediately following euthanasia. At harvest, one cross
section was placed in 4% neutral buffered paraformaldehyde for immunohistochemistry
analysis. The remaining tumor was sectioned into 1 mm pieces in a dish containing
chemically defined media, and distributed into tubes for protein, RNA, and DNA
processing before being flash frozen in liquid nitrogen, and was also distributed into
tubes containing freezing medium (CDM + 10% DMSO) before subsequent
cryopreservation for viable cell storage.
To derive tumor cell lines, the remaining media from the harvest was collected,
and live cells were pelleted, and resuspended in red blood cell lysis buffer for 10 minutes.

24

Cells were re-pelleted, and resuspended in CDM + 20% FBS, plated on fibronectin
coated 10 cm dishes, and maintained at 37ºC 5% CO2 with media added the following
day, and changed the third day.
In all animal studies, tumors were measured every other day, beginning at 200
mm3, and mice were euthanized when tumors reached 2000 mm3. All animal studies
were conducted in compliance with protocols approved by the St Jude Children’s
Hospital Institutional Animal Care and Use Committee.
Immunofluorescence
Primary neural crest cells were cultured in chemically defined media, and plated
in fibronectin coated 8-well chamber slides (ibidi cat #80826) at confluence. The next
day, media was aspirated, and cells were wasted with PBS. Neuronal differentiation
media was added and refreshed every three days for seven days. The differentiated
samples were rinsed 1x with PBS, and 4% neural buffered paraformaldehyde was added
for 10 minutes. Samples were then rinsed with PBS before ice cold 100% methanol was
applied for 30 minutes. Samples were briefly rinsed with PBST before a 10 minute
incubation with Triton-X and a 30 minute block in 5% donkey serum. Primary
antibodies were diluted in 5% donkey serum, Arid1a (1:500 CST #12354) and MAP2
(1:2000 abcam ab5392) and incubated overnight at 4ºC. Wells were washed 1x with
PBST before adding Alexa 555 anti-rabbit and Alexa 488 anti-chicken conjugated
secondaries (both at 1:1000 invitrogen A32794, A-11039) at room temperature for 1
hour. Secondary antibodies were removed and wells were washed 3x with PBST before
adding DAPI (0.7 ug/ul) in PBS for 10 minutes, and mounting in PPD mounting media
overlayed with mineral oil. Samples were analyzed under a fluorescent microscope, and
at least 300 cells were assayed per sample in each experiment.
Immunoblotting
Samples were collected on ice by washing 1x with PBS, then adding RIPA buffer
(Thermo Scientific, PI89900) and 2x Halt Protease Phosphatase inhibitor. Samples were
scraped into a tube, vortexed for 10 seconds and lysed for 20 minutes rotating at 4ºC.
Samples were sonicated for 10 second intervals totaling 30 seconds, then lysates were
cleared by centrifugation. Samples were incubated for 30 minutes in 1x SDS-loading
buffer with 9% BME and 50 ug of total lysate was separated by gel electrophoresis on 420% tris-glycine gels (BioRad #4561094) at 300V for 25 minutes. Samples were
transferred according to protein size. PVDF membranes were blocked for 1 hour at room
temperature (RT) in PBS .1% Tween 20 (PBST)/5% (w/v) milk. Membranes were probed
with primary antibodies incubated o/n at 4ºC with gentle shaking. Next, membranes were
washed with PBST and incubated with secondary antibody (1:4000, Cell Signaling
Technologies) in PBST/5% (w/v) milk for 1 hour at RT. Membranes were washed in
PBST and protein signal was detected using chemiluminescent substrate (Genesee
Scientific #20-302). Antibody concentrations and protein sizes reference Table A-3.
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Immunohistochemical staining and analysis
Samples were processed according to St Jude histology core protocol and
analyzed by board certified veterinary pathologist (HT) using color deconvolution
(Aperio sofware) described below:
Tumors were fixed in 10% neutral buffered formalin, embedded in paraffin,
sectioned at 4 μm, stained with hematoxylin and eosin (HE). All formalin-fixed,
paraffin-embedded (FFPE) tissues were sectioned at 4 μm, mounted on positive charged
glass slides (Superfrost Plus; Thermo Fisher Scientific, Waltham, MA), and dried at 60°C
for 20 minutes. The IHC procedures and antibodies used for mouse tissue to detect
protein markers are listed in Table A-2. All HEs and IHCs were reviewed by light
microscopy and interpreted by a board-certified veterinary pathologist (HT). IHCs were
scanned at a 20x (objective lens) magnification using an Aperio ScanScope XT scanner.
Immunoreactivity was quantified as a weighted IHC score (0-300) using a modified
version of the Color Deconvolution algorithm and ImageScope software (Leica
Biosystems).
Migration assays
Tumor derived cell lines were cultured in chemically defined media, accutased,
counted, and resuspended at 1 x106 cells per mL. The experiment was performed
according to the manufacturer’s protocol, and 300 ul of the suspension was plated per
boyden chamber. In the well, 500 μl of CD media containing 10% fetal bovine serum was
added. Samples were incubated at 37ºC 5% CO2 for 24 hours, then analyzed by crystal
violet staining followed by colorimetric analysis according to manufacturer protocol (Cell
biolabs #CBA-100).
RNA-sequencing sample processing
Tumor tissues were flash frozen in liquid nitrogen and stored at -80. The Qiagen
RNeasy kit was used to purify RNA from tissue samples. Approximately 15 ug of tumor
tissue was resected, and homogenized for one minute in Quiagen buffer RLT plus βME.
Next, 800 ul were removed, and samples were spun down for 5 minutes at 3000 rpm.
Supernatant was removed, and 600 ul was passed through a Qiashredder column. Each
tumor type was represented in biological quadruplicates. Samples were eluted in 50 ul of
RNAse/DNAse free water, and 500 ng/sample was given to the Hartwell Center at St
Jude CRH for an RNA purity check, and RNA sequencing analysis.
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Processing of RNA-sequencing results
FASTQ files were aligned to the mm10 genome and transcript level estimates
were generated with counts in units of transcripts per million (TPM). Next, transcripts
with less than ten total counts across all samples were filtered, and the remaining genes
were normalized and log2 transformed using the regularized log transformation (rlog)
function in the DESeq2 R package (M. I. Love et al., 2014). Samples were then averaged
to give mean expression values for the remaining genes for each experimental group.
DESeq2 and all downstream analyses were conducted using R version 3.6.1 (R Core
Team, 2019).
Differential gene expression analysis
The DESeq2 package was employed again to analyze genes that were
differentially expressed between sample groups. DEGs were generated based on three
comparisons of experimental groups: HET vs WT1, KO vs WT2, and HET vs KO. Log2
fold changes and adjusted P-values (Benjamini-Hochberg correction) were then used for
downstream analyses.
Consensus clustering and unsupervised analysis
For unsupervised clustering of the normalized gene expression data, we first
limited the gene set to only include those that were most variable with a median absolute
deviation (MAD) greater than the 75th percentile. Next, ConcensusClusterPlus was
implemented using the hierarchical clustering method with average linkage and one
minus the Pearson’s correlation coefficient as the distance measure, and k=2 clusters was
used for downstream analysis (Wilkerson & Hayes, 2010).
Supervised analyses
A supervised approach was employed using previously reported gene sets
characterizing genetic signatures in neuroblastoma. The first used a predictor based on
the MES and ADRN gene sets generated from human neuroblastoma cells (van
Groningen et al., 2017). For the purposes of applying this predictor to a murine model,
we used only the genes from the MES and ADRN sets that had orthologs in the murine
genome. Next, we applied an integrative correlations method to select only those genes
which displayed similar expression patterns between the human and mouse models
(Parmigiani et al., 2004). Only the genes with positive integrative correlation coefficients
(ICC) were used for the mouse predictor, and three genes were omitted due to the MES
and ADRN labels having inconsistent results with the human predictor. A gene set
enrichment analysis was then conducted for the new MES and ADRN gene signatures
derived from the murine predictor (Olsson et al., 2011; Subramanian et al., 2005). The
second supervised approach used a mesenchymal gene signature and a list of
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neuroblastoma master regulator genes from (Furlan et al., 2017) to visualize differences
in gene expression between sample groups based on previously characterized genes.
Results
Haploinsufficient Arid1a is a driver mutation that collaborates with MYCN in NBL
tumorigenesis
Arid1a mutations in a variety of cancers suggest that it is haploinsufficient in
some contexts and homozygous in others (J. N. Wu & Roberts, 2013). 1p36 LOH can
occur in patients without MYCN amplification, however, MYCN amplification is rarely
present without 1p36 LOH (Garrett M. Brodeur, 2003; Jiang et al., 2013). This suggests
1p36 LOH may provide an environment for MYCN amplification (Jiang et al., 2013). Our
laboratory previously identified Arid1a as potential MYCN-driven NBL TSG using
CRISPR to screen for candidates that increase tumorigenesis in combination with MYCN
overexpression (García-López et al., 2020). As reported previously, Arid1a deletion alone
does not cause tumorigenesis in NCCs (García-López et al., 2020). To validate and
explore the role of Arid1a deletions in MYCN-driven NBL in detail, we employed the
most published Arid1a mouse model which contains floxed sites at exon 8 that cause
nonsense-mediated mRNA decay as a result of CRE-mediated excision (Gao et al., 2008;
Sun, Chuang, et al., 2017; Sun, Wang, et al., 2017; S. C. Wang et al., 2019). Arid1aFl/Wt
and Arid1aFl/Fl mice were used to generate NCCs according to a previously described
method (Olsen et al., 2017). NCCs were pooled by genotype, and floxed Arid1a sites
were deleted before overexpressing MYCN. This approach generated two matched sets of
primary NCCs: 1). Arid1aFl/Wt+MYCN (WT1) and Arid1a-/Wt+MYCN (HET), or 2).
Arid1aFl/Fl+MYCN (WT2) and Arid1a-/-+MYCN (KO) (Figures 3-1A and B-1). To
determine whether Arid1a deletion and MYCN OE recapitulated the synergy expected
from a 1p36 LOH TSG, we evaluated the kinetics of primary cell transformation in our
NCC transformation model via a limiting dilution in vivo study. Previously published
reports in melanoma cells determined stemness using a rate-limiting dilution series down
to 1 initiating cell (Quintana et al., 2008). Using our modified primary cells, we tested a
2-fold dilution series from 6 x106 to 0.75 x106 cells per mouse to determine if restricting
cell number would exacerbate tumor initiation potential and identify if any stem-like
qualities were present in the different groups.
Tumor kinetics at tumor onset (300 mm3) and tumor endpoint (1500 mm3) were
analyzed. Kaplan-Meier curve and statistical analysis indicated significantly reduced
latency in the groups injected with 1.5 x106 and .75 x106 cells per mouse relative to WT1
(Figure 3-1D and E). WT1 cells resulted in 71% overall penetrance (WT1, n=10/14)
while HET cells resulted in 100% penetrance (HET, n=14/14), and time until tumor
initiation (300 mm3) was a median of 90.5 days in WT1and 56 days in HET across all
mice in the study (Figure 3-2A). Both WT1 and HET end-point tumors were highly
proliferative, as measured by immunohistochemistry (IHC) of Ki67 and phospho-
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Figure 3-1. Heterozygous Ardi1a deletion increases transformation kinetics of
Mycn overexpression in primary trunk NCCs.
(A) Arid1aflox/wild-type and Arid1aflox/flox NCCs were generated from Arid1a floxed mice.
Next, adeno-gfp or adeno-cre virus was used to transduce floxed cells in vitro, Mycn was
overexpressed (Mycn OE) using retrovirus, and cells were flank injected into mice.
(B-E) Matched pairs of Arid1aWT1 or Arid1aHET NCCs + Mycn OE were injected in a 2x
limiting dilution series into SCID mice. Kaplan–Meier plot of end point tumor growth
kinetics (1500mm3) in WT1vs HET using NCCs injected at the following numbers in
each mouse
(B) 6e6 (n = 3 per group), ns. p = 0.343,
(C) 3e6, (n = 4 per group), ns. p = 0.241
(D) 1.5e6, (n = 4 per group), *p = 0.027 and
(E) 0.75e6 (n = 3 per group), *p = 0.025
(F-I) Matched pairs of Arid1aWT2 or Arid1aKO NCCs + Mycn OE were injected in a 2x
limiting dilution series into SCID mice. Kaplan–Meier plot of end point tumor growth
kinetics (1500mm3) in WT2 vs KO using NCCs injected at the following numbers in each
mouse
(F) 6e6 (n = 3 per group), ns. p = 0.110,
(G) 3e6, (n = 4 per group) ns. p = 0.268
(H) 1.5e6, (n = 4 per group) ns. p = 0.248 and
(I) 0.75e6 (n = 3 per group), ns. p = 0.110.
p-values were calculated using the Log-rank (Mantel-Cox) test; (*p ≤ 0.05, ** p ≤ 0.01).
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Figure 3-2. Grouped data recapitulates trends in Kaplan-Meier limiting dilution
graphs.
(A) Grouped data from Figure 3-1 limiting dilution series for WT1 and HET. Kaplan–
Meier plot of end point tumor growth kinetics (1500 mm3) in HET vs WT1; total mice
injected per group (n = 14) **p = 0.004.
(B and C) Quantification of WT1 vs HET tumors at endpoint following IHC for
proliferative markers Ki67 (WT1 n = 9, HET = 14) *P = 0.039 and p-HistoneH3 (WT1 n
= 9, HET = 14) ns. p = 0.336. Samples were analyzed by color deconvolution analysis.
Points represent staining and quantification from individual tumors.
(D) Grouped data from Figure 3-1 limiting dilution series for WT2 and KO. Kaplan–
Meier plot of end point tumor growth kinetics (1500 mm3) in WT2 vs KO; total mice
injected per group (n = 14) ns. p = 0.093.
(E and F), Quantification of WT2 vs KO tumors at endpoint following IHC for
proliferative markers Ki67 (WT2 n = 8, KO n = 7) ns. p = 0.054 and p-HistoneH3 (WT2
n = 4, KO n = 2) ns. p = 0.800. Samples were analyzed by color deconvolution analysis.
Points represent staining and quantification from individual tumors.
(G), DNA genotyping analysis of Arid1a in representative tumor derived cell lines
derived from endpoint tumors. Primary cells were used as controls.
Grouped tumor study p -values were calculated using the Log-rank (Mantel-Cox) test;
Ki67 and pH3 analysis generated P-values using Mann Whitney test (*p ≤ 0.05, **p ≤
0.005). IHC Score = 1.0*(%Weak) + 2.0*(%Medium) + 3.0*(%Strong). IHC =
immunohistochemistry, pH3 = p-HistoneH3. Fl = intact Arid1a floxed allele at 845 bp.
WT = intact Arid1a wild-type allele at 669 bp. KO = excised Arid1a allele (HET) or
alleles (KO) at 298 bp.
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histone3 (pH3) analysis (Figure 3-2B and C). To further investigate the effects of
homozygous loss of Arid1a, we performed the same experiment in a matched pair of
NCCs to compare WT2 versus KO tumor growth characteristics. We found no significant
differences in tumor latency in KO compared to WT2 analyzed at tumor onset (300mm3)
and tumor endpoint (1500 mm3) in any of the four cell dilutions tested (Figure 3-1E and
H). However, KO tumors did have an increased penetrance of 100% (KO, n=14/14)
compared to the WT2 group’s overall penetrance of 79% (WT2, n=11/14). Time until
tumor initiation across all WT2 samples was a median of 55.5 days and 47 days in KO
(Figure 3-2D). Furthermore, tumors were highly proliferative, which was measured by
IHC against Ki67 and pH3 molecular markers (Figure 3-2E and F). To confirm that the
initial Arid1a deletions were maintained throughout tumorigenesis, tumor derived cell
lines (TDCLs) from representative samples were subjected to genotyping analysis, which
confirmed the expected Arid1a status in the samples analyzed (Figure 3-2G). These data
suggest a dose dependent requirement for Arid1a during MYCN-driven NCC
transformation.
To validate the findings of the limiting dilution experiment, NCCs were
generated, and genetically modified in matched groups as described above and mouse
numbers were expanded per group. These results further support the findings of the first
study. Again, HET NCCs transformed more readily than WT1 as indicated by KaplanMeier analysis (Figure 3-3A). Furthermore, no tumor initiation advantage was observed
in KO tumors compared to controls (Figure 3-3C). Tumor tissue was analyzed by
genomic PCR for Arid1a genotype, which confirmed that tumor genotypes were
consistent with the original genetic manipulations in parental NCCs (Figure 3-3B and
D). Furthermore, the expected Arid1a and Mycn expression levels were confirmed by
western analysis of final tumors (Figure 3-4A to C). Results were consistent with the
expected outcomes based on genetic manipulations. Taken together, these studies indicate
that Arid1a heterozygous deletion is a driver mutation that cooperates with MYCN in the
context of MYCN-driven NBL, which is consistent with the expected phenotype of a 1p36
haploinsufficient TSG.
Gene expression and pathological and molecular characterization of in vivo Arid1a
model
Four tumors per group (16 total) were subjected to deep sequencing analysis
(RNA-seq). Unsupervised hierarchical clustering analysis of RNA-seq expression levels
revealed that tumor samples grouped based on Arid1a status (Figure 3-5A), specifically,
WT1 and WT2 grouped together, while HET and KO tumors grouped together, and were
divided into 10 distinct groups. Our goal is to identify set of Arid1a dependent upregulated genes that may indicate a cellular pathway or mechanism involved in NCC
transformation; therefore, we chose to focus on genes that were determined to be upregulated in both HET and KO, but not WT1 or WT2 (light blue = group 1). This group
consisted of 800 genes. Many genes in this group have been identified previously as
genes consistent with de-reugulated expression profiles seen in NBL. In this study,
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Figure 3-3. Heterozygous Arid1a synergizes with MYCN-driven NBL.
(A and C) Arid1aflox/wild-type and Arid1aflox/flox NCCs were generated from Arid1a floxed
mice. Next, adeno-gfp or adeno-cre virus was used to transduce floxed cells ex vitro,
Mycn was overexpressed (Mycn OE) using retrovirus, and cells were flank injected into
mice.
(A) Matched pairs of Arid1aWT1 or Arid1aHET NCCs + Mycn OE were injected at 1.5e6
cells per mouse into nude mice. Kaplan–Meier plot of end point tumor growth kinetics
(1500 mm3) in WT1 vs HET groups; (n = 5 per group), **p = 0.003,
(B) DNA genotyping analysis of Arid1a in representative tumor derived cell lines derived
from endpoint tumors. Primary cells were used as controls.
(C) Matched pairs of Arid1aWT2 or Arid1aKO NCCs + Mycn OE were injected at 1.5e6
cells per mouse into nude mice. Kaplan–Meier plot of end point tumor growth kinetics
(1500 mm3) in WT2 vs KO groups; (WT2 n = 10, KO n = 7), ns. p = 0.954,
(D) DNA genotyping analysis of Arid1a in endpoint tumors. Primary cells were used as
controls.
p-values were calculated using the Log-rank (Mantel-Cox) test; (*p ≤ 0.05, **p ≤ 0.005).
Fl = intact Arid1a floxed allele at 845 bp. WT = intact Arid1a wild-type allele at 669 bp.
KO = excised Arid1a allele (HET) or alleles (KO) at 298 bp.
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Figure 3-4. Loss of Arid1a expression is consistent with Arid1a genotype in end
point tumors.
(A through C) Western analysis of end point tumors from Figure 3-3.
(A) ARID1A and N-MYC expression relative to actin loading control in WT1 and HET
tumors.
(B and C) ARID1A and N-MYC expression relative to actin loading control in WT2 and
KO tumors.
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Figure 3-5. RNA-sequencing and histological characterization distinguishes HET
and KO tumors from controls.
(A) Unsupervised hierarchical clustering heatmap of mean tumor samples reveals
differentially expressed genes generated from mRNA-sequencing analysis. Samples are
grouped into k = 2 clusters (gray and orange, top). Representative genes are grouped
according to the row dendrogram height of clustered genes (various colors, left).
(B1 through 4) Representative H&E images of WT1, HET, WT2 and KO tumors,
respectively. (C1 through 4) Representative IHC protein analysis images of Arid1a
staining in WT1, HET, WT2 and KO tumors, respectively.
IHC = immunohistochemistry, H&E = Haemotoxylin and Eosin.
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Twist1, Sox9, Foxc1, Zeb1, CD96, Snai2, Snai1, Shh, Pdgfrα, Eya1/2, Rara, Vnn1, Cdk6,
Six1, Trim7, Runx1, Wnt9, Ptch2, Hox9/10, Tert, Ascl2, Hoxa11, Shb, NeuroD1, and
Trim71 gene expression were upregulated in both Arid1a-depleted grouped samples (8
total tumors). Downregulated genes consisted of 670 genes downregulated in both HET
and KO, but not in WT1 or WT2. These genes were analyzed by STRING, a
bioinformatics tool that determines the likelihood of connections in biological pathways
based on a gene list. This analysis determined that the down-regulated genes were
predicted to be biologically connected (PPI enrichment p-value = 1 x10-16). The top GO
Biological processes affected were nervous system development, neurogenesis, and the
generation of neurons (Table 3-1).
Pathological review from board-certified veterinary pathologist Dr. Heather
Tillman indicated that tumor morphologies were consistent with MYCN-driven NBL. The
tumors were locally invasive, but metastatic spread was not observed in full-body
hematoxylin and eosin (H&E) analysis from representative samples, nor in lymph, lung,
or liver from samples collected at end-point analysis. Functional loss of Arid1a in murine
neural crest progenitor cells resulted in an undifferentiated NBL histology. WT tumors
show limited neuroblastomic differentiation and a high mitosis-karyorrhexis index that is
consistent with the histology of human tumors that have amplified MYCN (WT1, WT2)
(Figure 3-5B1 and B3). Furthermore, WT1 and WT2 tumors were consistent with
Schwannian-poor NBL (Shimada classification), with regions of undifferentiated, poorly
differentiated, or differentiating cellular morphology highlighted in the H&E sections
(Figure 3-5B1 and B3). Reduction (HET) or loss (KO) of Arid1a further synergizes with
Mycn OE resulting in an earlier arrest in differentiation in transformed neural crest cells.
Subpopulations within HET and KO allografts that have genetic and morphologic
changes that are reminiscent of embryonic ectoderm and mesenchymal cells that are also
able to give rise to terminally differentiated cell types, such as sensory neurons and glia,
within the bulky tumor as detected by IHC (Figure 3-5B2 and B4). HET and KO groups
presented with greater populations of poorly differentiated or undifferentiated
morphologies compared to controls (Figure 3-5B2 and B4). All tumor samples were
analyzed by IHC for Arid1a expression. Genetic targeting of Arid1a resulted in the
reduction of detection of protein expression by IHC. WT1 have nuclear localization of
Arid1a while HET tumors have a reduction and partial loss of nuclear localization of
Arid1a (Figure 3-5C1 and C2). Arid1a expression is drastically reduced in the knockout
tumors by IHC relative WT2 control (Figure 3-5C4 and C2, respectively). Arid1a
immunoreactivity remains localized to the nucleus of mouse host tissues when observed
in KO tissue (Figure 3-5C4, arrows, insert, dotted lines). In summary, these findings are
consistent with a phenotype characterized by deregulated differentiation in Arid1a
depleted tumors.
Arid1a loss causes a differentiation block in vivo and in vitro
NBL arises from a transient population of migratory trunk NCCs that specify into
Tuj1+ neurons, or GFAP+ glia of the SNS.

36

Table 3-1.
genes.
GO-term
GO:0007399
GO:0022008
GO:0048699
GO:0048731
GO:0007275

GOBiological processes affected by Arid1a-dependent down-regulated
Description
Nervous system development
Neurogenesis
Generation of neurons
System development
Multicellular organism development

Count in gene set
156 of 2181
127 of 1650
117 of 1538
211 of 4072
225 of 4603

FDR
2.40 x10-22
4.11 x10-20
5.45 x10-18
1.02 x10-15
2.55 x10-14

GO STRING analysis of top biological processes affected by concordant HET and KO
down-regulated genes. FDR = False discovery rate.
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One trait of HR NBL is poorly differentiated tumors and a block in SNS development
that are thought to contribute to NBL oncogenesis (Jiang, 2011). We used IHC to analyze
markers of sympathoadrenal development to characterize the differentiation status of our
model. We analyzed end stage tumors by IHC using molecular markers to measure
neuronal and glial commitment. Tuj1 is an early, post-mitotic neuronal marker, present
during NCC differentiation into SNS neurons. Both the HET and KO tumor samples
demonstrated significantly reduced Tuj1 expression compared to control tumor samples,
suggesting blocked neuronal differentiation (Figure 3-6A and C). A decrease in neuronal
differentiation suggested that Het and KO tumors would demonstrate one of two traits, 1.
an increase of glial cells suggestive of re-distribution of lineage commitment or 2. a
decrease of glial cells symptomatic of a block in SNS commitment to the glial lineage.
Analysis of GFAP positivity in tumors indicated no significant difference of GFAP
expression in HET compared to WT1 tumors (Figure 3-6B), however, KO samples
showed significantly reduced in GFAP expression relative to WT2 (Figure 3-6D). These
results suggest that Arid1a HET deletions inhibit neuronal differentiation, and KO
deletions result in a more severe block, perturbing both neuronal and glial differentiation.
Due to the Arid1a dependent differences in tumor differentiation, we wanted to further
test the effects of Arid1a dose in vitro, to determine if Arid1a loss alone could contribute
to a block in SNS development.
To evaluate if Arid1a loss affected differentiation in untransformed NCCs, we
chose to work with the parental primary NCCs that harbored Arid1a deletions, and wildtype Mycn. These cells were subjected to neural differentiation media and neuronal
differentiation properties were tested in vitro. Confocal immunoflurorescent (IF) analysis
was used to evaluate neuronal differentiation. Images for quantification were captured at
random. As indicated in Figure 3-6E and G, Neuronal projections were evident in WT1
and WT2 fields of view but were reduced in an Arid1a dose-dependent pattern.
Consistent with the tumor data, we found that both Arid1a+/- cells and Arid1a-/- cells
exhibited a reduced number of neurons compared to controls (Figure 3-6F and H). This
finding was also demonstrated in WT cells transfected with different gRNAs to target
Arid1a using CRISPR/CAS9 technology. Consistent with the floxed NCC data, Arid1a
depleted cells recapitulate the reduction in NCC neuronal differentiation (Figure 3-7B).
In summary, analysis of SNS differentiation distinguished WT1 and WT2 groups from
less differentiated HET and KO groups. This data indicates that the progression of NCC
differentiation was altered when Arid1a expression was reduced or absent, with and
without the presence of Mycn OE.
Arid1a loss up-regulates genes associated with a mesenchymal cell identity
Arid1a HET deletions in vivo and in vitro resulted in a block in neuronal
commitment, while Arid1a KO blocked neuronal and glial differentiation. Differentiation
programs involve a vast number of genes, and because ARID1A is an epigenetic
regulator, Arid1a loss may alter the expression of many genes that regulate development.
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Figure 3-6. Arid1a loss blocks differentiation in vivo and in vitro.
(A and B) Quantification of WT1 vs HET tumors at endpoint following IHC for
differentiation markers Tuj1 (WT1 n = 9, HET n = 13) *P = 0.0208 and GFAP (WT1 n =
9, HET n = 13) ns. p = 0.601 as analyzed by color deconvolution analysis. Points
represent staining and quantification from individual tumors.
(C and D) Quantification of WT2 vs KO tumors at endpoint following IHC for
differentiation markers Tuj1(WT2 n = 8, KO n = 6) **p = 0.008 and GFAP (WT2 n = 8,
KO n = 5) ns. *p = 0.030 as analyzed by color deconvolution analysis. Points represent
staining and quantification from individual tumors.
(E through H) Primary NCCs were cultured in differentiation media for one week, costained for ARID1A and MAP2, then cell morphology was analyzed using
immunofluorescence (IF).
(E) Representative staining of NCC neurons in WT1 and HET populations. (F)
Quantification of neurons counted in each field captured across n = 5 experiments.
Images analyzed were captured at random. *p = 0.0353.
(G) Representative staining of NCC neurons in WT2 and KO populations. (H)
Quantification of neurons counted in each image captured across n = 4 experiments.
Images analyzed were captured at random. **p = 0.0008.
(A, B, C and D) Tuj1 and GFAP analysis p-values were generated using Mann Whitney
test. (F and H) Neuron quantification p values were calculated using an unpaired t test
with Welch’s correction; (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.0005). ARID1A = red, MAP2
= green, DAPI = blue.
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Figure 3-7. CRISPR-mediated deletion of Arid1a impaired neuronal
differentiation.
(A) Wild type primary NCCs were electroporated with CRISPR guides to Arid1a (Guide1 and Guide-2), or a non-targeting guide (Control). Cells were placed in differentiation
media for one week, co-stained for ARID1A and MAP2, then cell morphology was
analyzed using IF.
(A1 through A3). Representative staining of NCC neurons in control and Arid1a
modified populations.
(B) Quantification of neurons counted across n = 4 experiments. Images analyzed were
captured at random. Control vs. Guide-1 *p = 0.038. Control vs. Guide-2 ns. p = 0.239.
p values were calculated using an unpaired t test with Welch’s correction; (*p ≤ 0.05).
Arid1a = red, Map2 = green, DAPI = blue.
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Therefore, we further analyzed our RNA-seq tumor comparisons to identify signaling
nodes that are up regulated in response to Arid1a depletion. The gene list included genes
that are concordantly up-regulated in Arid1a HET and KO tumors compared to WT1 and
WT2 control tumors (Figure 3-5A light blue - group1). This gene list was analyzed using
STRING protein analysis to identify possible functional protein associations. Outputs
were constrained to high-confidence data from experimental, textmining, and database
sources. The final list included 753 unique upregulated nodes and a PPI enrichment pvalue of 1e-16, indicating a significant amount of interactions that signifies connection
among groups of biologically connected genes (Figure 3-8A). Multiple signaling hubs
included genes involved in migration, EMT, and development (Figure 3-8A). EMT has
been shown in multiple adult cancer models to be regulated by Arid1a depletion (Wang,
Gut, 2019, Sun, 2016, Cancer Cell). Furthermore, we identified a node comprised of
multiple EMT-regulating genes that were connected to Twist1 (Figure 3-9A) These
genes included Twist1, Sox9, Snai1/2, Zeb1, and CD44 in our model. TWIST1 is a NCC
master regulator and EMT pioneering factor that is associated with poor patient outcomes
in MNA NBL cases (Selmi et al., 2015; Valsesia-Wittmann et al., 2004). Recently, a
landmark NBL study established that TWIST1 is necessary to regulate the oncogenic
effects of MYCN at enhancers (Zeid et al., 2018). Considering the role of TWIST1 in
MYCN-driven NBL, we highlighted the genes connected to the Twist1 node (Figure 39A). Other notable signaling hubs were centered around the genes Adamts,Wnt9a, Shh,
Ltbp1, Six1, Src, and Hoxa5 (Figure 3-8A).
Taken together, our previous results suggest Arid1a loss altered cell fate decisions
resulting in blocked NCC differentiation. Therefore, we expected tumors and tumor
derived cell lines (TDCLs) to demonstrate phenotypes and gene expression programs of
NCC progenitor cells. Migration due to an EMT transition during delamination is a
normal process that occurs early during NCC development between days e9.5-11.5. We
thought if transformed NCCs were blocked in an undifferentiated state, they would
behave similarly to uncommitted and delaminating NCC precursors. Therefore, to test the
connection between cell fate and behavior caused by Arid1a loss, we measured migration
rates of TDCLs. We expected that cells stuck in an uncommitted progenitor state would
have higher rates of migration than controls. As we anticipated, Boyden chamber
migration assays indicated that HET and KO TDCLs migrated significantly more than
controls (Figure 3-9B and C). We also evaluated expression profiles that were altered in
tumors and correlated with cell identity. The top hit based on GSEA analysis in KO
versus WT2 tumors indicated that KO tumor gene expression values significantly
correlated with the Wong Embryonic Stem Cell Core gene signature (Figure 3-9D).
However, this signature was not in the top 20 significantly enriched GSEA gene sets in
HET tumors versus WT1 tumors. This result indicates that KO tumors share genes that
are concordant with the Wong Emrbyonic Stem Cell Core signature. This gene signature
is indicative of embryonic stem cell-like transcriptional programs (Wong et al., 2009).
Taken together the KO data reinforces the concept that Arid1a ablation causes NCCs to
be blocked in an immature state during transformation. Our findings in Arid1a HET and
KO samples imply that NCCs transformed with reduced Arid1a levels display a
phenotype and gene expression profile consistent with NCC progenitors.
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Figure 3-8. Arid1a-dependent up-regulated signaling nodes.
(A) STRING analysis of all genes concordantly up-regulated in HET and KO tumors
identified by RNA-seq. Nodes were limited to high confidence textmining, experimental
and database mining nodes.
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Figure 3-9. Arid1a loss disrupts EMT in vitro and in vivo.
(A) Twist1 signaling node identified by STRING analysis of concordantly up-regulated
gene transcripts in HET and KO tumors.
(B and C) Boyden chamber migratory analysis of TDCLs in (B) WT1 and HET (n = 7);
**P = 0.006; or (C) WT2 and KO (n = 7); **P = 0.002.
(D) Gene set enrichment (GSEA) analysis of WT2 versus KO tumors indicated a
significant correlation with Wong embryonic stem cell core and KO samples, but not
WT2 samples (Wong, 2008, Cell Stem Cell).
(E) Expression heatmap for tumor samples using mesenchymal genes of the cluster 3
gene set described by (Soldatov et al., 2019).
(F) Schematic indicating the mapping of HET samples to mesenchymal genes in cluster
3. (Soldatov et al., 2019).
(*P ≤ 0.05, **P ≤ 0.01).
Data Source. Soldatov, R., Kaucka, M., Kastriti, M. E., Petersen, J., Chontorotzea, T.,
Englmaier, L., … Adameyko, I. (2019). Spatiotemporal structure of cell fate decisions in
murine neural crest. Science, 364(6444). https://doi.org/10.1126/science.aas9536
Data Source. Wong, D. J., Liu, H., Ridky, T. W., Cassarino, D., Segal, E., & Chang, H.
Y. (2008). Module Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem
Cells. Cell Stem Cell, 2(4), 333–344. https://doi.org/10.1016/j.stem.2008.02.009
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Our tumor latency data (Figures 3-1 through 3-3) and GSEA analysis suggests a
difference between HET and KO tumors. Considering that HET tumors showed a
reduced latency relative to WT1 samples and fit the genetic profile of a haploinsufficient
1p36 TSG, we were interested to determine if HET tumors mapped to a cell fate
associated with aggressive cellular behavior. Both HET and KO samples upregulated
genes associated with an EMT signature, but the KO versus WT2 GSEA signature
Figure 3-9D suggested along with differentiation data from Figure 3-6 that KO tumor
cells have a severely blocked, stem-like NCC identity. In summary our data suggests that
HET cells may have a different cell identity than KO cells. A recent paper eloquently
mapped NCC gene expression profiles to the physical location and cell fate decision
points during mouse development (Soldatov et al., 2019). Through extensive single-cell
sequencing studies during trunk NCC differentiation, they developed gene lists that were
associated with different cell fates in the developing SNS (Soldatov et al., 2019). This
group segmented NCC expression profiles into the following 6 key NCC cell identities:
premigratory, delaminating, sensory, glia, autonomic and mesenchymal. Mesenchymal
cells are associated with increased cell motility and aggressive behaviors (Dongre &
Weinberg, 2019; Flavahan et al., 2017; Douglas Hanahan & Weinberg, 2011). We
thought this cell state most closely associated with the expression profiles and behavior
of our HET samples so far. To test this assumption, we mapped our mean tumor RNAseq data against the cluster 3 list of genes associated with a mesenchymal NCC identity
(Soldatov et al., 2019). This revealed that HET tumors had the greatest number of
upregulated mesenchymal genes relative to the other three tumor types (Figure 3-9E).
Taken together, we interpret these results to suggest that the TSG function of Arid1a in
trunk NCCs is through the regulation of cell identity.
Arid1a heterozygosity correlates with an immature, mesenchymal cell state
The mapping of mean tumor gene expression values against the mesenchymal
gene list from Soldatov, et al. 2019 highlighted that there were gene expression
differences between not only HET and WT1, but also between HET and KO tumors.
Following from these findings, we were interested to see how substantially WT, HET, or
KO Arid1a expression shifted the cell identity in tumor populations toward different
NCC identities. Furthermore, we wanted to map our tumors to the established lineage
tracing gene lists. We used the comprehensive gene list of NCC master regulator genes
generated by Soldatov et al., 2019 as a rubric for comparison. We evaluated the mean
expression values in each of our tumor groups against their list to focus on the key
regulators of cell identity (Figure 3-10). This analysis determined that WT1 and WT2
gene expression values were most consistent with a glial cell identity. HET tumor gene
expression values were most consistent with a mesenchymal cell identity, and KO gene
expression values were most consistent with a sensory cell identity.
To look more closely at this result, we also evaluated whether the expression
levels of NCC master regulators differed based on Arid1a genotype. To do this, we
graphed the differentially expressed genes (DEGs) that were identified in at least one
tumor group (Figure 3-11A through C).
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Figure 3-10. Tumor fate mapping reveals differences in HET and KO tumor
samples.
(A) Gene expression heatmap for tumor samples using NCC master regulator gene
signatures from Soldatov, et al. 2019 revealed differential expression patterns related to
cell identity. (B) Schematic mapping of tumors to respective cell identity.
Modified with permission from AAAS. Soldatov, R., Kaucka, M., Kastriti, M. E.,
Petersen, J., Chontorotzea, T., Englmaier, L., … Adameyko, I. (2019). Spatiotemporal
structure of cell fate decisions in murine neural crest. Science, 364(6444).
https://doi.org/10.1126/science.aas9536
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Figure 3-11. Differential gene expression analysis reveals alterations of NCC
master regulators in tumor samples.
(A through F) Mean tumor values from RNA-sequencing were analyzed for differentially
expressed genes (DEGs) between the following tumor samples WT1 vs HET, WT2 vs
KO, and HET vs KO (n = 4 in each group). NCC master regulators were plotted to show
the Log2 fold-change between each comparison group. Statistical significance was
determined using adjusted p-values (Benjamini-Hochberg correction).
(A through C) Grouped list showing all master regulators that were altered in our system
in at least one comparison group.
(D through E) Summary graphs highlighting NCC master regulators identified as
significantly differentially regulated in the comparison listed.
(A) HET gene expression 2 log fold changes were set as the numerator. WT1 gene
expression 2 log fold changes were set as the denominator. Positive values represent
genes that are up-regulated in HET and down-regulated in WT1. Negative values
represent genes that are up-regulated in WT1, but down-regulated in HET.
(B) KO gene expression 2 log fold changes were set as the numerator. WT2 gene
expression 2 log fold changes were set as the denominator. Positive values represent
genes that are up-regulated in KO and down-regulated in WT2. Negative values represent
genes that are up-regulated in WT2, but down-regulated in KO.
(C) HET gene expression 2 log fold changes were set as the numerator. KO gene
expression 2 log fold changes were set as the denominator. Positive values represent
genes that are up-regulated in HET and down-regulated in KO. Negative values represent
genes that are up-regulated in KO, but down-regulated in HET.
(D) Summary of data from (A). Graphical representation of NCC master regulators that
were significantly altered in HET and WT1 tumors relative to one another.
(E) Summary of data from (B). Graphical representation of NCC master regulators that
were significantly altered in KO and WT2 tumors relative to one another.
(F) Summary of data from (C). Graphical representation of NCC master regulators that
were significantly altered in HET and KO tumors relative to one another.
Mean tumor values were calculated from 4 individual tumors for each genotype. Error
bars were generated using log fold change standard error. Significance was determined
using adjusted p values. (*p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005).
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Analysis of WT1 and WT2 in comparison to these lists identified two upregulated glial
regulators Plp1 and Zfp488. KO tumors had increased Zic3 expression relative to other
samples. Both HET and KO had increased Twist1 relative to their respective controls.
HET tumors demonstrated a modest increase in Prrx1 relative to all samples, but it was
the only gene significantly increased relative to KO samples (Figure 3-11F). This data
suggests that WT1 and WT2 have more glial characteristics than HET and KO, with KO
displaying high levels of the neural plate boarder specifying factor Zic3, and EMTpioneering factor Twist1, while HET samples had gene expression profiles consisting of
increased Twist1 relative to controls, and slightly increased Prrx1 relative to all groups. A
summary of this result is depicted in Figure 3-10B.
Arid1a heterozygous tumors gene signature recapitulates human NBL mesenchymal
signature
Through mapping the mean expression values from individual tumor groups, we
found that master regulatory genes of mesenchymal NCC cell fate were altered in HET
tumors. Following from this finding, we were interested to test whether our mouse model
of HR NBL faithfully recapitulates gene expression programs identified in HR NBL
patient tumors. One recent NBL study worked to define gene expression programs that
could be used to define the heterogeneity found in HR NBL tumors (van Groningen et al.,
2017). This work divided the cells comprising HR NBL tumors into two categories,
adrenergic (ADRN) and mesenchymal (MES) based on CD133 status and mRNA profile
(van Groningen et al., 2017). The adrenergic type (ADRN) was characterized by CD133cells expressing the classic NBL master regulators Phox2A, Phox2B, and DBH, while the
mesenchymal (MES) type was comprised of snail, vimentin, and fibronectin
mesenchymal markers (van Groningen et al., 2017). MES tumors were stem-like while
ADRN were more differentiated (van Groningen et al., 2017). Additionally, the MES
signature was correlated to more aggressive tumor behavior in patients (van Groningen et
al., 2017). We reasoned that if HET tumors expressed the most mesenchymal genes
relative to the remaining groups, as suggested by our data in Figures 3-9 and 3-10, then
we would expect our HET samples to display a greater amount of overlap to the human
MES signature than other groups. First, we compared our mean tumor expression profiles
to the gene list comprised of MES and ADRN associated genes to determine if our mouse
model tumor groups overlapped with MES or ADRN signatures identified in patient NBL
samples. We found that MES genes were increased in the HET samples, however the KO
tumor samples did not demonstrate a strong MES nor ADRN signature (Figure 3-12A).
We compared HET versus WT1, WT2, and KO tumor groups by GSEA analysis and
determined that the HET mouse model and MES patient tumor signatures overlapped
with statistical significance (Figure 3-11B). WT1, WT2, and KO versus HET tumors
using GSEA determined that the genes enriched in these groups statistically significantly
overlapped with the ADRN patient tumors gene set (Figure 3-11C). This gene set
comparison supports the hypothesis that suggests Arid1a loss contributes to a SNS
developmental block in lineage commitment leading to a cell identity that is associated
with aggressive NCC behavior.
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Figure 3-12. Mouse model comparison to human NBL adrenergic and
mesenchymal signatures.
(A) Comparison of tumor mRNA expression profiles to ADRN and MES genes identified
in NBL patient cells by van Groningen, et al. (van Groningen, 2018, Nat Gen)
(B) Gene set enrichment analysis (GSEA) of HET vs WT1, WT2, and KO tumors using
the MES gene signature indicated a significant correlation between HET and MES genes.
(C) GSEA of HET vs WT1, WT2, and KO tumors compared to ADRN gene signature
indicated a significant correlation between HET and ADRN genes.
Data Source: van Groningen, T., Kroster, J., Valentijn, L. J., Zwijnenburg, D. A., Akogul,
N., Hasselt, N. E., … Versteeg, R. (2017). Neuroblastoma is composed of two superenhancer-associated differentiation states. Nature Genetics.
https://doi.org/10.1038/ng.3899
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Discussion
Our study focused on the functional testing and characterization of a genotype
that has been posited for over 30 years as a detrimental combination in HR NBL (Attiyeh
et al., 2005; G M Brodeur, 1995; Garrett M. Brodeur, 2003; García-López et al., 2020;
Sausen et al., 2013; Schwab, Praml, & Amler, 1996). We generated a novel mouse model
of HR NBL by OE of Mycn and stepwise deletion of the putative 1p36 TSG, Arid1a, in
the NCC progenitor cells that give rise to this disease. Through this method, we asked if
Arid1a is a driver mutation in MYCN amplified NBL. We causally demonstrated that in
our in vivo tumorigenesis model, Arid1a heterozygous loss synergizes with MYCN
driven oncogenesis, which is consistent with the 1p36 LOH and MNA genotype found in
≥15% of HR NBL patients (Attiyeh et al., 2005; G M Brodeur, 1995; Garrett M. Brodeur,
2003; Caron et al., 1995, 1996; Davidoff, 2012; C. T. Fong et al., 1989; Jiang et al., 2013;
Maris et al., 1995; Nakagawara et al., 2018). Tumor histology analysis, in vitro
differentiation studies, and RNA-seq characterization of Arid1a mutant samples were
consistent with an Arid1a dependent block in differentiation resulting in altered cell
identity and with developmental literature describing Arid1a mutations in a variety of cell
types (Chandler & Magnuson, 2016; Han et al., 2019; Lei et al., 2015). Furthermore, we
extended the current literature findings by defining an Arid1a-dependent gene signature
in our Mycn-driven NBL model.
Haploinsufficient Arid1a is a driver mutation that collaborates with MYCN in
NBL initiation. Epigenetic regulators have been highlighted as the most frequently
mutated genes across pediatric cancers (Gröbner et al., 2018; Ma et al., 2018).
Furthermore, epigenetic complexes, such as SWI/SNF are known regulators of cell
identity (Lu & Allis, 2017). Disruptions in the complexes and their critical components
have been shown to subsequently disrupt normal progenitor commitment and
differentiation and to even initiate cancer in some instances (B. G. Wilson et al., 2010).
Pediatric cancer studies have collectively identified cell identity alterations to be a
hallmark of pediatric tumors, including solid tumors such as NBL (Flavahan et al., 2017;
Lawlor & Thiele, 2012). Our tumor studies indicate that Arid1a heterozygous loss is
sufficient to increase the transformation kinetics of NCCs driven by Mycn. Only HET
tumor groups demonstrated a consistent reduction in tumor latency. This finding is
consistent with the phenotype expected of the TSG residing in the region of 1p36 LOH
that is correlated to MNA. Large segmental gains and losses of chromosomes have made
the identification of specific gene mutations difficult in NBL (Pugh et al., 2013). As
stated by Pugh, et al “The notable lack of precisely defined genomic causes of this highly
aggressive pediatric neoplasm reinforces the need to understand the interplay of host genetic
factors, somatic mutations, chromosomal abnormalities and epigenetic alterations in the
context of nervous system development.” The increase of large NBL patient cohorts
sequenced using WGS has identified rare point mutations that can be functionally tested
(Sausen, et. al, 2014, Nat gen). We have worked to contribute a precise gene combination
evaluated in the correct context that we hope will help address this issue. Furthermore,
these data connect the concept of 1p36 LOH to the transformative events caused by loss
of a specific gene in this locus.
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Arid1a deletions cause a significant block in differentiation. The etology of
MYCN-driven NBL has been linked to possible shifts in NCC identity during
development (Huber, 2015; Tsubota & Kadomatsu, 2018). To broadly test this idea in our
model, we used in vivo and in vitro methods to study NCCs as they transformed, and
differentiated, respectively. In vivo, HET and KO tumors included undifferentiated,
poorly differentiated, and differentiating cell types throughout tumors as determined by
pathological review. Neuronal differentiation in tumors was substantially affected by
Arid1a loss in histological analysis of differentiation using Tuj1 as a molecular marker.
In vitro analysis of neuronal differentiation studies in primary NCCs with Arid1a partial
or full ablation also revealed a statistically significant blocks in neuronal differentiation.
Arid1a has a demonstrated role as a necessary component of SWI/SNF during cardiac,
SNS, and hematopoietic development in mouse models with homozygous deletions (Gao
et al., 2008; Han et al., 2019; M. R. Wilson et al., 2019) and hematopoietic development
in one heterozygous experiment (Han et al., 2019). Our model fits with the current
literature and highlighted an additional role for Arid1a in SNS lineage differentiation into
neurons and glial cells. These data suggest that NCCs display a broader sensitivity to loss
of Arid1a during development than previously expected.
The mesenchymal gene signature in Arid1a HET tumors is consistent with an
NBL MES signature derived from patient tumors. One theme consistent throughout
Arid1a developmental and cancer studies, is the ability of Arid1a to regulate EMT-related
phenotypes (Sun, Wang, et al., 2017; S. C. Wang et al., 2019). EMT is both a transition
state during development and an initiation step of metastasis. We compared our tumor
gene sets to two models published recently. The first was a developmental model that
developed lists of the master regulators of each step during trunk NCC maturation using
single cell sequencing throughout early SNS development. Using this the gene identified
in this study as NCC master regulators, the HET samples demonstrated a partial block in
differentiation characterized by an increase in Prrx1, a master regulator of mesenchymal
identity. Two additional genes that induce migration and mesenchymal identity, Twist1
and Meox1, were upregulated in both HET and KO tumors. However, KO tumors also
demonstrated an increase of the sensory glia inducer Pouf41, and two neural plate
boarder specifiers, Zic3 and Olig3 that were not up regulated in HET tumors. We
interpret this suggest a more immature gene signature in KO relative to HET tumors that
is supported by the significant block in differentiation identified by IHC, neuronal
differentiation IF studies, and significant Wong embryonic stem cell core signature
identified by GSEA. We found it interesting that KO did not confer a tumorigenic
advantage to NCCs and consider the data to collectively suggest a window of
transformation during NCC progenitor differentiation that left HET NCCs extremely
vulnerable to MYCN-driven transformation. Gene signature analysis indicates that HET
tumors are blocked in a state that significantly overlaps with the patient-derived
mesenchymal signature indicative of HR NBL. Furthermore, the remaining tumor groups
display a gene signature suggestive of the ADRN signature identified by van Groningen,
et al (van Groningen et al., 2017). One view describing the effects of epigenetic
deregulation in cancer points to deregulated cell fate as a tumorigenic consequence of
epigenetic mutations (Flavahan et al., 2017).This is consistent with large pan-pediatric
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cancer studies that identified cell identity as the top alteration consistently identified
across all pediatric cancers (Gröbner et al., 2018; Ma et al., 2018).
Here, we have built a novel option for future testing of fundamental mechanistic
questions, as well as tools for high-throughput drug screening and biomarker
development. In the context of our findings, we found that there are two limitations of
this study. The first that was partially addressed and warrants further study is the concept
of tumor heterogeneity. Our histological evaluation of tumors identified populations with
unique differentiation statuses, however, single-cell RNA-seq would be necessary to
evaluate the distribution of cell types comprising the tumor. Our findings support
continuing this path in future studies. Second, a key principle of tumor stem cells that
was not evaluated here is relapsed disease following a clinical treatment regimen.
Considering that our study focused on the initiation properties of Arid1a loss, we cannot
exclude the possibility that Arid1a heterozygous and full ablation may have functional
consequences in the context of disease relapse, therefore, the low frequency of
homozygous Arid1a mutations identified in NBL patients is worth noting. One NBL
patient tumor screen identified that 3 patients with 1p36 LOH also harbored point
mutations on the second allele of Arid1a (Sausen et al., 2013). The point mutations were
expected to result in premature protein termination functional loss of Arid1a protein
(Sausen et al., 2013). It is unclear if these were driver or passenger mutations and our
results suggest the later. However, further characterization is necessary to determine if
full Arid1a ablation contributes to any tumor relapse characteristics. Despite these
limitations we believe our work provides a springboard for future NBL studies. For
example, an interesting addition to this model would be to include 17q gain.
Chromosomal translocation and gain of chromosomal material at this locus is the most
common genetic lesion in NBL patients and also correlates with 1p36 LOH and MNA
tumors (Garrett M. Brodeur et al., 2014; Tolbert & Matthay, 2018). The prevalence of
17q gain in 50-80% of patient tumors suggests that this region may confer additional
tumor characteristics and is an important lesion to model in future studies (Garrett M.
Brodeur, 2003; Davidoff, 2012).
We interpret the Arid1a-dependent phenotype identified by our study to be linked
to cell identity, which is plastic in progenitor cells during development and can lead to
oncogenic adaptations of cell fate (Flavahan et al., 2017; J. N. Wu & Roberts, 2013). In a
recent pan-cancer study, pediatric cancers were reported to have 45% overlap with the
driver genes reported in pan-adult cancer studies (Ma et al., 2018). Currently, Arid1a has
been causally studied in developmental, and adult cancer mouse models, and defined as a
context specific TSG (Chandler & Magnuson, 2016; Gao et al., 2008; Han et al., 2019;
Mathur et al., 2017; Sun, Wang, et al., 2017). Consistent with this concept, our model
identified both similarities and differences to Arid1a mutated adult cancers. Our model
combines aspects of adult cancer studies, the ARID1A field, and developmental biology
to focus on the role of Arid1a as a driver mutation in trunk neural crest transformation
into the pediatric cancer NBL. Our findings in this novel mouse model of NBL support
the hypothesis that Arid1a is a haploinsufficient TSG that synergizes with MNA to
disrupt lineage development programs, resulting in increased oncogenesis due to altered
cell identity and furthermore, is a model consistent with NBL patient tumors by gene
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expression analysis. The results presented in this body of work highlight the importance
of context specific disease modeling, especially in high-mortality orphan diseases such as
this pediatric cancer. Therefore, this study functionally expands not only the NBL field’s
understanding of the consequences of deregulated epigenetic programs in pediatric
cancer, but also provides higher resolution and connectivity to 25 cancer types by
furthering our understanding of the most mutated member of the SWI/SNF epigenetic
complex.
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CHAPTER 4.

ARID1A AND DNA DAMAGE
Introduction

Arid1a is a known regulator of cell cycle. ARID1A has been shown to bind to the
MYC promoter, and subsequently regulate p21 expression, a target of C-MYC (Nagl et
al., 2005; Nagl, Zweitzig, Thimmapaya, Beck, & Moran, 2006). Furthermore,
deactivating ARID1A and P53 mutations are mutually exclusive across many cancer
types, and ARID1A mutations are found in cancers with multi satellite instability, while
P53 mutations are not (Kadoch et al., 2013; Mathur, 2018; R. C. Wu et al., 2014). This
suggests a partial overlap of ARID1A and P53 functions. Recently, two independent
groups published studies implicating ARID1A as a regulator of the DNA damage
response following double-stranded DNA damage through its binding partner ATR (Lord
et al., 2016; Shen et al., 2015). ATR induces phosphorylation of chk-1 causing cell cycle
arrest and apoptosis (Goto, Kasahara, & Inagaki, 2014). When ARID1A was
homozygously deleted in colorectal cancer line HCT116, the cell cycle checkpoint was
impaired, and cells were sensitized to PARP inhibitor (Shen et al., 2015). In the same cell
line, an additional study was published implying that ARID1A knockout cells impaired
the DNA damage response by ATR, which no longer transmitted the DNA damage
response through p-chk1(Lord et al., 2016). More recently, a third study was published
using “other” cell lines with shRNA mediated knockdown of ARID1A and ARID1A
depletion was strongly correlated to resistance in 496 cancer cell lines, but most notably
in sarcoma lines (Hu et al., 2018).
Materials and Methods
Proliferation assays and drug treatment
Tumor derived cell lines were plated in fibronectin coated 96-well plates at 6000
cells per well in IMDM + 10% FBS. Three hours after plating, the drugs were added at
the indicated concentrations and incubated for 72 hours at 5% CO2 until analysis. At the
experimental end point, CyQuant direct fluorescent cell detection reagent (Thermo
Fischer) was added to wells and incubated for 1 hour at 37ºC. Data was imported into
GraphPad Prism and
Cell lines
Neuroblastoma cell lines SK-N-AS, SY5Y, SK-N-SH, SK-N-DZ, Kelly, IMR-32,
and SK-N-BE2 were purchased from American Type Culture Collection (ATCC) and
cultured according to manufacture instructions. A table listing a summary of genetic
information from Harenza, et al. for MYCN and 1p36 status in common neuroblastoma
cell lines are listed in Table A-1 (Harenza et al., 2017).
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Histology analysis
Tumors were fixed in 10% neutral buffered formalin, embedded in paraffin,
sectioned at 4 μm, stained with hematoxylin and eosin (HE). All formalin-fixed,
paraffin-embedded (FFPE) tissues were sectioned at 4 μm, mounted on positive charged
glass slides (Superfrost Plus; Thermo Fisher Scientific, Waltham, MA), and dried at 60°C
for 20 minutes. The IHC procedures and antibodies used for mouse tissue to detect
protein markers are listed in Table A-2. All HEs and IHCs were reviewed by light
microscopy and interpreted by a board-certified veterinary pathologist (HT). IHCs were
scanned at a 20x (objective lens) magnification using an Aperio ScanScope XT scanner.
Immunoreactivity was quantified as a weighted IHC score (0-300) using a modified
version of the Color Deconvolution algorithm and ImageScope software (Leica
Biosystems).
Immunoblotting
Samples were collected on ice by washing 1x with PBS, then adding RIPA buffer
(Thermo Scientific, PI89900) and 2x Halt Protease Phosphatase inhibitor. Samples were
scraped into a tube, vortexed for 10 seconds and lysed for 20 minutes rotating at 4ºC.
Samples were sonicated for 10 second intervals totaling 30 seconds, then lysates were
cleared by centrifugation. Samples were incubated for 30 minutes in 1x SDS-loading
buffer with 9% BME and 50ug of total lysate was separated by gel electrophoresis on 420% tris-glycine gels (BioRad #4561094) at 300V for 25 minutes. Samples were
transferred according to protein size. Membranes were blocked for 1 hour at room
temperature (RT) in PBS .1% Tween 20 (PBST)/5% (w/v) milk. PVDF membranes were
probed with primary antibodies incubated o/n at 4ºC with gentle shaking. Next,
membranes were washed with PBST and incubated with secondary antibody (1:4000,
Cell Signaling Technologies) in PBST/5% (w/v) milk for 1 hour at RT. Membranes were
washed in PBST and protein signal was detected using chemiluminescent substrate
(Genesee Scientific #20-302). Antibody concentrations and protein sizes reference Table
A-3.
Neural crest cells
NCCs with Arid1a modifications were subjected to increasing amounts of Mycn
virus (Addgene #35394). Samples were harvested 72 hours following exposure to virus,
processed using the Qiagen RNeasy kit according to the manufacturer’s protocol. cDNA
was synthesized, and qPCR was performed with Taqman primer/probe sets for Mycn and
Arid1a. Ppib was used as the house keeping gene. Reads were normalized to the internal
control (Ppib), and reported as changes in expression relative to the control group.
Statistical analysis was used to test differences in Mycn expression between the two
groups, or Arid1a differences between the two groups.of NCCs. Statistical analysis was
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performed under the following parameters: RM two-way ANOVA with the GeisserGreenhouse correction, matched values are spread across a row. Sidak’s multiple
comparisons test, with individual variances computed for each comparison using
GraphPad Prism 8.2.1 (441).
Annexin V analysis
Statistical analysis was completed under the following parameters: Discovery
determined using the Two-stage linear step-up procedure of Benjamini, Krieger and
Yekutieli, with Q = 1%.Each row was analyzed individually, without assuming a
consistent SD. Number of t tests: 5 using GraphPad Prism 8.2.1 (441).
Results
ARID1A protein levels are increased in MNA cell lines
We were interested to evaluate relative protein levels of N-MYC and ARID1A in
1p36 deleted cell lines and in control cell lines, and to determine if expression of N-MYC
and ARID1A were as expected. The cell lines chosen for analysis had been analyzed
previously by sequencing studies that confirmed the chromosomal changes (Harenza et
al., 2017). We controlled this study by including three non-MNA/1p36 cells, one MNA
cell line, and next compared four cell lines with 1p36 and MNA. Interestingly, the cell
lines with 1p36 LOH did not exhibit an obvious expression decrease in ARID1A, even
though the genetic material was lost (Figure 4-1A). Furthermore, the only cell line
examined with MNA and WT 1p36 expressed increased levels of Arid1a protein relative
to NBL cell lines without MNA (Figure 1A). This suggested that MNA causes an
ARID1A expression response. To validate this result in primary NCCs, MYCN was
titrated into WT1, HET, WT2 and KO primary cells in a range of MOI 0-3 (Figure 4-1C
and D). Mycn and Arid1a levels were validated by qPCR. Consistent with our previous
results, Arid1a expression increased as MYCN expression increased at a MOI of 2 and 3
in WT1 and an MOI of 2 in HET NCCs (Figure 4-1C and D). This MYCN-dependent
increase of Arid1a expression suggested that Arid1a behavior in NCCs modeled the
expression of ARID1A in NBL cell lines. Next, we monitored cell death in response to
MYCN OE. As before, we transduced the cells with an increasing amount of Mycn virus
(MOI 0-3) and submitted the cells to annexinV flow-cytometry analysis at 72 hours posttransduction (Figure 4-2A and B). In this study, no significant differences in cell death
were identified between controls and Arid1a deleted samples. Taken together, this data
suggests a regulatory connection between MYCN and ARID1A, however our data did not
support the concept that Arid1a loss alters NCC cell death in response to MYCN
expression.
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Figure 4-1. N-MYC and ARID1A protein expression are correlated in NBL and
NCC samples.
(A) Panel of NBL cell lines with known chromosomal alterations analyzed for ARID1A
and N-MYC protein expression by western analysis.
(B) Schematic of proposed regulation of ARID1A by N-MYC.
(C and D) qRT-PCR results from Arid1a wild-type and heterozygous NCCs transduced
with increasing amounts of Mycn virus.
(C) Mycn mRNA was significantly increased in WT1 compared to HET NCCs in
samples transduced with a MOI of 2 (**p = 0.003) and MOI of 3 (***p = 0.00005).
(D) To determine if Mycn expression correlated to Arid1a expression, a 2way ANOVA
with multiple comparisons was run to evaluate Arid1a expression relative to its MYCN
MOI 0 control. Arid1a expression in WT1 samples significantly increased in response to
increasing amounts of MYCN at MOI 2 *p = 0.026 and MOI 3 *p = 0.01. Arid1a HET
demonstrated a significant increase at MOI 2 **p = 0.002 when compared to HET at
MOI 0. (*p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005). Representative results of n = 3
biological replicates.

58

Figure 4-2. Arid1a status was not correlated to apoptotic response when Mycn was
titrated into primary NCCs.
(A and B) Annexin V and DAPI were used to determine fractions of early and late
apoptotic and dead cells by flow cytometry. No statistical differences were observed
between WT1 and HET, or WT2 and KO at any MOI tested.
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Characterization of DNA damage and cell death in end-stage tumors
Arid1a loss has been shown to increase mismatch repair deficiency and
mutagenesis (Shen et al., 2018). One possible reason HET NCCs transformed more
readily than WT1 might be explained by DNA damage repair deficiency resulting in an
accumulation of genetic mutations, reduced DNA damage signaling, and decreased cell
death relative to controls. Therefore, we analyzed end stage tumors for signs of a mutator
phenotype (Loeb, 2001; Shen et al., 2018). We expected tumors with a possible mutator
phenotype to demonstrate a low rate of γH2ax induction, and low levels of cleaved
caspase 3 relative to controls. This would suggest possible genomic instability, and point
to a potential TSG caretaker role for Arid1a in our model (Shen et al., 2018; R. C. Wu et
al., 2014). To this end, we evaluated γH2ax, an upstream DNA damage sensor, and
cleaved Caspase-3, a downstream mediator of cell death by IHC in end point tumors
(Shen et al., 2018, 2015). Interestingly, no significant differences were observed in HET
samples (Figure 4-3A and B). KO samples indicated an increase in cleaved caspase-3
relative to controls, but no difference in γH2ax (Figure 4-3C and D). Therefore, we did
not observe leading indicators of a mutator phenotype or genomic instability in Arid1a
depleted tumors in our model. This suggests that if impaired DNA damage response is
involved in NCC transformation, it was not evident in the end-stage tumors.
Arid1a heterozygous and homozygous tumor derived cell lines do not have impaired
ATR signaling
ARID1A has been shown to bind p53 and to interact with ATR to induce DNA
damage signaling (Guan et al., 2011; Lord et al., 2016; Shen et al., 2015). We reasoned
that if Arid1a is involved in the DNA damage response, impaired DNA damage signaling
may be involved in our model of tumorigenesis. We did not see an increase of DNA
damage using γH2ax as a readout in in any tumor groups evaluated and considered that
one reason may be that a reduced DNA damage response may be evident during early
stages of NCC transformation but missed at end point analysis. Therefore, we decided to
induce DNA damage and measure the consequences in tumor derived cell lines (TDCLs).
Due to the emerging data indicating Arid1a-ATR interactions (Lord et al., 2016;
Shen et al., 2015), we decided to induce DNA damage in TDCLs to see if Arid1a
deletions affected ATR signaling, and altered drug resistance. We chose topotecan and
etoposide, two front line chemotherapeutics used in the COG treatment regimen, to
induce DNA damage in tumor derived cell lines (TDCLs) (Pinto et al., 2015). First, a
dose response was established in three TDCLs for each genotype. Next, TDCLs (three
per genotype) were treated with both compounds, collected across time points and probed
for key mediators of the DNA damage response. Phosphorylated chk1 was used as a
readout of ATR-mediated DNA damage. Chk1 is an effector protein that is
phosphorylated by p-ATR, and transduces the DNA damage signal downstream to p53
(Balmus et al., 2019).
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Figure 4-3. DNA damage and cell death analysis of tumors.
(A and B) Quantification of WT1 vs HET tumors at endpoint following IHC
(A) for the DNA damage response protein γH2ax (WT1 n = 9, HET n = 13) ns. p = 0.744
and (B) the cell death mediator Caspase3 (WT1 n = 9, HET n = 13 ) ns. p = 0.209 as
analyzed by color deconvolution analysis. Points represent staining and quantification
from individual tumors.
(C and D) Quantification of WT2 vs KO tumors at endpoint following IHC
(A) for the DNA damage response protein γH2ax (WT2 n = 9, KO n = 6) ns. p = 0.955
and
(B) the cell death mediator Caspase3 (WT1 n = 8, KO n = 7) *p = 0.029 as analyzed by
color deconvolution analysis. Points represent staining and quantification from individual
tumors.
p values were calculated using Mann Whitney test; (*p ≤ 0.05).
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As a dsDNA damage control, we used γH2ax, an upstream transducer of DNA damage.
HET lines did not demonstrate therapeutically relevant resistance to etoposide or
topotecan at any dose evaluated (Figures 4-4A and 4-5A). Similarly, KO lines were not
significantly resistant or sensitive to either drug relative to WT2 TDCLs (Figures 4-4B
and 4-5B). Our study did not demonstrate a relationship between Arid1a loss and
deficient ATR signaling at the time points evaluated for etoposide or topotecan induced
DNA damage in HET samples relative to WT1 control TDCLs (Figures 4-4C and 4-5C),
nor in KO TDCLs compared to WT2 control lines (Figures 4-4D and 4-5D). To
determine if our TDCL results were consistent with ATR-mediated DNA damage
response in NBL samples, we evaluated human NBL cell lines for signs of impaired ATR
signaling (Figure 4-6). We treated cells with increasing amounts of topotecan, and
evaluated the samples following six hours of treatment. Although DNA damage was
induced, no striking differences in ATR signaling were evident in cells with 1p36 LOH
and MNA (Kelly) relative to MNA only control cells (SK-N-AS) (Figure 4-6).
Taken together, the differences in tumorigenic advantage in HET tumors were not
explained by the ATR mediated DNA damage response. Arid1a has been implicated as a
modulator of lineage commitment in mouse embryoid bodies (Gao et al., 2008).
Considering these results, we hypothesized that rather than the DNA damage-mediated
proliferative advantage commonly seen in adult cancers, a developmental aberration may
result in a tumorigenic advantage in our pediatric cancer model.
Discussion
MNA upregulated ARID1a protein levels in NBL cell lines. Additionally, Arid1a
was slightly increased at the mRNA level following the titration of a Mycn OE virus.
ARID1A mutations and MYC amplification co-exist in a multiple cancers (Giulino-Roth
et al., 2012; Kim et al., 2018; C. Love et al., 2012; Muzny et al., 2012; Sun, Wang, et al.,
2017; Witkiewicz et al., 2015). This suggests that ARID1A, and possibly other BAF
family members, collaborate with MYC family oncogenes in many cancers, although
these synergies may present with cancer specific phenotypes. Furthermore, the regulatory
circuits controlling Arid1a have not been established. Further testing to determine if
MNA regulates ARID1A may provide insights into other cancers with synergy between a
transcription factor oncogene and a chromatin remodeling tumor suppressor. This link
may also provide details into broader regulation of SWI/SNF and its regulatory partners.
Our data suggest that further experiments using ChIP-PCR or ChIP-seq to determine if
N-MYC binds to the ARID1A promoter would provide insight into the mechanism of
ARID1A regulation.
Mycn OE did not induce differential apoptosis in HET and KO primary cells.
TSGs are classified as either caretakers or gatekeepers (Shen et al., 2015; R. C. Wu et al.,
2014). Caretakers comb the DNA to identify DNA damage and signal repair, and
gatekeepers regulate proliferation and apoptosis (R. C. Wu et al., 2014).
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Figure 4-4. Arid1a HET and KO tumor derived cell lines do not have impaired
ATR signaling in response to etoposide treatment.
(A and B) Tumor derived cell lines (n=3 per genotype) were treated with etoposide in
increasing half-log doses for 72 hours. Percent survival was measured by CyQuant (n=3).
Best curve fit and EC50 and AUC were calculated and determined to be statistically
insignificant.
(C and D) Representative western blots indicating ATR-dependent DNA damage
response activation following treatment with either etoposide (10 μM). Experiments were
repeated in three independent cell lines for each genotype.
(A and C) WT1 or HET TDCLs; (B and D) WT2 or KO TDCLs treated with etoposide.
EC50 = half-maximal response, AUC = area under curve
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Figure 4-5. Arid1a HET and KO tumor derived cell lines do not have impaired
ATR signaling in response to topotecan treatment.
(A and B) Tumor derived cell lines (n=3 per genotype) were treated with topotecan in
increasing half-log doses for 72 hours. Percent survival was measured by CyQuant (n=3).
Best curve fit and EC50 and AUC were calculated and determined to be statistically
insignificant.
(C and D) Representative western blots indicating ATR-dependent DNA damage
response activation following treatment topotecan (1 μM). Experiments were repeated in
three independent cell lines for each genotype.
(A and C) WT1 or HET TDCLs; (B and D), WT2 or KO TDCLs treated with topotecan.
EC50 = half-maximal response, AUC = area under curve
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Figure 4-6. 1p36 LOH did not alter ATR signaling in topotecan treated NBL cells.
(A) NBL cell lines were treated with topotecan in 10x increasing doses for 72 hours.
Representative western blot indicating ATR-dependent DNA damage response activation
following treatment topotecan (n=1).
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Arid1a is a known regulator of the G2-M transition, which suggests a gatekeeper role
(Shen et al., 2015). ARID1A and P53 mutations have been identified as mutually
exclusive, which may suggest a role for Arid1a in the apoptotic response. Avoiding
apoptosis is a hallmark of a transforming phenotype, and Arid1a deletion has been shown
to increase a mutability phenotype (Shen et al., 2018). Caspase 3 has also been shown to
increase in Arid1a KO tumors compared to controls (Shen et al., 2018). Furthermore,
MNA drives DNA synthesis, which causes replication stress and subsequent apoptosis
(Ham et al., 2016; Ruiz-Pérez et al., 2017). Therefore, it is possible that Arid1a loss may
relieve this path to cell death. It is interesting that we did not see significant differences
across our primary cells.
IHC analysis of tumors did not indicate a mutator phenotype in HET tumors.
Furthermore, our Caspase3 IHC results may suggest that Arid1a KO induces stress in
during tumor development. One possible explanation for this result is that it suggests a
necessary minimum requirement of Arid1a for NCCs to thrive. Next, it is possible that
differences in the DNA damage response are necessary for primary cells to establish
themselves in the host tissue. Therefore, differences may not be observed in endstage
tumors that have adapted to their environment. Considering this possibility, we decided to
induce DNA damage in TDCLs to determine if the DNA damage response was impaired
in vitro.
Arid1a loss does not impair the ATR-dependent DNA damage response. The role
of Arid1a as a TSG is emerging, and a burgeoning field of DNA damage studies have
suggested a caretaker role based on p53 and ATR experiments (Guan et al., 2011; Lord et
al., 2016; Mathur, 2018; Shen et al., 2018, 2015). Furthermore, multiple impactful studies
have indicated both increased resistance and increased sensitivity to chemotherapeutics in
Arid1a adult cancer models (Hu et al., 2018; Lord et al., 2016; Shen et al., 2015). One
explanation is that these differing results may be representative of the tissue dependent
role of ARID1A, or a difference in the role of ARID1A loss in adult versus pediatric
cancer. In the model presented here, we maintained tissue specificity while modifying
Arid1a dose to better understand the characteristics of ARID1A loss in NBL. The findings
of our pediatric model of NBL provides a tool and rationale for dosage and tissue
controlled Arid1a studies that may benefit therapeutic development efforts.
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CHAPTER 5.

DISCUSSION

Significance of Arid1a Findings in the NBL Community
In order to discuss the molecular mechanisms that underpin HR NBL, first we
must establish an understanding of the NBL patterns that can be identified clinically from
large patient cohorts.
Connecting causal gene mutations and patient outcomes
Briefly, the overarching theme of NBL patient care, is that low and intermediate
risk patients have good prognosis and >90% 5-year survival rates (Coughlan et al., 2017;
Davidoff, 2012; Nakagawara et al., 2018). Surgery and or limited exposure to
chemotherapy are enough to achieve these results (Coughlan et al., 2017; Davidoff,
2012). In some patients, disease spontaneously regresses without any clinical treatment.
However, as previously discussed, HR NBL patients present with a disease composed of
multiple compounding negative factors. Two of the most negative indicators of disease
progression include heterogeneous tumors and metastatic disease at diagnosis (Garrett M.
Brodeur et al., 2014; Tolbert & Matthay, 2018). Following intensive multimodality
therapy, HR patients often relapse and succumb to disease (Attiyeh et al., 2005; Garrett
M. Brodeur, 2003; Davidoff, 2012; Jiang et al., 2013; Maris & Matthay, 1999; Muzny et
al., 2012; Nakagawara et al., 2018; J. R. Park et al., 2010). It is important to understand
the primary event or events that link each of these issues to disease initiation and poor
outcomes. However, a common thread throughout the entire NBL community is a lack of
knowledge around the precise genes that initiate this disease. (Garrett M. Brodeur, 2003;
Pugh et al., 2013). This results in a disconnect between causal gene mutations and
resulting poor patient outcomes (Garrett M. Brodeur et al., 2014). Next, we consider one
potential mechanism of NBL initiation in the context of recent literature and results from
our study.
Genetic mutations that disrupt NCC identity may contribute to NBL initiation
Supportive findings
Disrupted cell identity of NCCs during SNS development is one possible route to
NBL initiation (Jiang et al., 2013; Tsubota & Kadomatsu, 2018). Clinical and causal
studies have supported the concept that poorly differentiated NCCs give rise to this
disease (Davidoff, 2012; Etchevers et al., 2019; Furlan et al., 2017; Jiang et al., 2013;
Soldatov et al., 2019; van Groningen et al., 2017). Some of the strongest evidence in
support of this argument come from clinical trials that found differentiation therapy using
retinoic acid added to multimodal therapy improved patient event free survival
significantly (Davidoff, 2012). Causal studies from models of MYCN-driven NBL also
support this argument. The first MYCN-driven mouse model of NBL spontaneously
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enforces MYCN expression off of a TH promoter, which leads to disrupted sympathetic
neuron commitment and function and is a faithful model of human disease (Weiss et al.,
1997). Two additional models generated by MYCN OE in SNS cells NBL have
reproduced these results (Olsen et al., 2017; Zhu et al., 2012). Our recent addition to
these causal models considers 1 and 2 copy deletions of Arid1a combined with Mycn OE,
resulting in reduced tumor latency in HET tumors (Figures 3-1, 3-2 and 3-3), and tumor
histology and gene signatures that distinguished HET and KO tumors from Mycn OE
controls (Figure 3-5). Our findings support the long standing hypothesis that NBL
initiation is due to the chromosomal aberrations MNA and 1p36 LOH (G M Brodeur,
1995; G M Brodeur et al., 1977; Garrett M. Brodeur et al., 2014; Caron et al., 1995; C.
Fong, Look, Vogelstein, & Cavenee, 1992; García-López et al., 2020; Olsen et al., 2017;
Sausen et al., 2013). Our findings further support a connection between disrupted cell
identity contributing to NCC transformation into NBL (Figures 3-6 through 3-12).
(Etchevers et al., 2019; Furlan et al., 2017; Jiang et al., 2013; Soldatov et al., 2019).
Outstanding questions
Despite the cumulative findings that support the idea that de-regulated SNS
differentiation is causal in NBL initiation, possibly through the oncogenic function of
MYCN, it is unclear whether de-differentiation or a block in differentiation during SNS
development are the causal routes (Tsubota & Kadomatsu, 2018). Conclusions from a
recent study experimentally illustrate this point. Van Groningen, et al. found that NBL
tumors were composed of cells with two unique identities (van Groningen et al., 2017).
This study viewed the two cell identities to be defined and regulated by super-enhancer
gene programs (van Groningen et al., 2017). This is consistent with recently published
data from multiple groups (Boeva et al., 2017; Decaesteker et al., 2018; L. Wang et al.,
2019). Furthermore, this study found that the mesenchymal type of NBL tumor cells
(MES) were more primitive, and expressed a genetic profile that resembled NCCs (van
Groningen et al., 2017). The second tumor cell group, adrenergic (ADRN), could be dedifferentiated into the MES cell type (van Groningen et al., 2017). Collectively, their data
supports the hypothesis that NBL tumors are comprised of cells with plastic cell identity
regulated by super enhancers (Boeva et al., 2017; Decaesteker et al., 2018; van
Groningen et al., 2017; L. Wang et al., 2019). Their work further highlights the lack of
clarity of whether NBL tumors result from blocked differentiation, de-differentiation, or a
mixture of both features. The TH-driven MYCN model suggests that de-differentiation of
committed SNS cells may contribute to tumorigenesis, since TH is expressed in
differentiated neurons. Our findings, however, suggest a block of differentiation during
NCC commitment to SNS lineages gives rise to an aggressive form of this disease.
Altogether, studies published across groups and NBL cancer models suggest that cancer
cell plasticity contributes to the heterogeneity of NBL. Additional insights can be gleaned
from the NCC field and a detailed discussion of recent studies regarding NCC progenitor
cell plasticity and cell fate can be found in the “Cell identity” section of this dissertation.
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Hunt for the 1p36 Tumor Suppressor Gene
In the context of intrinsic factors that contribute to disease onset and progression,
one needs to understand the mechanism underlying this disease and how these are
disrupted during disease onset. Therefore, the next question to consider is what are the
cellular disruptions that are proposed to lead to an altered cell identity and subsequent HR
disease. If we evaluate NBL genetic studies, we begin to see the supportive data linking
the cellular events of this disease to the mechanisms that are suspected to cause it. Over
40 years ago, the first chromosomal rearrangement that was consistently identified in
NBL patients were large deletions of 1p (G M Brodeur et al., 1977). These were found to
correlate with MNA, origin in the adrenal glands, and HR disease, which has been
supported by findings from multiple groups (Caron et al., 1995; C. T. Fong et al., 1989).
Dr. Brodeur’s findings suggested that at least one or a collection of TSGs resided in the
1p region of LOH lost in HR patients, based on the two-hit-hypothesis, the hunt for loss
of function genes driving this catastrophic illness ensued (G M Brodeur, 1995; Garrett M.
Brodeur, 2003; C. T. Fong et al., 1989; Maris et al., 1995; Versteeg et al., 1995; White et
al., 2005). Sequencing studies mapped chromosomal alterations with increasing
specificity, and causal studies systematically tested each putative gene (Maris & Matthay,
1999; White et al., 2005). The combination of these studies converged on the smallest
region of consistent deletion (SRCD), which is positioned in distal 1p36, and spans 261
kb at 1p36.3 (Maris & Matthay, 1999; Schulte & Eggert, 2015; White et al., 2005).
Overall, these studies have concluded that the chromosomal breakpoints in 1p36 do not
consistently map to one gene locus (Garrett M. Brodeur, 2003; Caron et al., 1995; Maris
& Matthay, 1999; Pugh et al., 2013). This inconsistency has complicated separating the
driving chromosomal lesions from passenger events in mapping studies. Because 1p36
deletions include large regions of chromosomal loss, the remaining allele was evaluated
for mutations that could result in complete loss of one gene, and suggest that it is a 1p36
TSG (Maris & Matthay, 1999). These mapping approaches did not reveal point mutations
on the second allele of any of the putative TSGs (Maris & Matthay, 1999). To
complement mapping studies, groups looked for gene and protein expression loss (Carén,
Fransson, Ejeskär, Kogner, & Martinsson, 2007; Fujita et al., 2008; Janoueix-Lerosey et
al., 2004; Okawa et al., 2008). However, these studies uncovered few TSG prospects that
demonstrate causal evidence in driving NBL (Garrett M. Brodeur et al., 2014).
In 2008, a bisulfite sequencing study revealed methylation on the sister allele of
CHD5, a 1p36 TSG candidate (Fujita et al., 2008). Additionally, a large sequencing study
identified point mutations corresponding to the TSG Arid1a in 4 of 71 patients studied
(Sausen et al., 2013). One of these was a single point mutation expected to cause
termination of the transcript and the resulting protein product of that allele (Sausen et al.,
2013). The additional three patients demonstrated a 1p36 LOH and a point mutation on
the sister chromatin (Sausen et al., 2013). These mutations were expected to result in the
early termination of mRNA transcript and a subsequent loss of protein expression
(Sausen et al., 2013). Furthermore, the CHD5 findings and ARID1A findings are
consistent with an earlier study that proposed two TSG regions in 1p36, one distal region
that was independent of MNA disease, and a larger proximal region that correlated to
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MNA (Caron et al., 1995). Taken together, these results supported further investigation of
CHD5 and ARID1A.
Further investigation of CHD5 in causal studies indicated that deletion of this
gene did not synergize with Mycn-driven disease but may be a contributor to tumors
containing 1p36 LOH without MNA, which correlates to a patient cohort with favorable
outcomes (García-López et al., 2020; Maris & Matthay, 1999). Consistent with the study
by Sausen et al., one study found that in MYCN-driven cancer during a tumor evolution
study, the tumor bulk maintained Arid1a deletions, but not Chd5 deletions, which
strengthened the evidence for further testing of ARID1A deletions in MYCN-driven causal
studies of NBL (García-López et al., 2020).
In Chapter 3 figures 1 and 2, we move the field forward by casually testing
Arid1a as a driver in NCC transformation into NBL. Our study provides a comprehensive
analysis of Arid1a as a driver mutation. To rigorously test the hypothesis that a
haploinsufficient gene loss collaborates with MYCN to drive NBL, we genetically
modified Arid1a by deleting none, one, or both alleles of Arid1a before enforcing Mycn
OE in untransformed primary NCCs (Figure 3-1A). Biological studies from different
NCC isolations reproduced the result that heterozygous Arid1a synergized with Mycn OE
to initiate NBL (Figures 3-1B through E, 3-2A and 3-3A). Therefore, we propose that
our findings connect the proximal 1p36 LOH identified in MNA patients to a specific
gene that functions as a haploinsufficient TSG, and these findings furthermore support
Arid1a’s candidacy as a proximal 1p36 LOH TSG that correlates with MNA.
Collaborative ARID1A and MYCN gene expression programs
Not only is it important to test cooperating mutations, but it is important to
validate that mouse models of cancer are faithful to human disease. Previous studies
published in a comparative model found that tumors resulting from MYCN-driven
transformation of primary NCCs molecularly and by pathology recapitulates NBL (Olsen
et al., 2017). To characterize the model developed in this study and identify disrupted
signaling events, we analyzed tumors by histology and mRNA sequencing analysis. We
thought that characterizing the consequences of Arid1a and Mycn alterations would
highlight disruptions that correlate to findings in HR NBL patients. To this end, we
investigated the gene signature resulting from sixteen tumors (n=4 per group). An
unsupervised hierarchical clustering analysis mapped the genes differentially expressed
in these four groups (Figure 3-5A). As expected, the controls from both WT1 and WT2
groups clustered together. Additionally, there are obvious differences in gene expression
in the HET compared to WT1 and KO compared to WT2 (Figure 3-5A). Subsequently,
we were able to identify genes that are sensitive to Arid1a dose (Figures 3-5A and 3-8).
These findings will be reviewed and discussed thoroughly in the upcoming sections.
In the past, a lack of identification and causal testing of precise genes and gene
combinations that initiate this disease has prevented downstream gene signature analysis
and therapeutic development (Garrett M. Brodeur et al., 2014). This was the result of
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inconsistent chromosomal deletions, lack of guiding point mutations, and a lack of the
scientific tools, such as bisulfite and high-throughput sequencing, needed to find these
genetic events. Our identification of a haploinsufficient TSG fits into the NBL field’s
expectations of the proximal 1p36 TSG, however it is an unconventional finding overall.
Finally, we consider these findings as a step toward identifying gene targets and
subsequent therapeutic testing and development with the aim of eventually improving
patient care and outcomes. Only through identifying the precise genes, their signaling
partners, and cellular consequences can we begin to build small molecule inhibitors
(SMIs) to target the causal molecular abnormalities underlying NBL initiation. The
remainder of this discussion will focus on the gene expression profiles and cellular
consequences found in our initial tumor study.
The oncogenic role of MYCN
MYCN is the oncogenic driver of HR NBL and has been connected to tumorigenic
cellular events, such as increases in proliferation and cell stemness (Rickman et al., 2018;
Ruiz-Pérez et al., 2017). However, as described previously, the majority of MNA is
present in combination with 1p36 LOH (Garrett M. Brodeur, 2003; Caron et al., 1995; C.
T. Fong et al., 1989; Jiang et al., 2013). Often these two mutations are combined with 17q
gain (G M Brodeur, 1995; Garrett M. Brodeur, 2003; Davidoff, 2012; Jiang et al., 2013;
Maris & Matthay, 1999; Maris et al., 1995; Pugh et al., 2013).The synergizing genetic
lesions that combine with MNA influence downstream gene expression and signaling
events. Therefore, the studies completed here are reviewed in the context of the
synergistic partner, Arid1a, identified through this body of work, and the resulting
cellular events.
Furthermore, following from recent studies in NBL with MYCN amplification,
one opportunity to understand how the oncogenic action of MYCN is actualized is
through the identification and study of deregulated enhancer modifying genes (Boeva et
al., 2017; Decaesteker et al., 2018; Durbin et al., 2018; van Groningen et al., 2017; L.
Wang et al., 2019). This approach may provide a point of connection between the
amplification of MYCN and its oncogenic behavior through synergy with epigenetic
regulators. In summary, MYCN is a key regulator of many genes. Targeting the
downstream processes associated with MYCN driven oncogenesis is an opportunity to
treat MYCN-driven NBL (Boeva et al., 2017; Garrett M. Brodeur et al., 2014; Rickman et
al., 2018; Zeid et al., 2018). To this point, identifying the collaborative initiating events,
and the resulting gene expression signatures will be vital to identifying new therapeutic
targets.
ARID1A and MYC family members
Our system provides a unique opportunity to modify primary NCCs step by step
and to functionally test the connection between genetic lesions and the transformative
events they confer. To this end, in Chapter 4, we explored how Mycn OE affected cell
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death in primary cells and tumors and asked if there was a connection between Mycn
overexpression and Arid1a regulation. Furthermore, we evaluated whether tumors and
TDCLs were competent in their DNA damage response. We did not identify consistent
differences in any attributes examined in this set of experiments.
Our studies in Chapter four began with protein expression analysis of Arid1a and
MYCN in a panel NBL cell lines. Although sequencing studies have confirmed ARID1A
deletions in the 1p36 Δ samples, we observed that MNA samples had higher than
expected Arid1a expression relative to controls (Figure 4-1A). Considering the synergy
observed in tumors, we thought this finding may indicate a MYCN-regulated increase in
ARID1A expression. To further test this idea, we evaluated Mycn and Arid1a mRNA
expression in heterozygous primary untransformed NCCs. We observed two results.
First, titration of Mycn did produce a small shift in Arid1a expression (Figure 4-1D).
Second, Arid1a was expressed at levels between 65 and 85 percent relative expression. If
this result holds under more rigorous analysis, then it is possible that the thresholds set
during mRNA analysis to screen for potential TSGs would cause false negatives. One
hallmark of cancer is escape from apoptotic cell death (D Hanahan & Weinberg, 2000;
Douglas Hanahan & Weinberg, 2011). Next, we considered that Mycn OE may induce
apoptotic pressure on WT1 samples, resulting in an escape from apoptotic death when
Arid1a is heterozygously lost. To test this possibility, we used flow analysis of AnnexinV to establish apoptotic cell fractions in primary cells treated with increasing amounts of
Mycn (Figure 4-2). We expected HET samples to demonstrate a decrease in cell death
relative to WT1 controls and that KO would demonstrate no difference or more
sensitivity to Mycn-induced apoptosis. However, no significant differences were
observed in the MOIs tested (MOI 0-3) (Figure 4-2A and B).
We considered that this result may be a consequence of the time points measured
(72hrs). If Arid1a loss resulted in a hypermutator phenotype, we expected that it might be
identified in end point tumors. Next, we evaluated γH2ax and cleaved caspase3 levels in
end point tumors (Figure 4-3). No statistically significant differences were observed in
HET tumors relative to controls (Figure 4-3A and B), however KO tumors displayed a
statistically significant increase in Caspase-3 (Figure 4-3C and D). Considering that
Arid1a has been identified as a regulator of the DNA damage response, is mutually
exclusive of p53, and has been linked to high rates of mutation, we were surprised that
these traits were not evident in our study.
Furthermore, in our model, no significant differences in resistance, sensitivity, or
ATR signaling of DNA damage were overserved in response to treatment of TDCLs with
chemotherapeutics (Figures 4-4 and 4-6). This study was limited to time points of 72hrs
and under. In the apoptosis experiments using primary cells, pilot studies out to 96 hours
were performed, and 72 hours was expected to capture differences. However, repeating
the experiments and extending the time points may highlight potential differences.
Furthermore, culturing cells in vitro using media spiked with low doses of
chemotherapeutics over weeks may highlight possible differences in drug resistance
across TDCLs.
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To summarize, our studies evaluated the hypothesis that Mycn OE inducesArid1a
expression to signal an apoptotic response that would be abrogated by Arid1a deletions.
This hypothesis was proven false to the extent tested. However, the increase in Arid1a
protein and mRNA suggests a feedback loop between ARID1A and MYCN that supports
the concept of co-regulation. Closer study of this system may uncover co-regulated genes
and the mechanisms that control them.
N-MYC and TWIST1 co-regulation of enhancers
Recently, one study determined how different MYCN expression levels regulated
MYCN positioning at promoters and enhancers in NBL (Zeid et al., 2018). They
identified that at promoters with canonical E-box sites, MYCN binding overlapped with
MYC binding signatures, however MYCN preferentially invaded enhancers that were
established critical lineage factors of the developing SNS (Boeva et al., 2017; Zeid et al.,
2018). Furthermore, MYCN amplified samples had a symbiotic relationship with
TWIST1, a pioneering factor of stemness and migration (Zeid et al., 2018). High levels of
TWIST1 cooperated with MYCN to facilitate binding at distal enhancers, suggesting that
MYCN binding at non-canonical sites is regulated by cell type-dependent proteins.
Although evident that TWIST1 expression correlated with MYCN binding at these
critical enhancer sites, the mechanism was not indicated. This paper applied a known
approach in a unique way. MYCN was studied by leveraging Chip-seq consistently
throughout the article. This approach used the binding of promoters and enhancers, a key
function of this TF, as a readout for MYCN activity following the manipulation of its
expression. Importantly, they defined one new possibility for how MYCN exerts its
oncogenic function, through cooperation with TWIST1 (Zeid et al., 2018).
TWIST1 is a bHLH transcription factor that can form either homo or
heterodimers before binding to E-box sites in promoters of its target genes (Castanon &
Baylies, 2002; Merindol et al., 2014). Twist1 was identified in cranial neural crest cells as
a key regulator of migration and stemness (Soldatov et al., 2019). Furthermore, Twist1
expression has been shown to regulate trans-differentiation of neuronal and mesenchymal
cell identity in cardiac NCCs (Vincentz et al., 2013). In trunk NCCs, TWIST1 expression
is regulated, at least in part, by PBAF, which was demonstrated in human NCCs (Bajpai
et al., 2010). In NBL, TWIST1 expression is correlated to MNA tumors, and poor overall
patient survival (Selmi et al., 2015; Valsesia-Wittmann et al., 2004; Zeid et al., 2018).
Two studies have suggested that N-MYC regulates TWIST1 expression, and one
suggested that MYC regulated TWIST1 expression, and a recent article determined that
MYC and TWIST1 cooperate to induce metastasis (Valsesia-Wittmann et al., 2004;
Selmi, de Saint-Jean, Jallas, Garin, Hogarty, Bernard, et al., 2015; Zeid et al., 2018).
Although N-MYC was shown to bind the TWIST1 promoter, experiments testing the
effects of MYCN modulation of TWIST1 expression have been inconsistent, suggesting
additional regulators of TWIST1 may contribute to its high expression levels in MNA
cases (Selmi et al., 2015; Valsesia-Wittmann et al., 2004; Zeid et al., 2018).
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Following from this more recent picture of MYCN amplification, one opportunity
to understand how the oncogenic action of MYCN is actualized is through the
identification and study of deregulated enhancer modifying genes. This approach may
provide a point of connection between the amplification of MYCN and its oncogenic
behavior through synergy with epigenetic regulators. In summary, MYCN is widely
expressed and is a key regulator of many genes. Targeting the downstream processes
associated with MYCN driven oncogenesis is an excellent opportunity to treat MYCNdriven NBL (Garrett M. Brodeur et al., 2014). To this point, identifying the collaborative
initiating events, and the resulting gene expression signatures will be vital to identifying
new therapeutic targets.
Potential synergies of ARID1A and N-MYC
Does ARID1A regulate TWSIT1 expression? Our data demonstrates that Arid1a
deletion causes an increase in TWIST1 expression in HET and KO tumors (Figure
3-10A). TWSIT1 is a master regulator of the normal NCC EMT process, and is an
initiating mutation in metastasis (Yang et al., 2004). Furthermore, the migration rates of
HET and KO TDCLs correlate to TWSIT1 expression levels in tumors. NCCs undergo
EMT as they migrate away from the neural tube and differentiate into the SNS (Jiang et
al., 2013; Kuo & Erickson, 2010; Soldatov et al., 2019). Interestingly, N-MYC and
TWSIT1 expression have been correlated in NBL by two groups, although the exact
mechanism of regulation has not been published (Selmi et al., 2015; Zeid et al., 2018).
We demonstrated that Arid1a heterozygous loss impaired differentiation and
induced an EMT gene expression signature (Figures 3-6 through 3-10). Taken together,
our studies support the role of Arid1a in EMT described in the current literature and
contributes additional details to the context dependent effects of Arid1a in cancer
initiation (Han et al., 2019; Sun, Chuang, et al., 2017; Sun, Wang, et al., 2017; W. Wang
et al., 2019). EMT is a highly regulated process that may become deregulated and initiate
metastasis (Yang et al., 2004). Our study supports the concept of a link between these
behaviors and cell maturity. Although suspected, failure to exit EMT has not previously
been linked to cancer initiation in NBL (Etchevers et al., 2019; Furlan et al., 2017;
Soldatov et al., 2019).
The ARID1A tumor suppressor gene
Identification of a causal role for Arid1a in our model may elucidate areas for
continued studies in HR NBL and may also influence how the SWI/SNF field studies
sub-unit loss. ARID1A protein function cannot be determined solely based on protein
expression, and our work suggests that genetic screens, and protein expression will need
to be complimented with immunoprecipitation (IP) analysis of the SWI/SNF complexes
(Figure 4-1). For example, preliminary evaluation ARID1A protein levels in MNA NBL
cases, and in response to Mycn titration suggest that ARID1A expression may be upregulated even when one copy of the gene is lost. The use of IPs to pull down the
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SWI/SNF complex following Arid1a deletion or ARID1A mutation, can determine if the
complex composition changes. For example, does ARID1B or ARID2 become the
predominant ARID subunit in the new complex (Bajpai et al., 2010; Helming et al.,
2014)? Furthermore, Zied et al., performed an analysis of MNA by not only evaluating
protein expression, but by using ChIP-seq binding patterns to connect expression levels
to activity (Zeid et al., 2018). Adapting their approach to a chromatin remodeling
complex would be a useful way to fully resolve the functionality and outcomes of
chromatin remodeler mutations, such as Arid1a loss in the SWI/SNF complex. As Zeid et
al. demonstrated, ChIP experiments can evaluate SWI/SNF targets when ARID1A is
absent (Zeid et al., 2018). Combining these approaches will likely provide more clarity
in studies aiming to represent how SWI/SNF functions in cancers with ARID1A
mutations.
Our data opens the possibility that some epigenetic TSGs may operate under the
goldilocks principle, rather than the framework posited by the two hit hypothesis or
current definitions of haploinsufficiency (Berger & Pandolfi, 2011; Knudson, 1971; D. S.
Park et al., 2019). Dose dependent TSGs, like P53 demonstrate a partial phenotype when
1 gene copy is lost, but the phenotype is further exacerbated when both gene copies are
lost, thus demonstrating that P53 haploinsufficiency is sufficient for tumor
transformation (Berger & Pandolfi, 2011). Another type of haploinsufficiency is
demonstrated by the PTEN TSG (Berger & Pandolfi, 2011). Haploinsufficient PTEN loss
is sufficient to induce cancer, however full ablation induced senescence (Berger &
Pandolfi, 2011; Chen et al., 2005). This is termed obligate haploinsufficiency (Berger &
Pandolfi, 2011).
For example, tumor latency differences were insignificant between KO compared
to WT2 tumor kinetics (Figures 3-1 through 3-3). Although HET tumors demonstrated
reduced latency. Further TSG studies across models and cell types will be needed to
confirm the effects demonstrated by Arid1a dose dependent loss. For example, in
embryoid bodies evaluated in this mouse model, one study reported differences between
Arid1a heterozygous and knockout deletions (Gao et al., 2008). In adult cancer studies,
Arid1a heterozygous deletions have demonstrated a tumorigenic advantage during tumor
outgrowth, but not initiation in MYC-driven mouse models of liver cancer (Sun, Chuang,
et al., 2017; Sun, Wang, et al., 2017). Our data suggests that in the context of Mycndriven NBL, heterozygous Arid1a deletion provide the most advantage during initiation,
indicating haploinsufficiency. However, rather than KO inducing senescence, we found
that KO reduced tumor initiation kinetics to that of WT2 tumors. We consider this to
demonstrate the goldilocks principle, where there is a critical gene dose for
transformation (Amin, Rajan, Groysman, Pongtornpipat, & schatz, 2015; D. S. Park et
al., 2019). Our study supports conclusions by by Sun et al. that suggest ARID1A is a dose
and context dependent TSG (Mathur, 2018; Sun, Wang, et al., 2017; J. N. Wu & Roberts,
2013). It is possible that a new category of TSGs may be uncovered as more epigenetic
TSGs are evaluated, and that phenotypes may be tissue and cancer type specific (Sun,
Wang, et al., 2017). However, further causal examination in mouse models of cancer will
be necessary to confirm our report.
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Arid1a loss has been implicated in adult cancer as an essential mediator of wound
healing, and initiator of metastatic spread (Sun, Chuang, et al., 2017; Sun, Wang, et al.,
2017). Taken together, multiple studies and our results suggest that EMT is involved
(Han et al., 2019; Sun, Chuang, et al., 2017; Sun, Wang, et al., 2017; S. C. Wang et al.,
2019). TWIST1 is a master regulator of EMT, and its overexpression has been causally
determined to increase metastatic spread of mammary tumors (Yang et al., 2004). EMT
induces a quasi-mesenchymal state, and is thought to induce cancer stem cells, although a
direct mechanism describing how EMT induces stemness has not been established
(Dongre & Weinberg, 2019). One area of metastatic spread that is lacking primary
literature is an understanding of the traits that confer an advantage to migrating cells
allowing them to colonize new tissue sites (Dongre & Weinberg, 2019). One possibility
is that stem-like traits are a feature of the original stem cell, rather than the EMT TFs,
which might explain some of the overlap between EMT and metastasis seen in various
cancer types (Etchevers et al., 2019).
While tumors were locally invasive, metastatic disease was not observed in our
sub-cutaneous mouse model. However, our molecular analysis suggested, and functional
analysis confirmed that tumors with Arid1a deletions had higher rates of migration than
WT controls (Figure 3-9B and C). Furthermore, one signaling node of genes
concordantly up-regulated in HET and KO was defined by multiple metalloproteases
(Figure 3-8A). Also considering the gene signatures identified in our study, we
interpreted these studies to collectively indicate an increase in metastatic potential of
Arid1a mutant NCCs.
Despite the wide relevance of Arid1a heterozygous mutation rates across adult
and pediatric cancers, to date, few cancer studies have directly tested the ability of Arid1a
heterozygous deletions to drive cancer in mouse models, and this work was performed in
adult cancers (Mathur et al., 2017; Sun, Wang, et al., 2017; S. C. Wang et al., 2019). The
most prevalent types of Arid1a cancer studies are performed in cancer cell lines with
siRNA mediated knockdown, or in models of Arid1a homozygous deletions (Guan et al.,
2011; Lord et al., 2016; Shen et al., 2018). Specifically, in one Arid1a deleted mouse
model of colon cancer, Arid1a was identified as a context-dependent TSG that was found
to control tumor metastasis (Sun, Wang, et al., 2017). Interestingly, in this adult cancer
model, Arid1a deletion was not implicated in tumor initiation of liver cancer (Sun, Wang,
et al., 2017). Our experimental findings of the Arid1a dose dependent regulation of
motility fit with this previously established liver cancer model. However, in addition to
regulating migration, multiple biologically independent mouse studies confirmed that
Arid1a deletion synergized with MYCN amplification in NBL initiation. The difference
between the two Arid1a mouse models is intriguing. One concept that may be useful in
framing the results from this pediatric study relative to the adult cancer study, is the role
of epigenetic mutations in pediatric disease.
Pediatric cancers were recently shown to have a high incidence of epigenetic
mutations relative to adult cancer (Filbin & Monje, n.d.; Flavahan et al., 2017; Gröbner et
al., 2018). Pediatric cancers can be considered a disease of development, and epigenetic
factors direct the biological systems of development. Alterations in cell fate contribute to
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tumorigenesis (Vogelstein, Papadopoulos, & Velculescu, 2013). The high incidence of
epigenetic mutations in pediatric cancers suggest that mutations in epigenetic regulators
during development influence cell fate. Outside of speculating why one mutation, such as
ARID1A los of function mutations, may disproportionally affect one cell type over
another, there is one conclusion that can be drawn when considering the role of ARID1A
in disease. Functional testing of genetic events via context specific disease models is
extremely important for identifying cancer drivers and the resulting downstream
consequences (Berger & Pandolfi, 2011; Garrett M. Brodeur et al., 2014; D. T. W. Jones
et al., 2019; Vogelstein et al., 2013).
Cell Identity
In Chapter 3, our work identified a gene signature that correlates to mesenchymal
gene signatures identified by two other studies (Soldatov et al., 2019; Zeid et al., 2018).
We interpret this phenotype to be linked to cell identity, which is plastic early during
development, but becomes restricted as differentiation progresses (Flavahan et al., 2017).
This is consistent with large pan-pediatric cancer studies that discovered mutations in
epigenetic regulators was the top alteration consistently identified across all pediatric
cancers (Gröbner et al., 2018; Ma et al., 2018). In a recent pan-cancer study, pediatric
cancers were reported to have 45% overlap of the driver genes mutated in adult cancer
(Ma et al., 2018). Currently, Arid1a has been causally studied in developmental, and
adult cancer mouse models (Chandler & Magnuson, 2016; Gao et al., 2008; Han et al.,
2019; Mathur et al., 2017; Sun, Chuang, et al., 2017; Sun, Wang, et al., 2017; S. C. Wang
et al., 2019). Our model combines aspects from adult cancer and developmental studies
and addressed the role of Arid1a as a driver mutation in trunk NCC transformation into
the pediatric cancer NBL. Although we did not establish a direct molecular mechanism,
our findings in this novel mouse model of NBL support the hypothesis that Arid1a is a
haploinsufficient TSG that synergizes with MNA to disrupt lineage development
programs, resulting in increased oncogenesis due to altered cell identity.
Cancer initiating stem cells
The cancer stem cell model is characterized by four drivers of disease, cancer
initiation, intratumor heterogeneity, metastatic disease and post-therapy relapse
(Meacham & Morrison, 2013). These key tumor traits are considered consequences of
cancer driven by a tumorigenic stem cell population (Meacham & Morrison, 2013). HR
NBL tumors as a group fit these criteria, and we interpret this to suggest that the genes
significantly contributing to disease may contribute to these phenotypes. Therefore, the
development of mouse models that faithfully exhibit the genotypes and phenotypes of
NBL are necessary to testing fundamental cancer biology questions.
In our model, we tested the hypothesis, does Arid1a loss contribute to NCC
transformation through a block in differentiation? Therefore, we focused on the role of
Arid1a as a loss of function initiator of Mycn-driven NBL. Consistent with this model, we
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did determine that Arid1a heterozygous loss was causal in initiating Mycn-driven NBL.
However, through characterizing our model, we identified signs of intratumoral
heterogeneity in HET and KO tumors by pathological analysis. Although not the primary
focus of this study, these results support our findings that our model faithfully
recapitulates traits of NBL and suggest a rationale for further studies evaluating
heterogeneity in this model.
Tumor model characterization revealed up-regulated migration and metastatic
signaling nodes We evaluated the evidence of metastatic disease in our model in vivo, in
vitro, and with RNA-sequencing to better identify the potential metastatic effects of HET
and KO cell populations. Furthermore, tissue invasion and metastatic disease is one of the
six original hallmarks of cancer and is a key trait of the cancer stem cell model (Douglas
Hanahan & Weinberg, 2011; Meacham & Morrison, 2013; Yang et al., 2004). One
interesting study of Arid1a in a MYC-driven model of liver cancer found that one and
two-copy loss of Arid1a did not initiate disease, but rather initiated metastasis when
conditionally ablated in pre-established tumors (Sun, Wang, et al., 2017). We evaluated
full body histology of mice hosting tumors with long latency. These experiments did not
identify metastatic colonization at distant sites however, allografts were locally invasive.
Boyden chamber migration assays testing migration traits of TDLCS indicated an
increase in cell motility in HET and KO populations (Figure 3-9B and C). Additional
results from STRING analysis of RNA-seq data identified two signaling nodes upregulated in both HET and KO tumors that are related to metastatic potential. These
included a Twitst1 EMT signaling node, and an Adamts metalloproteinase signaling node
(Figures 3-8 and 3-9A). In a breast cancer mouse model, Twist1 was causally studied
and found to be an essential master-regulator of EMT and metastasis initiation (Yang et
al., 2004). Adamts genes are associated with developmental and metastatic cellular
programs although causal evaluation is limited (Kelwick, Desanlis, Wheeler, & Edwards,
2015). Taken together, our results suggest that Arid1a HET and KO deletions are
insufficient to induce all steps of metastasis but do increase metastatic potential.
In chapter 4, we tested TDCLs for signs of resistance or sensitivity to
chemotherapeutics (Figures 4-4 and 4-5). However, we did not identify differences in
HET or KO TDCLs compared to controls that would indicate a clinically significant
resistance to etoposide or topotecan. Potential future studies will be discussed in the
future directions section of this discussion.
Cell identity master regulators
Heterozygous Arid1a deletion correlated with an immature, mesenchymal cell
state (Figures 3-6, 3-7 and 3-9 through 3-12). One theme consistent throughout Arid1a
developmental and cancer studies, is the ability of Arid1a to regulate EMT-related
phenotypes (Han et al., 2019; Sun, Wang, et al., 2017; S. C. Wang et al., 2019). EMT is
both a transition state during development and an initiation step of metastasis. Failed
NCC differentiation leading to inappropriate SNS patterning is considered a possible
explanation for NBL initiation (Jiang et al., 2013). Given the high prevalence of
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metastatic disease in HR NBL, it is possible that transformation of highly migratory
progenitors contributes to this phenotype. This fits with the suggested role of Arid1a in
oncogenesis, which suggests that when Arid1a loss, the results in de-regulated cell
commitment to differentiation or de-differentiated cells (Gao et al., 2008; Han et al.,
2019; Mathur, 2018; Sun, Chuang, et al., 2017). This is supported by findings in multiple
stages of development including liver, pancreatic, colorectal, and hematopoietic studies
(Han et al., 2019; Mathur et al., 2017; Sun, Chuang, et al., 2017; Sun, Wang, et al., 2017;
S. C. Wang et al., 2019). To evaluate the overall identity of the cells comprising the
tumors in our study, we compared our RNA-seq tumor gene expression data to the NCC
expression profiles recently posited by (Soldatov et al., 2019). Soldatov et al. mapped
NCC maturation during development using single cell RNA sequencing to focus on the
decision points of multipotent NCCs as they commit to cell fates of the SNS (Soldatov et
al., 2019). Their work describes the process of cell fate decisions as a process of coactivation, competition, and eventual up-regulation of one TF over a competing TF
resulting in commitment to one cell identity (Soldatov et al., 2019). Lineage tracing,
causal studies, and RNA-sequencing approaches resulted in lists of the TFs determined to
be the master regulators during each step of trunk NCC maturation (Soldatov et al.,
2019). This comparison enabled us to connect tumor group genotypes and the expression
profiles that are associated with cell identities of the developing SNS.
Cell identity studies of multipotent SNS progenitor cells have recently identified
key transcription factor programs that regulate NCC cell fate (Flavahan et al., 2017;
Soldatov et al., 2019). The differential genes identified in our tumors were mapped
against an expression profile that corresponds to NCC fates. Interestingly, HET tumor
samples mapped to a mesenchymal fate signature (Figure 3-9E), (Figure 3-10A). KO
tumor sample fate mapping revealed a signature defined by stem-initiating genes and
genes associated with sensory ganglia (Figures 3-10, 3-11B through F). WT1 and WT2
tumor gene signatures most closely mapped to a glial SNS signatures (Figures
3-10, 3-11A through E). Due to the nature of our analysis, this RNA-seq gene signature
represented a population of tumor cells. Histological analysis supported the RNA-seq
data and suggested that tumors are comprised of more than one cell population (Figure
3-5B). However single-cell sequencing studies, or cell sorting studies would be necessary
to better define the different cell populations and tumor compositions. In summary, our
tumor analysis data supports the idea that the tumors analyzed are heterogeneous but are
enriched with cells from one fate. This concept may apply to all tumor groups in this
study but is particularly supported by our findings in the KO tumor group. These tumors
demonstrated significant upregulation of master regulators from mesenchymal and premigratory cell profiles but mapped overall to a sensory cell profile. This work suggests
that the NCC master regulator gene list provided by Soldatov et al. is a useful framework
for interpreting our study. However, our RNA-seq data includes cell types represented
throughout the tumor, and furthermore, our data is from transformed NCCs. It is
unsurprising that fate mapping revealed an overlap of multiple gene signatures found in
non-transformed NC progenitors. Therefore, we wanted to further investigate and group
the differentially regulated genes in this model, to pull out interesting master regulator
candidates in this system.
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We identified gene signatures in our tumors that were consistent with the gene
expression NCC profiles developed by multiple single-cell sequencing studies (Figure
3-10A) (Furlan et al., 2017; Soldatov et al., 2019). These studies provide extensive
modeling and analysis of cell-fate tracing during adrenal gland development and trunk
NCC maturation, respectively (Furlan et al., 2017; Soldatov et al., 2019). We evaluated
the differentially expressed genes (DEGs) in three comparison groups, HET versus WT1,
KO versus WT2, and HET versus KO (Figure 3-11). Here, we graphically represented
differences between paired tumor sample groups. Notably, the glial master regulators
Plp1 and Zpf488 were upregulated in both WT1 and WT2 relative to their counterparts
Arid1a modified (Figure 3-11D and E). Furlan, et al. and Soldatov et al. described the
glial lineage as the cell population that gives rise to Schwann cell precursors (SCPs)
(Furlan et al., 2017; Soldatov et al., 2019). SCPs have been proposed as the cell type that
develops into the adrenal medulla during normal murine development (Furlan et al.,
2017). DEG analysis of HET tumors indicated a statistically significant increase in the
sensory lineage master regulator, Eya2, and the mesenchymal fate specifier,
Twist1(Figure 3-11A and D) (Soldatov et al., 2019). KO tumors demonstrated significant
increases in Zic3, a neural plate boarded specifier, Dlx5 a regulator of delamination ,
Eya2 and Twist1(Figure 3-11B and E) (Soldatov et al., 2019). Eya2 and Twist1 were
concordantly upregulated in HET and KO tumor samples (Figure 3-11D and E). Prrx1
was significantly upregulated in HET tumors relative to KO, and Zic3 was significantly
upregulated in KO tumor samples relative to HET tumor samples (Figure 3-11F).
HET samples demonstrated a partial block in differentiation characterized by an
increase in Prrx1, a master regulator of mesenchymal identity. Twist1 was upregulated in
both HET and KO tumors relative to controls. Electroporation of Twist1 to induce its
overexpression in chick embryos was sufficient to re-route trunk NC migration, and
induce a mesenchymal identity (Soldatov et al., 2019). Additionally, Twist1 was shown
to up-regulate Prrx1, a master regulator of mesenchymal identity at the autonomic/mesenchymal decision point (Soldatov et al., 2019). However, KO tumors also
demonstrated an increase of the sensory glia inducer the neural plate boarder specifier,
Zic3, that was not up regulated in HET tumors. We interpret this suggest a more
immature gene signature in KO relative to HET tumors that is supported by the
significant block in differentiation identified by IHC (Figure 3-6D through F), neuronal
differentiation IF studies (Figure 3-6H and I), and a significant Wong embryonic stem
cell core signature identified by GSEA (Figure 3-9D) (Wong et al., 2008). We found it
interesting that KO did not confer a tumorigenic advantage to NCCs relative to controls
(Figures 3-1F through I, 3-2D and 3-3C) and consider the data to collectively suggest a
window of transformation during NCC progenitor differentiation that left HET NCCs
vulnerable to MYCN-driven transformation relative to other NCC populations. In the
context of the mesenchymal gene signature identified in HET samples, Twist1 was
shown to increase the oncogenic effects of MYCN (Zeid et al., 2018). Prrx1 has been
identified as a gene of interest that is upregulated in NBL patients at post-therapy relapse
(van Groningen et al., 2017). Therefore, our data supports the concepts posited by two
studies suggesting a TWIST11 collaboration with MYCN, and our study contributes the
idea that other TFs regulating mesenchymal cell identity, like Prrx1, may synergize with
the oncogenic function of MYCN (van Groningen et al., 2017; Zeid et al., 2018).
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Arid1a heterozygous tumors model human mesenchymal NBL
The previous data set used as a framework to interpret our gene expression results
came from a study tracing non-transformed multipotent progenitor cells (Soldatov et al.,
2019)s. Following from that study and considering the Arid1a haploinsufficient genotype
that synergized with Mycn OE in NCCs, we decided to test whether HET tumors
recapitulated gene expression signatures identified in HR NBL patients. Therefore, the
second dataset we used as a rubric for our model was a sequencing analysis of NBL
patient samples (van Groningen et al., 2017). Evaluation of our tumors against the
signature identified by van Groningen, et al supported the concept that our tumors
developed a statistically significant mesenchymal gene expression signature that was
concordant with human HR NBL by GSEA (Figure 3-12) (van Groningen et al., 2017).
The premise of their study was to identify possible gene signatures that would help
characterize the cell types comprising HR NBL tumors. Overall their project evaluated
the stem cell heterogeneity in HR NBL tumors. Using the stem cell marker CD133 to sort
NBL patient tumors into CD133+ and CD133- populations, and CD133+ populations
generated a signature that was consistent with a mesenchymal phenotype and included
the EMT genes FN1, VIM, SNAI2, and PRRX1 (van Groningen et al., 2017). In contrast,
CD133- cells expressed gene signatures consistent with established adrenergic lineage
markers of NBL, like PHOX2A/B, GATA2/3, and DBH which the authors termed
ADRN (adrenergic) (van Groningen et al., 2017). CD133+ cells would be expected
generate tumors that demonstrate aggressive traits like metastatic disease and relapse
after therapy (Meacham & Morrison, 2013). The CD133- tumors would be expected to
lack tumorigenic ability or have greatly reduced tumor initiation ability (Meacham &
Morrison, 2013). Interestingly, van Groningen et al. found that both CD133+ and
CD133- cells could form tumors in vitro, which may suggest that tumors are composed of
cells with a flat hierarchy of cancer initiating stem cells. Interestingly, both populations
were tumorigenic, however, the CD133+ cells demonstrated more aggressivity, such as in
vitro resistance to chemotherapy, and they mapped more closely to NCC progenitor cells,
suggesting immaturity relative to the adrenergic counterparts, which is consistent with a
study by Boeva et al. (Boeva et al., 2017; van Groningen et al., 2017). To establish the
master regulators of the MES phenotype, the authors enforced PRRX1 expression in the
ADRN cells, which induced SNAI2 and was sufficient to re-program ADRN into a
mesenchymal state (van Groningen et al., 2017). This experiment confirmed that these
two cell populations were from the same lineage, and led authors to interpret that NBL
cells were able to transdifferentiate, which was also proposed in another study (Boeva et
al., 2017; van Groningen et al., 2017). PRRX1 positive cells were present in a small
population of cells in pre-treatment patient samples but was enriched post-therapy in the
two patients evaluated (van Groningen et al., 2017). This indicates a correlation between
PRRX1 and NBL resistance to chemotherapy. In summary, this publication supports the
idea that cell identity is regulated by master transcription factors. The authors proposed
that the cell MES and ADRN cell identities were defined by TFs that form feed-forward,
or core regulatory circuits at super-enhancers resulting in alterations of cell identity and
tumorigenic properties (van Groningen et al., 2017). This idea is consistent with other
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recent NBL literature (Boeva et al., 2017; Decaesteker et al., 2018; Durbin et al., 2018; L.
Wang et al., 2019; Zeid et al., 2018). Their conclusions provide a helpful framework that
can be used to interpret our findings and consider future studies to validate TFs we
identified.
Furthermore, gene expression and histological analysis support the idea that our
model is consistent with altered SNS differentiation causing HET tumors to sustain a
mesenchymal phenotype that is consistent with HR NBL patient tumors (Soldatov et al.,
2019; van Groningen et al., 2017). Further analysis indicated that HET tumors are
blocked in a state that significantly overlaps with the patient-derived MES signature
indicative of HR NBL while the remaining tumor groups display a gene signature with
statistically significant overlap with the ADRN signature identified in patient samples
(Figure 3-10C) (van Groningen et al., 2017). Therefore, our model may be a useful tool
for future testing of fundamental mechanistic questions, as high-throughput drug
screening and biomarker development.
Tying Together MYCN, ARID1A and Cell Identity
Pan-cancer studies of pediatric cancer identified the top significantly mutated
genes to be epigenetic regulators (Gröbner et al., 2018; Ma et al., 2018). Modeling
Arid1a as an initiating event allowed close monitoring and capture of the downstream
effects of Arid1a alterations. ARID1A literature is founded on powerful genetic and
expression screens across many tumor types, and these have correlated the effects of
Arid1a mutations to haploinsufficient and initiating events in a variety of cancers
(Gröbner et al., 2018; Kadoch et al., 2013; Tomlinson, Lambros, Roylance, & CletonJansen, 2002; J. N. Wu & Roberts, 2013). Altogether, these studies have demonstrated
that Arid1a is a context dependent TSG. Furthermore, our findings expand Arid1a mouse
model work into the pediatric cancer field and contribute causal evidence of an epigenetic
loss of function mutation driving a HR pediatric cancer.
A working model connecting ARIDIA loss, MYCN enhancer invasion and TF
circuits
This dissertation has focused on the interplay of an oncogene and TSG during
NBL initiation. Our studies support the hypothesis that MNA and heterozygous ARID1A
synergize to disrupt normal NCC differentiation during a window of transformation. To
summarize, we now describe a possible mechanism behind this synergy and its effects on
cell identity. TWIST1 is a helpful example in thinking about this mechanism. MYCN has
been shown to bind to the promoter of TWIST1 in NBL (Selmi et al., 2015; ValsesiaWittmann et al., 2004; Zeid et al., 2018). However experiments performed in these three
studies did not demonstrate an increase in TWIST1 protein levels following increased
MYCN expression (Selmi et al., 2015; Valsesia-Wittmann et al., 2004; Zeid et al., 2018).
Taken together, it is possible that MYCN does not directly regulate Twist1 expression. It
is clear that MYCN and TWIST1 synergize to bind enhancers (Zeid et al., 2018). This
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leaves us with the question, if not MYCN, then what causes TWIST1 up-regulation in
MNA NBL? Our studies identified that Twist1 mRNA expression was significantly
increased in tumor samples when Arid1a expression decreased (n=8). This suggests that
Twist1 expression is regulated by Arid1a at the mRNA level. Furthermore, the mRNA
gene signature of up-regulated genes in HET samples indicates that loss of Arid1a leads
to an up regulation of multiple TFGs—especially TFGs that regulate EMT. TF circuits
have been shown to produce feed-forward loops that bind one another’s super enhancers
and define cell identity (Hnisz et al., 2013; van Groningen et al., 2017; Whyte et al.,
2013; Young, 2011). Considering the findings presented here, we modify our hypothesis
to include a mechanism and to propose the working model that loss of function ARID1A
mutations disrupt enhancers that regulate cell identity, thus, leaving enhancer binding
sites open to act as reservoirs for abundant proteins, such as MYCN (Zeid et al., 2018).
Furthermore one may envision the possibility that if master regulators of stemness are deregulated and overexpressed in this environment, for example MYCN and TWIST1,
these oncogenic proteins may saturate normal DNA binding sites resulting in enhancer
invasion, the reprogramming of normal cell fate commitment TF circuits and
consequently holding NCCs in an immature cell state that is oncogenic.
Disease modeling – key features and limitations
Our mouse model was neither spontaneous nor orthotopic. Lack of modeling in
the adrenal medulla was a limitation and an advantage of our study. For example, in our
sub-cutaneous model, tumors were measured on a regular basis without the
administration of luciferase and use of an imaging machine (D. T. W. Jones et al., 2019).
Furthermore, compared to spontaneous models, gene modifications in primary cells can
be added in vitro, without the need to produce an additional mouse model (D. T. W.
Jones et al., 2019). Although we did not use an orthotopic model, one insight into the
origin of NBL can be gleaned from sub-cutaneous disease modeling. Taken together, our
data suggests that modifying NCCs before sub-cutaneous injection faithfully models this
sub-type of MYCN-driven NBL.
One challenge in relating our model to the field’s experimental results can be
easily contextualized with the following example. In bioinformatic analysis that
compared samples from our four tumor groups to the patient samples derived by van
Groningen et al., we saw a significant overlap of our model’s gene expression signature
compared to their patient samples’ gene expression signature (van Groningen et al.,
2017). However, the patient samples’ genetic characterization at the time of analysis was
unpublished, making this comparison valuable, but open to the following questions: Do
the patient samples analyzed by van Groningen, et al. have MYCN amplification and/or
1p36 LOH? Additionally, during CD133 separation by cell sorting, are there any
chromosomal differences in the positive vs negative groups that may further support a
link of chromosomal mutations to cell identity? The ADRN/MES distinction overall is an
interesting approach to grouping patient tumors based on gene expression signatures and
provides a helpful rubric for the comparison and evaluation of our model. However,
chromosomal information, such as amplifications and deletions in patient samples,
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remains an important refence in order to classify and compare samples across patients
and experimental models. Additional consideration for referencing samples based on
genotype would be an excellent way to organize and streamline the communication
around experimental findings and appropriately correlate experimental results back to
patient samples. Improving this step in communicating experimental findings in the NBL
field would improve the speed and accuracy of interpreting experimental findings as it
relates to patient samples. Our data supports the hypothesis proposed by Dr. Brodeur, that
1p36 LOH contributes to tumor aggressivity (Brodeur, Sekhon and Goldstein, 1977;
Maris et al., 1995; Brodeur, 2003). As the NBL field moves toward precision medicine,
communicating the exact genetic events found in patients will become increasingly
important.
Future Directions
Oncogene and tumor suppressor gene disruptions are fundamental to
tumorigenesis. Identifying driver mutations is critical to resolving each cancer type’s
unique genetic footprint and gene expression signatures. However, the gene expression
cascades that act downstream of driver mutations to signal these disruptive inputs are
opportunities for synthetic-lethal therapeutics. It is obvious that oncogenes and tumor
suppressors that are frequently mutated together enable a proliferative advantage and
tumor onset. A better understanding of the regulatory mechanisms essential to the
establishing feedback loops between these driver mutations, leading to their synergy, may
provide insights into the disrupted core regulatory circuits in NBL. Identifying the genes
that connect mutant TSGs and oncogenes may uncover options for therapeutic targeting
that would disrupt feedback and feed-forward oncogenic circuits and ultimately reduce
tumor burden (Garrett M. Brodeur et al., 2014; Durbin et al., 2018; van Groningen et al.,
2017; L. Wang et al., 2019; Zeid et al., 2018).
Our trunk neural crest explant model is positioned to connect developmental
biology concepts to the pediatric cancer community. An additional advantage of this
NCC cell model is the option to modify progenitor cells using combinations of GEMM
and gene editing techniques simultaneously. For example, 17q translocations have been
identified as the most frequent chromosomal abnormality in HR NBL (Garrett M.
Brodeur et al., 2014; Davidoff, 2012; Pugh et al., 2013; Tolbert & Matthay, 2018).
Modeling candidate oncogenic chromosomal events in these primary cells may further
pinpoint the genetic events that are causal in de-regulation of normal cell properties and
transformation of NCCs into NBL.
This body of work connected epigenetic de-regulation to the oncogenic action of
MYCN through a demonstrating a collaboration between Arid1a loss and MYCN
overexpression. Furthermore, gene expression profiling identified a set of genes that are
linked to altered cell identity in other cancer models. Finally, a de-regulated cellular
identity was characterized by in vitro assessment of primary cells, and in vivo
tumorigenesis studies and subsequent analysis of tumor tissue and TDCLs. Following
from this work, there are key experiments that could be performed to validate the
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findings discussed in this dissertation and propel this work toward clinical applications.
To close this discussion, I have developed an approach of validation and pre-clinical
modeling of these findings that is described below. I end this discussion with a short list
of ideas that would link this body of work to outstanding NBL questions that may be
addressed through additional experimentation in our model.
Functional validation of the Arid1a-regulated gene signature
First, the up-regulated Arid1a-dependent gene targets identified by RNAsequencing studies need to be confirmed with Arid1a modulation experiments. A
sleeping beauty transposase system can be used to re-introduce Arid1a into TDCLs. Next,
the Arid1a depletion and re-introduction could be confirmed with immunoprecipitation
analysis of the SWI/SNF complex, shown in Figure B-2. If it is possible to modulate
Arid1a’s association with the complex following the re-introduction of Arid1a, a qPCRbased check for Arid1a-dependent modulation of the proposed Arid1a targets before and
after Arid1a addition would validate the findings of this work and suggest top hits.
Next, small molecule inhibitors (SMIs) could be used to target and modulate the
Arid1a down-stream genes that regulate EMT and differentiation. For positive controls,
SMIs can be pooled 5+ (each for a different target), before assaying multiple SMIs that
target the same protein. To confirm SMI efficacy, one or two down-stream targets could
be validated using an ELISA, which can be purchased or built in-house.
Once Arid1a-dependent targets and SMIs have been validated, high-throughput
screening methods using robotics monitoring of cell viability and migration could be used
to determine whether cell viability and migration are affected by inhibition of target
proteins. The top 10 SMIs that affect both viability and migration would then pass into
the next set of screens.
Hits from the SMI in vitro screen would need to be screened in vivo. First, a pilot
experiment would need to be performed using only controls to determine the critical
experimental conditions. Only two cell lines would be necessary for the pilot study— one
Arid1a WT+MYCN OE (Arid1a re-expressing if possible), and one Arid1a HET + MYCN
OE cell line. Injecting 1.5e6 cells per mouse would ensure time until tumor could be
accurately monitored and treated after establishment (300 mm3). To establish the controls
for SMIs, one drug that failed from the first screen could serve as a negative control.
DMSO should also be included as a negative SMI control. A combination of all drugs
could serve as positive SMI controls (60 mice) (Table 5-1).
Following the establishment of experimental conditions, the in vitro hits could be
confirmed in vivo using results from the pilot experiment in Table 5-1. In all
experiments, at least one Arid1aWT TDCL treated with one of the positive SMI controls
and a DMSO negative control would need to be included. Injecting five mice per drug
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Table 5-1.

Pilot drug study in mice.
Cell Lines
Drug
DMSO (- ctrl)
Failed Drug (- ctrl)
Combo 1 (+ ctrl)
Combo 2 (+ ctrl)

Arid1aWT
n=5
n=5
n=5
n=5

Arid1aRe-WT
n=5
n=5
n=5
n=5

Arid1aHET
n=5
n=5
n=5
n=5

Notes: (- ctrl) = negative control, (+ ctrl) = positive control, Arid1are-WT = Arid1a
depleted TDCL with re-expression of Arid1a and Mycn OE, Arid1aHET = Arid1a
heterozygous TDCL with Mycn OE.
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would ensure top drug hits could be separated from negative controls (Table 5-2). To
allow appropriate monitoring of the experiment, the top 10 list of SMI hits should be split
in half, resulting in two experiments that include five SMIs each (68 mice for 5 SMIs).
Repeating Table 5-2 a second time would complete in vivo screening of the top 10 SMI
hits (136 mice total).
Dissociated patient-derived xenografts could be used to confirm top in vivo hits in
human samples. NBL xenografts would need to be tested for (proximal) 1p36 and MYCN
amplification status first. The following xenograft genetic sub-types would be needed for
experimental and control groups. Xenografts: 1x Non-MNA/1p36 LOH (negative
control), 3x MNA alone (1p36 negative control), 4x MNA + 1p36 LOH (NBL sub-type
of interest), 3x 1p36 LOH (experimental group to test effects of this deletion in the
absence of MYCN). These sub-groups could be supplemented with cell lines if necessary.
Descriptions of genetic alterations in NBL cell lines can be found in Table A-1.
Following sample validation, xenografts could be injected into their respective original
host mouse strains in a pilot study. Injecting a varied number of cells per mouse would
determine optimal establishment and growth conditions. Recommended doses are 1.5e6,
3e6, and 9e6 (99 mice) (Table 5-3). Once the optimal conditions are established, hits
from the Arid1a SMI screen in human xenografts could be validated in the xenografts
(341 mice for five SMIs) (Table 5-4).
Intratumoral heterogeneity
Another avenue that would be interesting to explore in more detail, is fate
mapping of the cells that initiate tumorigenesis, followed by single-cell sequencing to
generate gene expression profiles that are consistent across the tumor sub-types generated
in this study. This approach is not only relevant to NBL and could easily be expanded to
other adult and pediatric cancer types. However, for simplicity in our model, I have
generated over 100 cell lines that could be transduced with a ROSA-confetti expressing
virus, and re-injected orthotopically, or sub-cutaneously, then harvested at 300mm3, and
cell sorted into populations for evaluation.
This experiment could be approached with a limiting dilution series that would be
calculated based on the number of colors expressed by the ROSA system. This is
necessary to evaluate and expand rare populations of stem-cells presumed to initiate this
disease. Unfortunately, no true tumor stem cell markers have been established in NBL.
Currently used markers include CD133, and CD44 (van Groningen et al., 2017). CD44
was upregulated in Ardi1a HET and KO tumors according to RNA-seq analysis, and
subsequently, may be a useful marker in our system. Additional projects in the Freeman
lab are related to the identification of NCC markers that can be used for lineage tracing
and may elucidate other tumor stem cell markers relevant to our system.
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Table 5-2.

Drug study in mice.
Drug
DMSO (- ctrll)
Failed Drug (- ctrl)
Combo 1 (+ ctrl)
SMI 1
SMI 2
SMI 3
SMI 4
SMI 5

Arid1aRe-WT
n=3
n=3
n=3
n=5
n=5
n=5
n=5
n=5

Arid1aHET
n=3
n=3
n=3
n=5
n=5
n=5
n=5
n=5

Notes: (- ctrl) = negative control, (+ ctrl) = positive control, Arid1are-WT = Arid1a
depleted TDCL with re-expression of Arid1a and Mycn OE, Arid1aHET = Arid1a
heterozygous TDCL with Mycn OE.

Table 5-3.

Cell #
1.5 x106
3.0 x106
9.0 x106

Validation of xenograft growth in mice.
NonMNA/
1p36
1
n=3
n=3
n=3

MNA
1
2
3
n=3 n=3 n=3
n=3 n=3 n=3
n=3 n=3 n=3

MNA + 1p36
1
2
3
4
n=3 n=3 n=3 n=3
n=3 n=3 n=3 n=3
n=3 n=3 n=3 n=3

Notes: MNA = MYCN amplified, LOH = loss of heterozygosity

88

1p36 LOH
1
2
3
n=3 n=3 n=3
n=3 n=3 n=3
n=3 n=3 n=3

Table 5-4.

Xenograft drug study.

NonMNA
/1p36
Sample #

MNA

MNA + 1p36

1p36 LOH

1

1

2

3

1

2

3

4

1

2

3

DMSO (- ctrl)

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

Combo (+ ctrl)

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

n=3

SMI 1

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

SMI 2

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

SMI 3

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

SMI 4

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

SMI 5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

n=5

Notes: MNA = MYCN amplified, LOH = loss of heterozygosity
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Modeling and testing metastatic disease
Metastasis has been described as a multistep process that leads to dissemination of
primary disease and colonization at distant sites (Dongre & Weinberg, 2019). The study
by Sun et al that found loss of Arid1a was an initiator of metastasis but not tumorigenesis
is intriguing. Paired with our study indicating that Arid1a loss is a driver of a frequently
metastatic disease, these findings warrant further exploration. For example, it would be
informative to compare metastatic biopsies to primary tumors then evaluate them for
Arid1a deletions. Furthermore, analysis of the expression levels of other genes, like
TWIST1 and PRRX1 in metastatic colonies would directly test hypotheses posited by
multiple groups (Soldatov et al., 2019; Sun, Wang, et al., 2017; van Groningen et al.,
2017).
Furthermore, our NBL cancer model indicated altered EMT, but did not
demonstrate an increase in metastatic disease. However, Sun et al. demonstrated a
significant increase in metastatic disease following Arid1a deletion (Sun, Wang, et al.,
2017). The discrepancy between these results may be due to a difference in the cancer
models, but there are additional interesting plausible biological explanations: 1: The
SWI/SNF complex is comprised of different members in each cell type, resulting in over
288 combinations; therefore, deletion of Arid1a has different outcomes in HCC versus
NBL models (Weissman & Knudsen, 2009). 2: ARID1A loss deregulates the same set of
genes (EMT factors) in all cell types, and this has a variety of effects depending on the
cell type and differentiation stage, ranging from a block in differentiation in progenitor
cells, to increased metastatic potential in differentiated cells. Mouse models of disease
will be increasingly useful in determining the effects of ARID1A mutations across
pediatric and adult cancers. We have precisely regulated Arid1a dosage in the NCC cell
type, and have determined that Arid1a loss blocks the differentiation of NCCs. Our data
supports the hypothesis that ARID1A is a haploinsufficient 1p36 TSG that collaborates
with MYCN in NBL initiation.
Conclusion
The results presented in this body of work highlight the importance of context
specific disease modeling, especially in high-mortality orphan diseases such as this
pediatric cancer. Not only do these findings identify a distinct set of genes with
functional consequences in cancer, they also direct our focus to potential new drug targets
for MNA NBL. Finally, this data functionally and molecularly supports data from studies
across a variety of ARID1A mutated cancers and expands not only the NBL field’s
understanding of an epigenetic regulator in pediatric cancer, but also provides higher
resolution and connectivity to 25 cancer types by furthering our understanding of the
most mutated member of the SWI/SNF epigenetic complex and its connection to cell
identity.
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APPENDIX A. ADDITIONAL MATERIALS AND METHODS TECHNICAL
INFORMATION
Table A-1.

Predicted ARID1A genetic status in common neuroblastoma cell lines.

Cell Line
SK-N-AS
SH-SY5Y
NBL-S
SK-N-FI
SK-N-SH
NB-16

Sequenced Genetic Event
MYCN
1p36 LOH
Non-Amp Loss p36.22-36.32
Non-Amp None
Non-Amp None
Non-Amp None
Non-Amp None
Non-Amp None

Predicted Protein Status
N-MYC
ARID1A
WT
WT

NB-EBc1
NB-69

Non-Amp
Non-Amp

Loss p35.2-pter
Loss p13.3-pter

WT

LOH

NB-1,691
SK-N-DZ

Amp
Amp

None
None

Amp

WT

CHP-134

Amp

Amp

LOH

IMR-05
IMR-32
KELLY

Amp
Amp
Amp

LA-N-5
NB-1
NB-1,643
NB-SD
NGP
NLF
SK-N-BE(2)
SK-N-BE(2)-C
NB-SD
NGP
NLF
NMB
SMS-KAN
SMS-SAN

Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp

LOH p32.3-pter; Gain p34.3p36.22; Loss p36.22-pter
Gain+LOH p32.3-pter
Loss p32.3-pter
LOH p21.3-pter; Loss p36.32;
Gain p36.33
Loss p33-pter
Loss p32.2-pter
Loss p34.2-pter
Loss p21.3-pter
cnLOH p32.3-pter
Loss p32.2-pter
cnLOH p21.3-pter
cnLOH p21.3-pter
Loss p21.3-pter
cnLOH p32.3-pter
Loss p32.2-pter
cnLOH p34.2-pter
Loss p13.3-pter
Loss p32.3-pter

Notes: WT = wild-type, Amp = MYCN gene amplification, LOH = loss of heterozygosity,
pter = p-terminal, cn = copy number.
Modified with open access permission. License
https://creativecommons.org/licenses/by/4.0/. Harenza, J. L., Diamond, M. A., Adams, R.
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Table A-1.

Continued.

N., Song, M. M., Davidson, H. L., Hart, L. S., … Maris, J. M. (2017). Transcriptomic
profiling of 39 commonly-used neuroblastoma cell lines. Scientific Data, 4(1), 170033.
https://doi.org/10.1038/sdata.2017.33
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Table A-2.
Immunohistochemistry primary antibodies, type, concentrations,
supplier and technical procedures for visualization.
Antibody
ARID1A
BAF47 (Clone 25)
Cleaved-CASPASE 3
GFAP
Phospho-Histone H2A.X
KI67 (Clone SP6)
MAP2
PHOX2B
Phospho-Histone H3 (S10)
Synaptophysin
S100
Tyrosine Hydroxylase (TH)
Tubulin β3 (TUJ1)

Type
Rabbit poly
Mouse IgG2α
Rabbit poly
Rabbit poly
Rabbit mono
Rabbit mono
Rabbit poly
Rabbit poly
Rabbit poly
Rabbit poly
Rabbit poly
Rabbit poly
Mouse
IgG2α,κ

a

Conc.
1:25
1:1000
1:500
1:4000
1:200
1:200
1:250
1:100
1:200
1:400
1:2000
1:500
1:9000

Supplier
Sigma-Aldrich, HPA005456 a
BD Biosciences, 612111b
BioCare Medical, CP229C b
DAKO, Z0334 b
Cell Signaling, 9718 b
ThermoFisher, RM-9106 b
Millipore, AB5622 c
Abcam, ab183741 b
Bethyl laboratories, IHC-00061 a
Spring Biosciences, E2172 b
DAKO, Z031129 b
Millipore, AB152 b
Biolegend, 801202 a

Heat-induced epitope retrieval, Cell conditioning media 2 (Ventana Medical Systems,
Tucson, AZ), 32 minutes; Visualization with DISCOVERY OmniMap anti-Rb HRP
(760-4311; Ventana Medical Systems), DISCOVERY ChromoMap DAB kit (760-159;
Ventana Medical Systems)
b
Heat-induced epitope retrieval, Cell conditioning media 1 (Ventana Medical Systems,
Tucson, AZ); Visualization with biotinylated rabbit anti-mouse IgG secondary antibody
(Abcam, ab133469), DISCOVERY OmniMap anti-Rb HRP (760-4311; Ventana Medical
Systems), DISCOVERY ChromoMap DAB kit (760-159; Ventana Medical Systems)
c
Heat-induced epitope retrieval, Epitope Retrieval solution 1 (ER1), 20 minutes;
Visualization with rabbit anti-goat (BA-5000; Vector Laboratories), Bond Polymer
Refine Detection (DS9800, Leica Biosystems).
Notes: conc = concentration, mono = monoclonal, poly = polyclonal
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Table A-3.

Immunoblotting antibody information.

Antibody
anti-total ATM (D2E2) rabbit mAb CST #2873
anti-phos ATM (Ser1981) (D6H9) rabbit mAb CST #5883
anti-ATR (phos T1989) (1:500) (ab227851) rabbit pAb
anti-phos ATR (1:500) Ser428 rabbit pAb CST #2853
anti-total ATR (1:1000) rabbit mAb E153S CST #13934; 5% BSA in PBST
anti-total Chk1 (2G1D5) mouse mAb CST #2360 (1:2000)
anti-Phos Chk1 (1:500) (Ser317) (D12H3) XP® rabbit mAb CST #12302
anti- Chk2 rabbit pAb CST #2662
anti-Phos-Chk2 (Thr68) (C13C1) rabbit mAb CST #2197 (reacts w H)
anti-toal Histone H2A.X rabbit (c term) pAb CST #2595 (1:2000)
anti-phos-H2A.X (Ser139) (1:2000) mouse mAb, JBW301 Millipore 05-66
anti-p53 (1C12) Ser20 mouse mAb CST #2524
anti-p21WAF1/Cip1 mouse mAb Sigma #P1484
anti- Caspase-3 rabbit pAb CST #9662
anti-Cleaved Caspase-3 (Asp175) (5A1E) rabbit mAb #9664
anti-ARID1A (1:2000) rabbit mAb CST; 5% BSA in PBST, CST 12354
anti-N-MYC (1:1000) rabbit pAb; 5%BSA in PBST, CST #9405
anti-53a (1:2500) rabbit pAb bethyl A301-391A 5% BSA in PBST
anti-53b (1:2500) rabbit mAb ab180927
anti-BAF 155 (SMARCC1) (D7F8S) CST 11956 rabbit mAb
anti-actin (1:10:000) ac-15 Sigma mouse mAb; 5% BSA in PBST

Protein
Size (KDa)
350
350
300
300
300
56
56
62
62
15
17
53
31
35, 19, 17
19, 17
250
62
53
53
155
42

Notes: mAb = monoclonal antibody, pAb = polyclonal antibody, phos = phosphorylated
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APPENDIX B. SUPPLEMENTAL EXPERIMENTAL FIGURES

Figure B-1. Comparison of ARID1A and N-MYC protein levels in WT1 and HET
primary NCCs.
Western analysis of protein levels prior to NCC injection into mice.

Figure B-2 Enrichment of BAF155 protein following immunoprecipitation and
immunoblotting.
Immunoprecipitation of SWI/SNF using an anti-BAF155 antibody to pull down the
complex using a core subunit of BAF and pBAF complexes. (A) Light exposure. (B)
Dark exposure.
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